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Abstract 
 
This thesis describes field and experimental investigations on various aspects of the 
immunopathogenesis, diagnosis and vaccination of infectious bronchitis virus (IBV) 
and avian metapneumovirus (aMPV) in the chicken.  
 
The immunopathogenesis of an economically important variant IBV 
(IS/885/00-like) seen in the Middle East and North Africa was examined in one day 
old specific pathogen-free (SPF) and commercial broiler chicks (Chapter 3). The 
virus caused respiratory distress, depression and diarrhoea in both SPF and broiler 
chicks but the severity was milder in the latter. Mild head swelling was observed in 
one infected broiler chick at 15 days post infection (dpi) and virus with 100% 
nucleotide level similarity to the inoculum was detected by reverse transcription 
polymerase chain reaction (RT-PCR) and virus isolation (VI). In the IS/885/00-like 
infected SPF chicks, cystic oviducts were found in two female chicks. IBV with 
99% part S1 sequence similarity to the initial inoculum was isolated from the cystic 
fluid.  
 
The protection provided by current commercial vaccines against variant IBV 
IS/885/00-like and IS/1494/00-like was investigated in day old commercial broiler 
chicks (Chapter 4). Protection was evaluated based on the clinical signs, gross 
lesions, tracheal ciliary scores and virus detection by RT-PCR. It was found that 
administering combined live H120 and CR88 vaccines simultaneously at day old, 
followed by CR88 vaccine at 14 days-old gave more than 80% ciliary protection 
against both of the Middle East isolates. 
 
Cellular and local immune responses in the trachea following vaccination of day old 
broiler chicks with different live IBV vaccines were evaluated (Chapter 5). In 
addition, protection conferred against virulent IBV was also examined. All 
vaccination programmes were able to induce measurable levels of CD4+, CD8+ and 
IgA-bearing B cells in the trachea following vaccination when compared to 
unvaccinated birds. Expression levels of CD4+ and CD8+ cells varied between the 
vaccinated groups. Vaccines containing Mass2 combined with 793B2 produced good 
protection against challenge with virulent IBV QX compared to vaccines containing 
Mass (Mass1 or Mass2) alone or Mass1 with D274 or CR88. All vaccination 
programmes produced more than 80% protection against homologous (M41 and 
793B) challenge. 
 
In Chapter 6, IBVs with high nucleotide level similarity to IS/885/00-like and 
IS/1494/06-like strains were detected by RT-PCR in a broiler flock exhibiting high 
mortality and respiratory distress in Libya. For the first time, these findings have 
highlighted the circulation of variant IBVs in the Eastern part of Libya. 
 VIII 
 
Humoral and cellular immune responses and protection studies in SPF chicks that 
received live Newcastle disease virus (NDV), aMPV and IBV vaccines in single, 
dual or triple combinations were examined (Chapter 7). Protection against virulent 
IBV or aMPV was not affected when the vaccines were given either singly or in 
combination. There were no significant differences in the mean antibody titres of the 
NDV-vaccinated groups and they remained above the protective titre. The mean 
titres of antibodies against aMPV were suppressed when aMPV vaccine was given 
with other live vaccines but the aMPV-vaccinated groups were fully protected when 
challenged with virulent aMPV. The mean titres of antibodies were similar in the 
IBV-vaccinated groups and all IBV-vaccinated groups gave almost 100% protection 
against M41 challenge. Between the vaccinated groups, there were no significant 
differences in the mean numbers of CD4+, CD8+ and IgA-bearing B cells, reflecting 
similar levels of tracheal cellular and IgA responses irrespective of single, dual or 
triple vaccine applications. Despite the aMPV humoral antibody suppression, the 
efficacy of the live vaccines was not compromised when they were given 
simultaneously to young SPF chicks.  
Comparative studies in day old SPF chicks using both aMPV subtype A or B, 
separately or in combination, were evaluated (Chapter 8). There were significant 
differences in the degree of the clinical signs induced by the single subtypes A, B or 
A+B given together, with most severe signs observed in the latter two groups. By 
RT-PCR or VI, subtype B virus persisted longer than subtype A. Even though 
similar titres of the viruses were used, birds given subtype B alone or in combination 
showed a greater increase in antibody titres than those given A. These findings 
demonstrate that for the two strains used, subtype B was more pathogenic than 
subtype A and was excreted and persisted in the tissues for longer. 
 
The use of Flinders Technology Associates (FTA) cards for detection of several 
avian pathogens has been previously reported. To date, no information has been 
published on the use of FTA cards for detection of aMPV. In Chapter 9, the 
feasibility of using FTA cards for the molecular detection of aMPV subtype A and B 
by RT-PCR was investigated. Findings showed that FTA cards are suitable for 
collecting and transporting aMPV-positive samples, providing a reliable and 
hazard-free source of RNA for molecular characterization. 
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I.1.1. IBV –a short history  
 
  
Infectious bronchitis (IB) was first observed in 1931 by Schalk and Hawn in North 
Dakota in the USA in 2-3 week old chickens (Schalk and Hawn, 1931). However, 
the nature of the infectious agent was not determined at that time and was assumed 
that IB was mainly a disease of young chickens. However, it was later observed in 
laying flocks and the nature of the infectious agent was not determined at that time, 
which actually may have been a mild form of infectious laryngotracheitis (ILT) 
(Bushnell and Brandly, 1933). In 1936, it was proved by cross-immunity that the 
IBV was distinct from ILT (Beach and Schalm, 1936). In 1937, the virus was  
propagated in the allantoic cavity of embryonating eggs (Beaudette and Hudson., 
1937). In 1941, Delaplane and Stuat suggested that IBV propagated in embryonating 
chicken eggs (ECE) might have immunizing value. The first IBV vaccine in the 
United States was developed using the van Roekel M41, which is a Massachusetts 
(Mass) serotype of the virus, and was isolated at the University of Massachusetts in 
1941 (Jackwood and de Wit, 2013). In 1956 researchers in Connecticut identified a 
strain (Connecticut strain) that showed distinct antigenic differences from the Mass 
strain (Hitchner, 2004). This led to the awareness that different serotypes of the virus 
exist and that they did not cross protect (Jackwood and de Wit, 2013). In 1962, 
nephritic disease related to IB in the USA was first reported (Winterfield and 
Hitchner, 1962). The following year an IB outbreak causing severe kidney lesions in 
chickens was reported in Australia (Cumming, 1963). In 1956, IB was diagnosed 
and isolated for the first time in the Netherlands (Bijlenga et al., 2004). This virus 
was used to prepare a vaccine by serial passage in ECE up to 52
nd
 level passage in 
early 1960s. The vaccine was named IBV H52 (Bijlenga et al., 2004). Most of the 
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work in 1970s and 1980s involved identification of different serotypes of the virus 
by serum neutralization tests. In the 1990s several laboratories began identifying the 
type of IBV using molecular techniques (Jackwood et al., 1997; Keeler et al., 1998; 
Worthington et al., 2008). This allowed for the rapid identification of many isolates 
and the comparison of the viruses around the world. Since then, a wide range of 
different IBV serotypes and genotypes have been detected globally and the 
emergence of new and variant IBVs is rapidly increasing (de Wit et al., 2011a; 
Jackwood, 2012).   
I.1.2. The disease 
 
IBV has an incubation period of 24 to 48 hours and viral spread occurs rapidly 
among chickens in a flock by aerosol and mechanical means. The most common 
route of transmission is the airborne one. The spread between flocks where the farms 
are in close proximity is also likely to occur by aerosol (Jackwood and de Wit, 
2013). Other important routes of spread may include contact with faeces and 
fomites, since the virus has been reported to replicate in the chicken’s intestine 
(Ambali and Jones, 1990). Vertical transmission has been reported (Cook, 1971) but 
is considered to be of little importance. The morbidity rate can reach 100% but the 
mortality rate depends on the presence of secondary infection, flock age, immune 
status, management and environmental factors (Ganapathy, 2009). In young chicks 
the mortality rate is typically 25-30 % but it can approach 80%, depending on the 
virulence of the strain. Even though all age group of chicks are susceptible to IBV, 
young chicks are more susceptible than older ones (Jackwood and de Wit, 2013). 
 
The most notable signs are those affecting the respiratory tract hence the disease was 
named IB (Jackwood and de Wit, 2013). The severity of the clinical signs is 
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influenced by several factors associated with the IBV (eg. strain, virulence and 
dosage), the host (eg. age, sex, type and immune status), the environment (eg. dust, 
ammonia and stress), management and biosecurity levels (Ganapathy, 2009). IBV 
also affects the reproductive (Crinion et al., 1971; Jones and Jordan, 1972) renal 
(Meulemans et al., 1987) and gastro-intestinal systems (Ambali and Jones, 1990; 
Wang et al., 1998; Yu et al., 2001; Ganapathy et al., 2012; Chacón et al., 2014). It 
has been reported that the virus can cause infertility in male chickens (Boltz et al., 
2004; Boltz et al., 2007).  
The typical signs of IBV in chickens of less than six weeks of age are depression, 
huddling under the heat source, gasping, coughing, tracheal râles, nasal discharge, 
lethargy, watery eyes and  mild swollen sinuses in severe conditions (Jackwood and 
de Wit, 2013).Young chicks may die due to IBV but in uncomplicated infections in 
chicken more than five weeks of age the disease may not be serious. In any age 
group, if IBV is mixed with other pathogens more severe diseases can occur (Smith 
et al., 1985).  
Following infection via the respiratory route the virus spreads to other tissues 
including the reproductive tract. Infection at an early age may result in false layer 
syndrome in the case of certain IBV strains (Crinion et al., 1971; Muneer et al., 
1986), while infection of laying birds produces a range of effects varying from 
eggshell pigment changes to production drops (Jones and Jordan, 1971). Layers 
experiencing egg production loss or quality decline may show mild (Muneer et al., 
1986) or no respiratory signs (Cook and Huggins, 1986). However, the severity of 
the egg production decline in quantity and quality may vary, depending on the IBV 
strains (Dhinakar Raj and Jones, 1997; Jackwood and de Wit, 2013). 
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The nephritic form of IBV mostly occurs in broiler chickens (Butcher et al., 1989) 
but it might also affect layers (Selim et al., 2013). Initially the virus cause signs of 
respiratory distress followed by severe signs of wet droppings which may contain 
excessive urate, increase in water intake and high mortality due to kidney damage 
(Cumming, 1963; Meulemans and van den Berg, 1998). 
Swollen head syndrome (SHS) is a condition where chickens have swollen heads 
due to fascial cellulitis and swollen eyelids. Although SHS has been associated with 
aMPV (Picault et al., 1987; Jones et al., 1991; Aung et al., 2008), a coronavirus was 
isolated by Morley and Thomson (1984) in the first description of SHS in Southern 
Africa. IBV M41 has also been isolated from commercial broiler flock in the Central 
Valley of California experienced respiratory disease and signs of SHS (Droual and 
Woolcock, 1994). The role of IBV in the pathogenesis of SHS is not certain 
although it has been postulated that Escherichia coli (E.coli) may invade the air 
spaces of the cranial bones through the Eustachian tube following an upper 
respiratory tract viral infection (Droual and Woolcock, 1994). 
I.1.3. Infectious bronchitis virus properties 
 
Avian IBV is a single-stranded positive sense, enveloped RNA virus that belongs to 
the Group 3 of the coronavirus genus with other avian coronaviruses (Cavanagh, 
2003). The Coronaviridae family is, together with the Arteriviridae and Roniviridae, 
within the order Nidovirales. The virus is round to pleomorphic in shape, possesses 
an envelope that is 120 nm in diameter with club-shaped surface projections or 
spikes (Jackwood and de Wit, 2013). The IBV genome is composed of 
approximately 27.6 kilobases (kb). Four structural proteins have been recognised 
spike (S), membrane (M), envelope (E), and nucleoprotein (N). The S protein 
located at the surface of the virion, consists of two subunits, S1 and S2 with 
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molecular weights of 92k and 84k respectively. Neutralizing antibodies are elicited 
by the S1 portion. The E protein is essential for virus particle formation, the M 
protein is exposed 10% at the outer virus surface; the N protein surrounds the single 
stranded positive sense RNA genome to form the ribonucleoprotein (Lai and 
Cavanagh, 1997; Jackwood and de Wit, 2013). IBV has an enormous capacity to 
change both by spontaneous mutation and by genetic recombination (Jackwood and 
de Wit, 2013).  
The virus first attaches to the appropriate host cell receptor followed by entry into 
the cell either by fusion with the plasma membrane or endocytosis (Li and 
Cavanagh, 1992). A replicate complex is also encoded, which carries out the unique 
discontinuous transcription process resulting in five subgenomic mRNAs (Stern and 
Kennedy, 1980; Stern et al., 1982; Jackwood and de Wit, 2013). At the molecular 
level, coronaviruses employ a variety of unusual strategies to accomplish a complex 
programme of replication and gene expression (Masters, 2006). These uncommon 
strategies are important factors in the generation of the virus’s genetic diversity and 
continuous evolution. The virus replicates in the cell cytoplasm and within 3-4 hours 
after infection, new virus particles emerge with maximum output per cell being 
reached within 12 hours at 37°C (Jackwood and de Wit, 2013).  
I.1.4. Incidence and geographical distribution 
In the USA, the most commonly isolated type of IBV is Arkansas (Ark) (Jackwood 
et al., 2005), and the presence of Ark-like isolates indicates that this virus continues 
to change (Nix et al., 2000). Other commonly detected viruses in the USA are Conn 
and Mass types (Jackwood et al., 2005). In 1992, the Delaware variant was first 
reported in Delmarva Peninsula region. The Delaware serotype was found to be 
antigenically unrelated by virus neutralization test (VNT) to reference IBV serotypes 
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( M41, Ark DPI, Conn and JMK)  from North America (Gelb et al., 1997), but it was 
found to be closely related to the Dutch variant, D1466 (Lee and Jackwood, 2001). 
California-type viruses were first isolated in the 1990s and were designated 
California variant (Moore et al., 1998). In 1999, another related but unique virus 
designated Cal99 was reported (Schikora et al., 2003; Mondal and Cardona, 2007). 
The S1 hypervariable region of Cal99 genome was most closely related to Ark 
serotype viruses (Mondal and Cardona, 2007). From late 1997 to 2000, 
PA/Wolgemuth/98 and PA/171/99 nephropathogenic strains were identified in 
Pennsylvania (Ziegler et al., 2002). In 2007 and 2008, two new IBV variants were 
detected in Georgia and South Carolina broilers with respiratory disease. The viruses 
were distinct from each other and designated GA07 and GA08 (Jackwood et al., 
2010).  
In Latin America, in addition to the local strains ( BR-I and BR-II), Mass type  and 
viruses similar to the 793B type have been reported, which has not been detected in 
Brazil (Villarreal et al., 2010). In Mexico, several different genotypes have now 
been isolated include Conn, Mass and Ark type (Jackwood, 2012). In recent years 
IBVQ1 type, originally isolated in China has been detected in Chile, Peru, Argentina 
and Colombia (Sesti et al., 2014).  
The Australian 'T' strain was the first IBV strain isolated in Australia in 1962 
(Cumming, 1963). Many different IBV variants have been isolated and characterized 
since then IBV has always evolved independently here from the rest of the world 
due to its geographical isolation. The Australian isolates have been separated into 
subgroup 1 (classical strains) and subgroups 2 and 3 (novel strains) based on genetic 
analysis of S1, 3’ ends of the genome and serologic cross-reaction (Ignjatovic et al., 
2006). Subgroup 1 viruses include the Australia/N1/62 strain and the vaccine strain 
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Australia/VicS/62. Subgroup 2 viruses included Australia/ N1/88, Australia /Q3/88, 
and Australia/V18/91. Subgroup 3 strains are represented by isolate 
chicken/Australia/N2/04 (Ignjatovic et al., 2006). 
Until the late 1970s, it was believed that only IBVs of the Mass serotype were 
important causes of disease in Europe (Jones, 2010; de Wit et al., 2011a). In 1980s 
disease outbreaks occurred in the Netherlands in H120 or H52 vaccinated flocks 
(Davelaar et al., 1984). New strains isolated form these flocks and following 
differentiation by VN, they were described as Dutch strains; D207, D212, D3128 
and D3896 (Davelaar et al., 1984). Many IBV variants  were isolated, from other 
European countries including IBV PL-84084 in France (Picault et al., 1986), B1648 
in  Belgium (Meulemans et al., 1987), 624/I, Fa 6881/97, AZ 27/98, AZ 20/97, and 
BS 216/01 in Italy (Capua et al., 1994; Zanella et al., 2003) and Spanish strains of   
97/314, 98/313, 00/337 and 00/338 (Dolz et al., 2006).  
In the UK, Parsons et al. (1992) reported a new type of IBV. This type, mostly 
known as 793B (also 4/91 or CR88) was shown to have a nucleotide sequence in the 
hypervariable regions of the S1 spike gene quite distinct from Mass and Dutch 
variant viruses (Cavanagh et al., 2005). This virus has a global distribution (Cook et 
al., 1996a), except USA and Australasia (Jones, 2010).  
In 2002 the sequence of a new IBV genotype named Italy 02 (It-02) was submitted 
to the GenBank. Using VNT it was demonstrated that little antigenic relatedness 
exists between It-02 and some of the reference IBV serotypes (M41, D274, D1466 
and 4/91) which means that It-02 can be classed as a new serotype (Dolz et al., 
2006). The origin of It-02 is unknown, but it has been spreading predominantly 
throughout Europe (Worthington et al., 2008). A pathogenic strain of D1466 that has 
been detected in some Western European countries for three decades, it has hardly 
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been reported outside Western Europe, although it is very difficult to achieve a 
sufficient level of protection against this strain through current vaccines and 
vaccination strategies (Cook et al., 1999a).  
The other important genotype in the region is called QX. The virus was first isolated 
in China in 1996 and associated with proventriculitis (Wang et al., 1998).  
In Europe, a QX-like (D388) strain was first detected in 2003 in The Netherlands in 
young broiler flock that was suffering from nephritis and respiratory signs (de Wit et 
al., 2011b) then based on RT-PCR survey the QX-like was detected in 2003 in 
Germany (Worthington et al., 2008), and since then it has been detected in Poland, 
Belgium, France and Italy (Beato et al., 2005; Domanska-Blicharz et al., 2006). 
In the UK, IBV QX-like was first isolated from kidneys and caecal tonsils of 
backyard flock (Gough et al., 2008) and from the proventriculus of broiler flocks in 
(Ganapathy et al., 2012). The virus has been associated with nephritis, respiratory 
distress in broilers and false layer syndrome in breeders and layers (Jones, 2010; de 
Wit et al., 2011a). 
Another IBV genotype, Q1, which was genetically and serologically distinct from 
IBV classical strains, was reported in China from 1996 to 1998 (Yu et al., 2001). 
The virus is associated with respiratory disease and proventriculitis in layer 
chickens. Recently, IBV Q1 strain has also been identified in Europe (Italy) (Toffan 
et al., 2011b; Toffan et al., 2013).  
In the Middle East, the IBV Mass, 793B, QX and Dutch strains has been reported 
(Abdel-Moneim et al., 2006; Amin et al., 2012; Boroomand et al., 2012). IBV 
genotypes with certain regional importance such as IBV IS/855/00 (Meir et al., 
2004), and IS/1494/06 were isolated in Israel in 2006 (Meir, R. Personal 
communication, 2012). Later on these strains were also reported in Egypt (Abdel-
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Moneim et al., 2012), Iraq (Mahmood et al., 2011). There are also unpublished 
reports of IBV Q1 detection in Saudi Arabia (K. Ganapathy, unpublished data). 
In Western Asia, respiratory disease outbreaks were investigated in Iraq, Jordan, and 
Saudi Arabia in early 2011. Five IBV isolates (JOA2, JOA4, Saudi-1, Saudi-2, and 
Iraqi) were detected by RT-PCR. These five IBV isolates were found to be of the 
IBV strain CK/CH/LDL/97I, that  is known to have originated in China and Taiwan 
(Ababneh et al., 2012).  
In Eastern Asia, many published reports have revealed the diversity of IBVs causing 
disease in different part of China. But, possibly the most significant IBV variant that 
has emerged from China is the QX variant reported in association with 
proventriculitis (See Europe section), which spread throughout Russia (Bochkov et 
al., 2006) and then appeared in much of Europe (Worthington et al., 2008). IBV Q1 
was first isolated in China (Yu et al., 2001), and the virus has been reported in 
Taiwan (Jackwood, 2012). In Korea, a nephropathogenic strain designated KM91 
was detected in 1990s. The KM91 type seems to be a major IBV circulating in 
Korea (Lee et al., 2004). 
In North Africa, an unusual enterotropic variant, known as IBV G strain was isolated 
in Morocco in the early 1980s (El-Houadfi et al., 1986). Interestingly, S1 sequence 
data have shown that IBV G and 4/91 are very closely related (Jones et al., 2004). In 
Tunisia, three isolates were identified by molecular and VNT and designated 
TN20/00, TN200/01, and TN335/01. These isolate were found  closely related to 
European strains including D274 and 793B (Bourogaa et al., 2009). In Libya, the 
IBV genotype of IS/885/00-like and IS/1494/06-like were detected by RT-PCR in 
broiler flocks (Awad et al., 2014).  
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On the other hand, the major strain of the USA, the Ark strain, has hardly been 
reported outside the USA. In brief, variants of most importance in major parts of the 
world, such as 793B  or QX that have spread over Asia, Europe and Africa in a short 
period have not been reported in the USA or Australasia. It seems likely that 
geographical isolation and control measures employed in countries may play a part 
in preventing entry of IBV variants (de Wit et al., 2011a).  
 
 
I.1.5. Host range  
 
It is accepted that chickens are the most significant natural hosts of IBV (Jackwood 
and de Wit, 2013). However, IBV has also been isolated pheasants in association 
with a history of clinical respiratory disease, reduced egg production (Spackman and 
Cameron, 1983; Gough et al., 1996) or nephritis (Gough et al., 1996). There is more 
evidence which suggests that IBV has a wider host range than was previously 
thought where it is not only limited to galliform birds (Cavanagh, 2007). Mass type 
was detected in pigeons (Columba livia) (Felippe et al., 2010). However, Group 3 
has been detected in geese, duck and pigeon using RNA-sequences (Chen et al., 
2013). Most recently IBV-like viruses were detected by real time RT-PCR in wild 
birds which includes swans, mallards, geese and gulls and most of the detected 
fragment genes seem to be IBV; the most of the frequent lineages of IBV were M41, 
793B and QX (Domanska-Blicharza et al., 2014).  
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I.1.6. Pathogenesis  
I.1.6.1. Trachea  
The trachea is the main site of IBV replication, following which a viraemia occurs 
and the virus get widely disseminated to other tissues. Many studies have shown 
virus replication in ciliated epithelial and mucus-secreting cells of the trachea 
(Yagyu and Ohta, 1990; Nakamura et al., 1991; Owen et al., 1991; Benyeda et al., 
2010) and the virus has been isolated from trachea (Otsuki et al., 1990; Janse et al., 
1994; Lee et al., 2002). Persistence of the virus in the trachea may vary with strain. 
For examples, isolation of strain G has been reported in the trachea up to 14 dpi 
(Ambali and Jones, 1990), while IBV 793B was isolated from the trachea of infected 
SPF chicks for up to 7 dpi (Dhinakar Raj and Jones, 1996a). Some live vaccine 
strains such as the Ark strains  have been shown to persist (28dpi) in the trachea 
especially when administered in combination with Mass strains (Alvarado et al., 
2006).  
 It has been suggested that the tracheal damage in terms of ciliary activity is variable 
since is depends on the virulence of IBV strains for the trachea (Otsuki et al., 1990; 
Dhinakar Raj and Jones, 1997). The severity of the ciliostasis caused by 793B strain 
proved to be the mild, while the effect of M41 was more severe (Benyeda et al., 
2009). IBV strains damage the respiratory epithelium, often predisposing young 
chickens to secondary infections such as E. coli. Experimental infection with 
virulent M41 followed by administration of E. coli produced airsacculitis, 
pericarditis, and perihepatitis, which often observed under field condition 
(Peighambari et al., 2000; Matthijs et al., 2005), while administration of IBV alone 
failed to induce lesions (Peighambari et al., 2000). 
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I.1.6.2. Kidney 
In addition to replicating in trachea, IBV associated with nephritis can also replicate 
mainly in the lower nephron of the kidney down to the collecting duct epithelial 
cells. Evidence shows that the virus replicates in all segments of tubules and ducts, 
but more often in the epithelial cell of the collecting ducts (Cavanagh et al., 1997). 
Importantly, high titres of the virus in kidney do not correlate with overt kidney 
disease. For instance, Moroccan G strain replicates to similar titres in the kidney or 
trachea (Ambali and Jones, 1990).  
I.1.6.2. Oviduct 
IBV can replicate in the epithelium of the oviducts in young chicks (Crinion and 
Hofstad, 1972a) and in laying hens (Jones and Jordan, 1971). Pathogenicity of IBV 
strain for the oviduct varies, as some IBV strains cannot replicate in the oviduct, 
neither causing lesions nor showing significant amount of viral antigens in the 
epithelium cells (Crinion and Hofstad, 1972a). Following infection of day-old chicks 
with IBV M41, virus was isolated between 5 and 11 dpi (Jones and Jordan, 1972) 
and was also found to replicate in the epithelium of the oviducts (Crinion and 
Hofstad, 1972a; Crinion and Hofstad, 1972b; Jones and Jordan, 1972).When laying 
hens were infected with IBV M41, viral antigen was demonstrated in the epithelium 
of the oviducts between 6 and 9 dpi (Jones and Jordan, 1971). 
I.1.6.3. Other tissues 
IBV has also been isolated from a variety of other tissues such as lung, airsacs, 
oesophagus, proventriculus, duodenum, jejunum, liver, spleen, bursa of Fabricius, 
caecal tonsils, ileum, rectum, cloaca, semen and eggs (Cook, 1971; Ambali and 
Jones, 1990; Lucio and Fabricant, 1990; Otsuki et al., 1990; Dhinakar Raj and Jones, 
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1996a) and virus isolation from the Harderian gland (HG) has been reported 
following experimental infection with live attenuated H120 (Toro et al., 1996).  
I.1.7. Gross pathology changes 
 
I.1.7.1. Respiratory tract  
 
Infected chicken have serous or catarrhal exudate in the nasal passages, sinuses and 
trachea. The incidence of nasal exudate in infected chickens has been used to assess 
the severity of disease in different lines of chickens (Parsons et al., 1992). Caseous 
casts may be seen blocking the lower trachea or bronchi which may result in the 
death of bird by asphyxiation. Small areas of pneumonia may be observed in the 
lungs. The air sacs may foamy during the acute infection and then became cloudy 
and contain yellow caseous exudate (Jackwood and de Wit, 2013).  
I.1.7.2. Kidney 
 
The kidneys infected with nephropathogenic IBV are swollen and pale with tubules 
and ureters distended with urates. The kidney weight and kidney asymmetry are 
increased (Cumming, 1963). Despite lack of gross lesions microscopic changes of 
nephritis may still be present (Winterfield and Albassam, 1984).  
I.1.7.3. Oviduct 
Cystic oviducts may be consequences of IBV infection at a very young age (Crinion 
et al., 1971; Crinion and Hofstad, 1972a; Jones and Jordan, 1972; Benyeda et al., 
2009; de Wit et al., 2011b; Ganapathy et al., 2012). Gross changes in the oviduct 
may vary from the presence of a continuous patent but underdeveloped structure to a 
blind sac projecting forward from cloacae (Jones and Jordan, 1972). The middle 
third of the oviduct is the most severely affected with area of localised hyperplasia 
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seen in between normal patent oviducts. Caudal to the hypoplastic regions 
macroscopic cysts filled with a clear serous fluid may be seen (Crinion et al., 1971).  
I.1.7.4. Other tissues 
 
Infection with IBV 793B strain was initially associated with  deep pectoral 
myopathy as another clinical finding in chickens (Gough et al., 1992). IBV serotype 
793B was isolated from a broiler breeder flock which had a bilateral myopathy 
affecting both deep and superficial pectoral muscles. It is characterised by paleness 
and swelling of the deep pectoral muscles with the presence of occasional facial 
haemorrhages (Gough et al., 1992; Dhinakar Raj and Jones, 1996a). 
I.1.8. Histopathology 
I.1.8. 1. Trachea 
The nature of the microscopical changes in the infected chicks caused by IBV is 
similar, but the severity and persistence of the lesions may differ between the IBV 
strains (Benyeda et al., 2010). The trachea of the infected chicks appears 
oedematous with extensive loss of cilia, rounding and sloughing of the epithelial 
cells following infection (Nakamura et al., 1991). Minor infiltration of heterophils 
and lymophocytes may occur within 18 hours following infection. Regeneration of 
the epithelium starts within 48 hours and may be completed by 7-10 dpi. 
Hyperplasia is followed by massive infiltration of the lamina propria by lymphoid 
cells and a large number of germinal centres, which may be present after 7 dpi. 
Increase hetrophils can be observed later with lymphoid nodules and fibroblast 
proliferation (Riddell, 1987).  
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I.1.8. 2.  Kidney  
The kidney lesions of IB are principally those of interstitial nephritis (Riddell, 
1987). The virus cause granular degeneration, vacuolation and desquamation of the 
tubular of the tubular epithelium, and massive infiltration of hetrophils in the 
interstitial acute stage of the disease. Focal areas of necrosis may be seen as well as 
indications of attempted regeneration of the tubular epithelium. During recovery, the 
inflammatory cell population change to lymphocytes and plasma cells. In some 
cases, degenerative changes may persist and result in severe atrophy of one or all of 
the divisions of the kidneys. In urolithiasis, the ureters associated with atrophied 
kidneys are distended with uretes and often contain large calculi composed mainly 
of urates (Riddell, 1987). 
I. 1.8. 3. Oviduct 
Experimental IBV infection of the oviduct of adult hens showed decrease height and 
loss of the epithelial cells, dilution of the tubular gland and infiltration by 
lymphocytes, plasma and hetrophils especially around the blood vessels. Oedema 
and fibroplasias of the submucosa of the oviduct have been observed (Crinion et al., 
1971). Oviduct cysts were observed following IBV M41 infection and microscopic 
cysts wall was thin, but had an intact internal layer of ciliated epithelium (Crinion et 
al., 1971). However, the virus serotypes varied in their ability to produce 
histopathological changes in the oviduct. Two serotypes, Conn and Iowa 609, failed 
to produce any pathological change. IBV M41 serotype produced the greatest 
number of changes, followed by Australian T (Crinion and Hofstad, 1972a).  
However, if young chicks without maternally derived antibody (MDA) become 
infected, the damage to the oviducts was found to be more severe and permanent 
(Crinion et al., 1971). 
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I.1.9. Immune responses 
The immune response to IBV infection can be divided into local, humoral and 
cellular.  
I.1.9.1. Local immunity  
 
The importance of locally produced antibodies in the defence of mucosal surfaces 
against IBV infections has been well documented (Gomez and Raggi, 1974; 
Nakamura et al., 1991; Dhinakar Raj and Jones, 1996a; Dhinakar Raj and Jones, 
1996c). Trachea being the main target organ of IBV, IgG, IgM and IgA in that organ 
have been demonstrated (Nakamura et al., 1991). Following infection with virulent, 
IBV specific IgG and IgA have been detected in tears, tracheal washes, oviduct 
washes, duodenal and caecal contents using class-specific monoclonal antibodies in 
enzyme-linked immunosorbent assay  (ELISA) (Hawkes et al., 1983; Dhinakar Raj 
and Jones, 1996c; Ganapathy et al., 2005b; Meir et al., 2012) and in HG using 
enzyme linked immune-spot forming (ELISPOT) (van Ginkel et al., 2008). IBV 
specific IgM was also detected in the tracheal, lung and kidney section of infected 
chickens using immunohistochemistry (IHC) (Dhinakar Raj and Jones, 1996a). 
Following infection, from 7 to 21 dpi, high level of the IgG, IgM and IgA cells were 
detected in the trachea (Nakamura et al., 1991). IBV-specific IgA and IgM secreting 
cells response in the HG increased following IBV infection (van Ginkel et al., 2008). 
The removal of the HG resulted in a decreased level of protection against IBV 
infection in day-old vaccinated chicks (Davelaar and Kouwenhoven, 1980). IgG and 
IgA levels in tears appear a good correlates of protection against IBV or indicative 
of effective immunisation, induced by attenuated IBV vaccines (Okino et al., 2013). 
However, the level of IBV-specific IgG, IgM and IgA varies in the different types of 
chicken lines (Nakamura et al., 1991).   
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I.1.8.2. Humoral immunity 
 
In the early studies the antibody response to IBV was described in terms of levels of 
neutralizing antibodies and HI antibodies (Raggi and Lee, 1965; Cowen et al., 1971; 
Davelaar and Kouwenhoven, 1977; Gough and Alexander, 1979). The development 
of IBV specific ELISAs and IHC techniques enabled a more detailed analysis of 
IBV-specific antibodies and their distribution in different chicken tissues (de Wit et 
al., 2011a).  
IgM is the first antibody detected in serum after IBV infection (Gillette, 1974). Its 
concentration is maintained in blood for a shorter period than other antibody classes 
following administration of a virulent (Mockett and Cook, 1986) or an attenuated 
IBV (Martins et al., 1991). Following infection with IBV M41, significant amounts 
of IgM were detected in serum between 5 to 18 dpi with highest titres at 8 to 10 dpi 
and then gradually decline until they became undetectable by 21 dpi (Mockett and 
Cook, 1986). The IgM response in serum correlated with the protection to challenge 
with IBV M41 in chickens (De Wit et al., 2010b). Thus, IBV specific IgM 
antibodies in serum can serve as an indication for a recent IBV infection (Mockett 
and Cook, 1986) or efficacy of IBV vaccinations (De Wit et al., 2010b).  
IgG, the major circulating Ig, is the antibody detected by HI and an ELISA 
developed to measure it is more sensitive (Mockett and Darbyshire, 1981). Anti-IBV 
IgG can be detected as early as 3dpi, reaches a peak at about 21 days but can remain 
in high titre in the serum for many weeks (Mockett and Darbyshire, 1981). After 
reinfection, IgG levels in sera were much higher than those observed in the primary 
infection response. IgG persisted for a longer period than IgM following IBV 
infection (Mockett and Cook, 1986). This is the antibody measured in conventional 
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serological tests to monitor IBV infections or vaccine uptake (Dhinakar Raj and 
Jones, 1997). 
A previous study has reported the differences in the humoral antibody response 
following vaccination and it related to vaccination dose and application route. 
Application of different dose of live H120 vaccine resulted in a dose-related IgA 
response in the lachrymal fluid (Toro et al., 1997). 
Higher IgG levels in lacrimal fluid were detected by ELISA following vaccination 
by the ocular route as compared with vaccination via the drinking water or cloaca. 
All routes of vaccination tested resulted in an increase of specific IgA in lacrimal 
fluid following vaccination (Toro et al., 1997). 
MDA can provide protection against IBV infection at one day and one week but not 
two weeks (Mockett et al., 1987). It has been shown that chicks hatched with high 
MDA had excellent protection against IBV infection at day old of age but not one 
week (Mondal and Naqi, 2001). However, the presence of MDA at the time of the 
vaccination or infection can delay and decrease the serological response to 
vaccination or infection (de Wit, 2000). It has been reported that vaccination of 
1-day-old chicks did not result in antibodies detectable by VN test, in contrast to 
vaccination of 6 to 20 day old hens (Davelaar and Kouwenhoven, 1977).  
I.1.9.3. Cellular immunity 
 
Infection of IBV leads to the induction of both humoral and cell mediated immune 
(CMI) response (Mockett and Cook, 1986; Martins et al., 1991; Collisson et al., 
2000). Although humoral immunity to IBV in the systemic immune compartment is 
important, it does not correlate with protection against IBV (Raggi and Lee, 1965; 
Darbyshire and Peters, 1985). The CMI response is critical in the recovery from IBV 
infections (Collisson et al., 2000). CD4+ and CD8+ were shown in section of  
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trachea, lung and kidney following infection with virulent IBV 793B (Dhinakar Raj 
and Jones, 1996a). The CD4+ and  CD8+ response were detected as early as 3dpi 
and peaked at 10 dpi and begins to decline at the same time the viral load starts to 
decline and the IgG humoral response appears (Seo et al., 1997).This indicates that 
the CMI response may be an early stage response to IBV infections (Seo and 
Collisson, 1997).  
However, varying results have been reported for the CD4+ and CD8+ functions in 
the immunotherapy. CD8+ cells are critical in controlling many virus infections 
(Whiteside et al., 1993; Pei et al., 2003). It was demonstrated that adoptive transfer 
of IBV specific CD8+ memory T cells collected from infected birds between 3 to 6 
weeks post infection were able to protect chicks from IBV infection (Pei et al., 
2003). The IBV-specific cytotoxic T cells (CTL) collected from spleen within the 
period where CTL response was declining, did not protect against IBV presumably 
due to the rise in number of apoptotic cells and at later time points after memory 
cells had been established, 3 to 6 weeks post infection, those CD8+ T cells were 
protective against infection (Pei et al., 2003). Adoptively transferred CD4+ cells do 
not seem to be important in initially resolving IBV infection in the chicken (Seo et 
al., 2000), but for long term virus control CD4+ and B cells were also required 
(Reddehase et al., 1988; Thomsen et al., 1996). These observations demonstrate the 
importance of a better understanding of the CMI response following IBV 
vaccination in chickens. To date, little information is available regarding the CMI 
responses following IBV vaccination. Okino et al. (2013) reported expression of 
various cytokine genes in the trachea after vaccination with different doses of live 
H120 vaccine. Their result showed that vaccinated birds were protected against M41 
infection and the protection depends on the levels of CMI responses.  
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I.1.10. Diagnosis  
 
I.1.10.1. Isolation of the causative agent 
To isolate IBV from infected birds, OP, tracheal or cloacal swabs can be collected 
especially within the first week of the infection. Samples of trachea, lungs and 
caecal tonsils can be collected during post mortem examination, which can be of 
particular value in cases in which more than one week may have elapsed since the 
start of infection. Samples of the kidney and oviduct should be considered 
depending on the clinical history of the disease (Jackwood and de Wit, 2013). 
Samples collected from the swabs or organs can be used for inoculation of 10-day 
old SPF ECE (Hitchner and White, 1955), TOC (Cook et al., 1976) or  primary 
chicken kidney cell culture (Otsuki et al., 1979). Procedures for the VI in ECE or 
TOC have been described in detail in Chapter 2. 
I.1.10.2. Detection of IBV antigens  
I.1.10.2. 1.  Agar gel precipitation test  
The agar gel precipitation test (AGPT) can be used for the detection of IBV antigen. 
The test is very cheap, fast and requires few laboratory facilities, but is relatively 
insensitive (de Wit, 2000). For best results, several antisera at different dilutions 
should be used, to prevent false negative results caused by imbalance of the antigen 
(Lohr, 1981). In recent decades, this test is rarely used.  
I.1.10.2. 2.  Immunofluorescent assay  
 
The immunofluorescent assay (IFA), which requires an ultraviolet microscope, is a 
relatively cheap and fast technique for detecting IBV antigen in chickens, eggs, 
TOCs and cell culture. The IFA is group-specific when using group-specific 
monoclonal antibodies (Mabs). When using type specific Mabs, the IFA can be a 
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type-specific test (De Wit et al., 1995). When using the IFA directly on the tissue 
from field material, the sensitivity can vary from equal to or much less than VI. 
However, the sensitivity of the IFA is usually lower than that of VI, especially in the 
later stages of the infection (de Wit, 2000). Similar to AGPT, this test is not 
commonly used other than for research work.  
I.1.10.3. Detection of IBV genome  
RT-PCR can been used to detect the presence of viral genome. This method can be 
applied directly to samples obtained from infected chickens, but more often the virus 
is first propagated in in vitro  to increase viral load and  improve sensitivity of the 
test (de Wit, 2000; Jackwood and de Wit, 2013). Viral RNA extracted from samples 
can be subjected to RT-PCR with primer pairs that are specific for whole or part of 
the genome. Primer pairs are designed from hypervariable regions in the S1 gene 
that are specific for the different IBV strains. Primers specific for IBV serotypes 
Mass, Conn, Ark, JMK, DE and California (CA/633/85) (Keeler et al., 1998),793B, 
D274 and D1466 (Cavanagh et al., 1999) have been reported. Universal 
oligonucleotide primers corresponding to the S1 gene are available and designed to 
work with many types of IBV (Adzhar et al., 1996; Worthington et al., 2008).  
Detecting the presence of IBV genome using RT-PCR methods requires additional 
steps such as sequencing the PCR product, subjecting the DNA to restriction enzyme 
fragment length polymorphism (RFLP) or hybridization using IBV specific probes 
(Binns et al., 1985; Jackwood et al., 1992; Moore et al., 1998). Another method for 
detecting IBV genome is through the use of nested RT-PCRs, which is more 
sensitive than the conventional RT-PCR (Cavanagh et al., 1999). In this approach a 
second amplification step is added using DNA produced from the first PCR. The 
primers used in the nested PCR would only amplify part of the original product. This 
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method is rarely used due to the high sensitivity and the increased possibility of false 
positive results from contaminations (de Wit, 2000; Jackwood and de Wit, 2013). 
However, positive RT-PCR result is not sufficient for diagnosis, sequences of the 
RT-PCR product should compared with the corresponding sequences of the vaccine 
strains (Jackwood and de Wit, 2013). 
I.1.10.4. Strain classification 
Using in vivo or in vitro methods, IBV can be classified into three major groups, i) 
serotype, ii) genotype and iii) protectotype. 
I.1.10.4. 1. Serotype 
 
Conventionally serotyping has been performed by VNT in various biological 
substrates (See VNT below). Serotyping has also been conducted by HI (Toro et al., 
1987). Some laboratories have used MAbs that corresponding to epitopes formed by 
the S1 protein. Within the S1 region of the spike gene, there are epitopes which 
defines the different strains of viruses. These epitopes are common only within those 
groups of viruses and therefore induce type specific antibodies (Niesters et al., 1987; 
Cavanagh et al., 1988; Moore et al., 1997). In the VNT, the antibody binds to type 
specific antigens and neutralizes the virus while in HI tests the serum prevents 
agglutination of chicken red blood cell (RBC). Though these tests are used to detect 
serotype specific epitopes, cross-reactions may occur between serotypes especially 
when sera is collected from field samples (Jackwood and de Wit, 2013). VNT and 
HI are not commonly used for serotyping because of the limited availability of the 
increasing number of reference sera, corresponding to different serotypes, which 
required for analysis. In the last two decades, more than serotyping, laboratories are 
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using RT-PCR to produce DNA copies of IBV gene followed by DNA sequences 
and genotyping (Jackwood and de Wit, 2013). 
I.1.10.4. 2. Genotype  
 
Classifying IBV strains based on genotype has become the method most widely used 
for IBV typing (Jackwood et al., 1992; Cavanagh et al., 1999; Lee et al., 2000), and 
it replaced HI and VN serotyping for determining the identity of a field strain 
(Jackwood and de Wit, 2013). This method involves using RT-PCR techniques to 
amplify parts of the viral genome, mainly the S1 gene, followed by DNA sequencing 
or  RFLP (Lin et al., 1991). The information obtained from these procedures has 
been used widely in molecular epidemiology studies (de Wit, 2000). Unfortunately, 
the correlation between genotype and serotypes in IBV strains has been 
contradictory; while several authors have been reported high correlation (Kwon et 
al., 1993; Keeler et al., 1998). A number of reports by others has shown conflicting 
results (Kusters et al., 1987; Capua et al., 1999). Therefore, the use of genotyping as 
the only tool is not recommended and conventional testing such as serotyping and in 
vivo studies should be paired with genotyping in order to corroborate the results 
obtained (de Wit, 2000).    
I.1.10.4. 3. Protectotype  
 
Protectotypes provide information about the efficacy of vaccines. Strains inducing 
protection against each other belong to the same protectotype (de Wit, 2000). 
However, live H120 vaccine was shown to induce protection against challenge from 
the Australian T strain (Darbyshire, 1985), even though VNT suggested that they are 
not serologically related (Darbyshire et al., 1979). Protectotype classification is 
useful because it reduces the large and growing number of serotypes to a smaller 
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group of protectotypes so that when considering the types of vaccines to use in the 
field one protectotype may serve the purpose of several vaccine strains (de Wit, 
2000). For determining the protectotype of a strain, a cross-immunization study has 
to be performed and this is labour intensive, expensive and requires many animals 
and isolation facilities (de Wit, 2000). Alternatively, cross-immunization test have 
been done using TOCs (Lohr et al., 1991; Dhinakar Raj and Jones, 1996d) and 
oviduct organ cultures (OOCs) (Dhinakar Raj and Jones, 1996d) prepared from 
vaccinated chickens. These cultures were challenged in vitro with homologous and 
heterologous viruses to assess tracheal and oviduct cross-immunity. Cross protection 
was seen between serologically related and unrelated viruses (Dhinakar Raj and 
Jones, 1996d). At the tracheal level, it was seen that H120 and M41 belonged to the 
same protectotype as expected. However, serologically unrelated viruses (D274 and 
793B) also belonged to same protectotype (Dhinakar Raj and Jones, 1996d), despite 
a 21% variation in the amino acid sequences of the S1 gene of these viruses (Adzhar 
et al., 1995). Protectotype has been also seen between Australian T strain and New 
Zealand A strains of IBV, which are serologically unrelated (Lohr et al., 1991). 
However, when the challenge is performed in chickens, the whole immune system is 
available, whereas this is not the case in the TOCs (de Wit, 2000).  
I.1.10.5. Amino acid analysis 
 
The amino acid sequences of viral proteins is a very useful instrument to help locate 
conserved domains in proteins which might be essential for their structure and 
function, and for epidemiological studies (de Wit, 2000). Sequencing can be 
performed on any part of the genome, but is most usually performed on a selected 
part of the S protein gene (Keeler et al., 1998; Cavanagh et al., 1999), but sometimes 
on the M gene (Cavanagh and Davis, 1993) or N gene (Williams et al., 1992). Based 
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on sequence data, a phylogenic tree can be made, revealing the genomic relatedness 
between different strains. 
I.1.10.6. Detection of IBV antibody 
 
I.1.10.6. 1.  Virus neutralization test  
 
The VNT is the gold standard test for the detection of IBV serotype-specific 
antibodies (de Wit, 2000). The test can be performed in various biological substrates 
including ECE (Davelaar et al., 1984; Gelb et al., 1989; Gelb et al., 1991), cell 
culture (Hopkins, 1974) and TOCs (Darbyshire et al., 1979; Cook, 1984). However, 
lack of standardization between the different VNT systems and users makes it 
difficult to compare results between laboratories (de Wit, 2000). 
I.1.10.6. 2.  Haemagglutination inhibition test 
 
HI test is considered to be strain-specific (King and Hopkins, 1983; Monreal et al., 
1985; de Wit et al., 1997). This may limit the use of the HI test to monitor vaccine 
response. The HI test with strain M41 as antigen performed poorly when used to 
detect antibodies following vaccination with H120 compared to  using H120 antigen 
(de Wit et al., 1997). Terrigeno et al. (2008), vaccinated birds with Mass and 793B 
types and then did the HI against M41, 793B, 624/I, It-02 and QX. The HI response 
to heterologous antigens was lower, compared to homologous antigens. Procedures 
of preparation of IBV HA antigens and HI test are described in Chapter 2.  
I.1.10.6. 3.  Enzyme-linked immunosorbent assay 
    
The ELISA assay is a convenient method for monitoring of both the immune status 
and virus infection in chicken flocks (de Wit et al., 1997). Several commercial 
ELISA kits for IBV specific antibodies detection are already available. Antibody 
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titres obtained by ELISA were considerably higher than those obtained by HI (de 
Wit et al., 1997) or VN (Marquardt et al., 1981). Two serum samples are required, 
one at the first sign of infection and one a week or more later; delay of the first 
sampling can prevent detection of seroconversion (Jackwood and de Wit, 2013). The 
use of two different commercial ELISA kits is described in Chapter 2.  
 
I.1.11. Vaccination  
 
Vaccination and good management practices help in controlling the spread of viral 
infections. Both live attenuated vaccines and inactivated vaccines are used in IB 
immunization programmes in broilers and breeders (Jackwood and de Wit, 2013). 
Live viruses used as vaccines have been attenuated by successive passage in ECE 
(Klieve and Cumming, 1988). However, extensive passage is avoided to prevent 
reduction in immunogenicity. The decrease in immunogenicity adversely affects the 
protection offered by the vaccine against the challenge. However, the immunity 
induced by live IBV vaccines depends on the replication of the virus in the tissue of 
the host (Jackwood and de Wit, 2013). Evidence suggests that some of IBV vaccines 
(e.g. Connaught and Ark vaccine strains) increase in virulence after back passage in 
chickens, demonstrating the potential for enhancement of the virulence of such 
vaccines by a cyclic infection in a flock (Hopkins and Yoder, 1986). 
The serotypes variation of IBV is due to high point mutation or recombination 
(Cavanagh et al., 1986b). IBV mutations and recombination may be associated with 
some management practices like high density, multi-age flock with different 
antibody levels, different vaccination programmes and methods of application (Gelb 
et al., 1991). The mutations are natural mechanisms of the defence of the virus to 
avoid the defensive mechanism of chicken immune system. These results in 
emergence of variant strains that may have new neutralizing epitopes that may not 
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be recognized by the antibodies exerted by the use of current vaccines (Gelb et al., 
1991). The emergence of multiple serotypes or genotypes has led to the production 
of different vaccines or vaccination strategies in different countries, depending on 
the prevalent serotypes, in order to obtain optimal protection.  
The appropriate strategy for control of IBV is to use vaccine strains that are similar 
to those found in a particular area. In areas where this is not possible or where there 
were no vaccines available for the prevalent strains, vaccination with different 
serotypes either sequentially or simultaneously provides better protection against 
challenges with several heterologous strains than vaccination with a single serotypes 
(Cook et al., 1999a; Alvarado et al., 2003; Martin et al., 2007; Terregino et al., 2008; 
de Wit et al., 2011b).  
For example, in the USA, Mass types, Conn, JMK, Ark and Cal99 are currently used 
for vaccination programme (Gelb et al., 1989; Alvarado et al., 2003; Martin et al., 
2007). Vaccination using the live Ark strain is widespread within the USA and 
offers good protection against circulating field strains of Ark type (Sander et al., 
1997) but has not eliminated the strain from the poultry population (Nix et al., 
2000). When combined with Mass type the vaccine has been shown to offer good 
cross protection against other strains of IBV including Conn, JMK, M41, Ark DPI 
and other variant strains (Gelb et al., 1991; Gelb et al., 2005).    
In Europe and Asia, the Mass types, 793B (4/91 and CR88) and D274 vaccines are 
used (Cook et al., 1999a; Terregino et al., 2008; de Wit et al., 2011b). In some 
counties in Asia, vaccines based on the local strains have been used widely (Lin et 
al., 2005; Lee et al., 2010).   
Combination of two serologically different vaccines (e.g. Ma5 and 4/91) have been 
shown to give wide immunity against many heterologous strains (Cook et al., 1999a; 
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Cook et al., 2001a; Terregino et al., 2008), and this vaccination protocol was found 
more effective than revaccination with a vaccine of the same serotype as the first 
vaccine (Cook et al., 1999a). Live vaccines combinations of IBV with NDV or 
aMPV or infectious laryngotracheitis virus (ILTV) have been used in the vaccination 
programme. However, it has been shown that IBV interference with the replication 
of attenuated aMPV, although it did not prevent the induction of protective immune 
responses by the aMPV (Cook et al., 2001b). Quantitative RT-PCR was successfully 
used to evaluate the replication interference potential of IBV and NDV after 
vaccination of chickens with live vaccines administered together either in 
manufactured combinations or single entity preparations (Gelb et al., 2007). 
Protection induced by combined ILTV and IBV, the results indicate that IBV did not 
interfere with the protection induced by ILTV vaccine (Vagnozzi et al., 2010).  
Experimental administration of live IBV vaccine can be performed individually  by 
oculonasal (Cook et al., 1999a) or intratracheal routes (Yachida et al., 1986). In the 
field the live vaccines are usually applied by mass application methods include 
coarse spray aerosol, and drinking water (Jackwood and de Wit, 2013). Mass 
administration methods are popular because of convenience, but problems in 
attaining uniform vaccine application can occur, and the aerosol method may cause 
more severe respiratory reactions. Broiler are most commonly vaccinated with live 
IB vaccine at one day old in the hatchery and then revaccinated with same or 
different serotype at 10-18 days of age (Jackwood and de Wit, 2013).  
Inactivated oil-emulsion IBV vaccines are commonly used to obtain long-lasting 
immunity to protect breeders and layers prior to the onset of the egg production 
(Cavanagh, 2003). Single applications of inactivated virus induce little or no 
protection against egg loss (Muneer et al., 1986; Cavanagh, 2003), and no protection 
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against loss of ciliary activity in the trachea (Martins et al., 1991). Significantly  
higher protection against the infection has been observed when birds are vaccinated 
at least twice with inactivated IBV(Gelb et al., 1989). The common approach in the 
poultry industry is to vaccinate young females with live vaccines two or more times, 
followed by one dose of inactivated vaccine before the birds come into lay. 
However, the efficacy of inactivated vaccines depends on the proper priming with 
live vaccines (Cavanagh, 2003; Jackwood and de Wit, 2013). Inactivated vaccines 
are given individually by intramuscular or subcutaneous injections for induction of 
high levels of humoral antibodies, which will protect the oviduct of the birds against 
circulating IBVs and avoids drops in egg production or quality. Such vaccination in 
breeder birds helps in ensuring transfer of high and uniform levels of MDA to 
hatching chicks (Jackwood and de Wit, 2013). MDAs are important in conferring 
some protection against of virulent IBVs (Davelaar and Kouwenhoven, 1977; 
Mondal and Naqi, 2001). 
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Part II: Avian metapneumovirus 
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II.1.1 History 
 
Avian metapneumovirus was first isolated in 1978 from sinus exudates of turkeys in 
South Africa (Buys et al., 1989). Subsequently, aMPV isolations were reported in 
the UK in 1985 (Anon, 1985) , Germany (Hafez et al., 2000), France (Picault et al., 
1987), Israel (Banet-Noach et al., 2005) Brazil (Chacón et al., 2011). Apart from 
Australasia, all major poultry rearing regions of the world have reported the 
presence of aMPV infection (Jones and Rautenschlein, 2013). It is also referred to as 
turkey rhinotracheitis virus (TRTV) or avian rhinotracheitis virus (ARTV). 
 
II.1.2. Aetiology 
II.1.2.1. Classification  
 
Avian metapneumovirus is one of the two viral species, with human 
metapneumovirus (hMPV), belonging to the Metapneumovirus genus; 
Metapneumoviruses are part of the subfamily Pneumovirinae within the 
Paramyxoviridae family, including single stranded, negative sense RNA, and 
enveloped viruses (Pringle, 1998; Jones and Rautenschlein, 2013). 
II.1.2.2. Morphology  
 
Negative staining electron microscopy, aMPV appears as highly pleomorphic 
fringed particles ranging from 50 nm to more than 200 nm in diameter. These are 
frequently spherical, but often appear in long filamentous form, over 1000 nm in 
length, particularly in preparations from organ culture propagation. Their 
nucleocapsids have a helical shape and on the envelope surface projections of about 
13-14 nm are clearly distinguishable (Cook and Cavanagh, 2002; Jones and 
Rautenschlein, 2013). 
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II.1.2.3. Genome  
 
The virus genome is non-segmented and composed of single stranded negative sense 
RNA of approximately 14 kb (Jones and Rautenschlein, 2013). The virus has the 
following genes: Nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), 
second matrix (M2), small hydrophobic (SH), surface glycoprotein (G) and viral 
RNA-dependent RNA polymerase (L), flanked by a leader and trailer at the 3′ and 5′ 
ends, respectively (Ling et al., 1992; Easton et al., 2004). 
II.1.2.4. Virus attachment, entry and replication 
 
The G protein enables virus attachment on the cell receptors, while F promotes the 
fusion of the envelope with the cell membrane; the nucleocapsid is then released in 
the cytoplasm, where aMPV replication occurs (Easton et al., 2004). aMPV follows 
the generally accepted replication and transcription models for other 
Mononegavirales (Fearns et al., 2002). Negative single stranded RNA viruses 
require the ribonucleic complex both for transcription and replication. This means 
their genome needs to be encapsidated with N, P and M2 protein together with the 
viral polymerase to initiate the infectious cycle (Jones and Rautenschlein, 2013).  
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II.1.3. Subtypes of aMPV 
 
Avian metapneumovirus is classified into four subtypes based on nucleotide and 
deduced amino acid sequence data (Pringle, 1998). Subtype A (aMPV/A) and B 
(aMPV/B) are prevalent in Europe and a number of other countries (Cook, 2000; 
Juhasz and Easton, 1994). Subtype C (aMPV/C) ( Colorado)  was isolated in USA 
(Seal, 1998), France (Toquin et al., 1999), Korea (Lee et al., 2007), and more 
recently isolated from chickens in China (Wei et al., 2013). A phylogenetic study 
revealed that subtypes A and B were more closely related to each other than to 
subtype C (Seal, 1998). Subtype D (aMPV/D) isolated in France showed a low G 
gene sequence identity with aMPV A , B and C subtypes (Bäyon-Auboyer et al., 
2000). Sequence data have revealed that hMPV is more closely related to subtype C 
than to the other subtypes (Toquin et al., 2003). In addition, when the four subtypes 
were compared in the phylogenetic analysis, subtype A, B and D were more closely 
related to each other than to subtype C (Bäyon-Auboyer et al., 2000).        
 
II.1.4. Host range  
 
Natural hosts of aMPV are turkeys and chickens (Cook, 2000). However, guinea 
fowl and pheasants have been shown to  be susceptible to the infection (Gough et al., 
1988). Antibodies to aMPV  have been detected in farmed ostriches in Zimbabwe, 
although no virus was isolated (Cadman et al., 1994). aMPV has been detected by 
RT-PCR and occasionally isolated form  nasal turbinates of sparrows, ducks, geese, 
swallows, gulls and starlings sampled in the North Central Region of the United 
States and shown to be closely related to subtype C viruses isolated from 
commercial turkeys (Shin et al., 2000b; Shin et al., 2002a; Bennett et al., 2004; 
Bennett et al., 2005). There have also been reports of aMPV/C isolated from  
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pheasants in Korea  (Lee et al., 2007), Muscovy ducks (Sun et al., 2014) and  
chickens in China (Wei et al., 2013). In Brazil, subtypes A and B have been detected 
in wild birds and pigeons (Felippe et al., 2011). 
 
II.1.5. Virus transmission  
 
Bird-to-bird transmission within flocks seems to occur by direct contact and 
inhalation of virus-infected respiratory secretions (Cook et al., 1991b; Mcdougall 
and Cook, 1986). Epidemiological studies indicate that migratory birds may play a 
critical role in viral transmission in different geographic regions (Cook, 2000; Shin 
et al., 2000b; Bennett et al., 2004). There is no published evidence that aMPV can be 
vertically transmitted (Jones and Rautenschlein, 2013), even though high level of 
virus can be detected in the reproductive tract of laying  turkeys (Jones et al., 1988). 
 
II.1.6. Pathogenesis in chickens 
 
Relatively few experimental studies with aMPV had been done in chickens (Jones et 
al., 1987; Majó et al., 1995; Catelli et al., 1998; Aung et al., 2008). The virus targets 
the ciliated columnar epithelium of the upper respiratory tract and induces 
inflammatory lesions in the nasal turbinate, trachea, infraorbital sinuses between 3 to 
14 dpi (Majó et al., 1995; Catelli et al., 1998) and can be re-isolated from nasal 
secretion, nasal turbinate, sinus tissue, trachea to 5 or 14 dpi (Catelli et al., 1998). 
However, occasionally aMPV can reach the lungs and the air sacs (Cook et al., 
1993; Catelli et al., 1998; Van de Zande et al., 1999). Bacterial co-infection such as 
E. coli (Al-Ankari et al., 2001), Bordetella avium (Jirjis et al., 2004) and  
Mycoplasma gallisepticum (Naylor et al., 1992) seem to facilitate viral penetration a 
long lower respiratory tract and to enhance the virus distribution in infected birds. It 
is still not clearly understood how the virus can infect other organs outside the 
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respiratory system, but aMPV detected in the reproductive tract (Jones et al., 1988), 
HG (Khehra and Jones, 1999; Aung et al., 2008) spleen, caecal tonsil and bursa of 
Fabricious (Aung et al., 2008). No clear differences have been found in the 
pathogenesis among different subtypes and the different results could be related to 
the virulence of the single strain rather than to the subtype (Van de Zande et al., 
1999; Aung et al., 2008).  
 
II.1.7. The disease in chickens 
 
In chickens the role of aMPV as a primary pathogen was until quite recently 
questioned and infection may not always be associated with clinical signs (Jones and 
Rautenschlein, 2013). It is well known that aMPV can infect chickens and induce a 
specific antibody response (Wyeth et al., 1987) and the chickens have been 
experimentally infected with aMPV (Jones et al., 1987; Cook et al., 1993; Catelli et 
al., 1998). However, the disease in turkey is characterized by prominent respiratory 
signs and in breeder turkey flocks infection causes loss of eggs production (Jones, 
1996). In contrast to disease in the turkey, uncomplicated infection in the chicken is 
frequently so mild that in may go unnoticed unless perhaps SHS develops (Jones, 
1996). Decrease in egg production and increase of abnormal eggs due to 
malformation of egg shell were observed in experimentally infected chicken 
(Sugiyama et al., 2006). The virus plays a role in the complex disease, SHS, which 
characterized by apathy and swelling of the face and infraorbital sinuses. Cerebral 
disorientation, torticollis and opisthotonus frequently follow (O'Brien, 1985; 
Pattison et al., 1989). The morbidity for SHS is often less than 4 %, but respiratory 
signs are often widespread in the flock. The mortality is low, usually not more than 2 
% (Cook, 2000). 
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However, aMPV is not the only agent associated with SHS (See above, I.1.2). It had 
been difficult to produce SHS in chickens under experimental conditions with 
typical signs of swollen sinuses that had been observed in field outbreak (Jones et 
al., 1987; Majó et al., 1995; Catelli et al., 1998; Al-Ankari et al., 2001). Aung et al. 
(2008) reported that aMPV subtypes A and B of turkey origin were pathogenic for 
broiler chickens, and induced swelling of periorbital sinuses and histopathological 
lesions in upper respiratory tract.  
 
II.1.8. Immunity  
 
MDAs are passed from hens to their progeny, but their role does not seem to be 
important as the virus may infect birds with high levels of circulating MDA in 
turkeys (Naylor et al., 1997a) and chickens (Catelli et al., 1998). aMPV MDA do not 
interfere with early vaccination, allowing young chicks to be immunized in early 
stages (Cook et al., 1989b). Chickens develop high aMPV serum antibody levels at 
about 2 weeks post infection (Picault et al., 1987; Cook et al., 1993). The virus may 
induce an antibody response in chickens without obvious clinical signs (Gough et 
al., 1988). The antibody responses seem to be lower in chickens as compared to 
turkeys after infection with vaccine or virulent aMPV strains (Cook et al., 1993; 
Cook and Cavanagh, 2002).Vaccinated turkey poults without a detectable antibody 
response were protected against challenge with virulent aMPV (Jones et al., 1992). 
In chickens, no antibodies response to aMPV vaccine, were detected in spray or 
drinking water vaccinated chicks but increasing level in the oculo-oral group were 
observed. Despite these differences, all vaccinated  birds were protected against the 
challenges with virulent aMPV (Ganapathy et al., 2010). Humoral antibody levels 
are not associated with protection against infection. Instead, the local and cellular 
immunities have been shown to play the major role in protection against disease and 
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virus clearance (Jones et al., 1992; Ganapathy et al., 2005a). Vaccinated turkey 
poults, which had been B cell depleted by cyclophosphamide treatment did no 
seroconvert, but were still protected against challenge with virulent aMPV (Jones et 
al., 1992). Infected broilers chicks with virulent aMPV subtype A and B showed a 
clear CD4+ T cell accumulation in the HG at 6 dpi and the specific IgA-ELISA and 
VN-antibody levels in tracheal washes decreased by 10 and 14 dpi, respectively 
(Rautenschlein et al., 2011).Vaccination of 1 day-old SPF chicks with live 
attenuated strains stimulates the release of aMPV-specific IgA in the lachrymal fluid 
after 14 dpv (Ganapathy et al., 2005a). A study has shown that following respiratory 
exposure to aMPV subtype C, there was an increase of IgM, IgG and IgA cells in the 
respiratory mucosa (Cha et al., 2007).  
 
II.1.9. Diagnosis 
 
II.1.9.1. Virus isolation  
 
Isolation of aMPV has proven to be extremely difficult because the virus has a 
fastidious nature and VI attempts from clinical cases often result in contamination 
with secondary organisms (Worthington et al., 2003). VI from chickens appears to 
be more difficult than from turkeys and the reason for this is not understood (Jones, 
1996). However, the best material source is from nasal secretions or tissue scraped 
from the sinuses of affected birds obtained within 6 to7 dpi (Gough et al., 1988; 
Cook and Cavanagh, 2002; Worthington et al., 2003). Difficulty may be found in 
isolating virus beyond 6 to 7 dpi and this may be only 3 days after the onset of 
clinical signs (Jones, 1996).TOCs of turkeys and chickens were extensively used to 
isolate subtypes A and  B in Europe (Cook and Cavanagh, 2002). However, the TOC 
system was not suitable for the isolation of subtype C (Cook et al., 1999b). Instead, 
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multiple blind passages in chicken embryo fibroblasts (CEF) were successfully used 
in the primary isolation of aMPV subtype C (Shin et al., 2002b).  
TOC are prepared from tracheal rings of chicken (19 -20 day old) or turkey (8-10 
day old) embryos (Cook et al., 1976; Mcdougall and Cook, 1986). After inoculation 
strains of aMPV subtype A and B cause ciliostasis at 6 to 10 dpi. The virus titre peak 
is reached at 3 to 5 dpi (Cook et al., 1991b). Procedure of aMPV isolation is 
described in Chapter 2. 
II.1.9.2. In vitro adaptation of aMPV to cell cultures 
 
Primary avian cell cultures, namely CEF (Goyal et al., 2000), chicken embryo liver 
cells (CEL) (Baxter-Jones et al., 1989; Williams et al., 1991) and the mammalian 
VERO cell line (Williams et al., 1991) can readily be used to adapt any aMPV field 
strain to the cell culture system. A primary isolation of either subtypes of aMPV can 
also be conducted in cell culture, such as in VERO cells. This method is even less 
laborious than isolation in the two host systems described above (Toquin et al., 
2006; Guionie et al., 2007).  
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II.1.9.3. Serology  
 
Extensive efforts have been made on the development of serological methods for 
detection of aMPV-specific antibodies. Although methods like VNT and indirect 
immunofluorescence tests exist (Baxter-Jones et al., 1989).  
Today a number of commercial aMPV specific ELISA kits are available each of 
which can be used to test both turkey and chicken sera (Cook, 2000). However, the 
kits greatly vary in subtype specific sensitivity. This was demonstrated by 
comparing three commercial aMPV specific ELISA kits. All kits revealed 100% 
specifity but varying sensitivity (Mekkes and de Wit, 1998). Eterradossi et al. (1995) 
used in-house and commercial ELISA kits as well as VNT for the detection of 
aMPV-specific antibodies following vaccination and/or challenge with a range of 
different attenuated and virulent aMPV isolates. This study revealed that the 
inadequate choice of coating antigen may totally hinder or interfere with the 
detection of actually existing antibodies following vaccination or challenge 
infection. It may be beneficial to use homologous antigen for detection of antibodies 
of suspected subtype (Toquin et al., 1996; Mekkes and de Wit, 1998).  
 
Detection of aMPV-neutralizing antibodies is done by standard neutralization 
techniques. This technique is meaningful and adaptable to scientific approaches, but 
more time consuming and expensive than ELISA technique and for this reason less 
applicable for serological screening in the field. With respect to the subtype-specific 
application a variety of host systems, such as CEF, CEL, VERO cells or TOC can be 
used for VNT (O'Loan et al., 1989; Williams et al., 1991; Cook et al., 1993). 
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II.1.9.4. Virus detection  
Initially detection was conducted by electron microscopy (Mcdougall and Cook, 
1986), immunoperoxidase (Catelli et al., 1998) immunofluorescence (Jones et al., 
1988; Baxter-Jones et al., 1989) or immunogold (O'Loan et al., 1992) techniques. 
More recently, RT-PCR provided a tool for specific detection of aMPV. This PCR 
techniques allow the detection of aMPV or the specific detection of subgroups 
aMPV A to aMPV D (Cavanagh et al., 1999; Bayon-Auboyer et al., 1999; Bäyon-
Auboyer et al., 2000; Toquin et al., 2003). In addition to specific detection of aMPV 
this technique provides amplicons that can be sequenced for further phylogenetic 
characterization of the isolate. These days the PCR techniques are complemented by 
subtype-specific real-time RT-PCR assays (Guionie et al., 2007). 
 
II.1.10. Vaccines and vaccination  
 
Both live attenuated and inactivated aMPV vaccines are available commercially for 
use in turkeys and chickens. Early work on the attenuation of the virus was difficult 
due to poor attenuation of the virus and problems in reproducing a suitable challenge 
model in the laboratory (Tiwari et al., 2006). However, there are now a number of 
reports on the successful attenuation of aMPV strains in a variety of cell cultures and 
their effective use as vaccines (Cook et al., 1989a; Cook et al., 1989b; Patnayak et 
al., 2005). The live attenuated vaccines have been shown to stimulate both systemic 
immunity and local immunity in the respiratory tract (Khehra and Jones, 1999). Live 
attenuated vaccines are usually administrated  by several methods ( oculo-oral,  
drinking water or spray) (Ganapathy et al., 2010). Live attenuated vaccines are used 
in growing turkeys and broiler chickens and to prime future layers and breeders for 
injection of inactivated vaccines prior to onset of lay (Cook, 2000). It is most 
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important that the live-attenuated vaccines are administered very carefully to ensure 
that all birds receive an adequate dose at the same time (Cook, 2000). 
Administration of a live attenuated aMPV vaccine at 1 week of age did not protect 
turkey hens against respiratory signs, but provided good protection against drop in 
egg production and quality (Cook et al., 1996b). A combination of live priming 
followed by a booster with an inactivated vaccine provided excellent protection 
against both respiratory infection and drop in egg production in laying turkey.  
There is excellent cross protection between subtype A and B in turkey (Cook et al., 
1995) and chicken (Santos et al., 2012). However, subtype A and B vaccines 
protected turkeys against challenge with aMPV/ C, whereas, subtype C vaccines do 
not protect against A and B subtypes in turkey and chickens (Cook et al., 1999b). 
Simultaneous vaccination of live aMPV and IBV (Cook et al., 2001b), NDV 
(Ganapathy et al., 2005a) or aMPV, NDV and IBV (Tarpey et al., 2007) have been 
reported. In these studies there were reduction in the humoral antibody response to 
aMPV when co-delivered with IBV and/ or NDV. Despite the reduced antibody 
response to aMPV vaccine, the birds were fully protected against challenge with 
virulent aMPV.   
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Chapter 2: General materials and methods 
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This chapter describes the general materials and methods used throughout the 
experimental work. Details of specialised procedures used in specific experiments 
are included in relevant chapters in which they are applied. Methods for preparing 
all reagents, buffers and media used in these studies are given in Appendix 1. 
 
2.1. Embryonated chicken eggs  
 
ECE were used for virus propagation, preparation of TOC and as a source of day-old 
SPF chicks. The SPF eggs were obtained from a commercial supplier
1
. The parent 
flock was free from all major infectious disease agents, including IBV and aMPV.  
 
2.2. Incubation  
Incubation was conducted in a commercial incubator
2
 at 37
o
C with humidity 
controls and automatic hourly turning. Fertile eggs were used at the ages required.  
 
2.3. Experimental chickens  
 
i) SPF chicks  
Fertile SPF eggs were set for incubation at 37
o
C and checked for their fertility on 
day ten. They were transferred to a tray at the bottom of the incubator in a static 
condition for hatching at 21 days (Figure 2.1). 
 
 
 
 
                                                          
1
 Lohman, Cuxhaven, Germany 
2
 Victoria, Fort Dodge animal health, USA 
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Figure 2. 1. SPF eggs incubated at 37
o
C for 21 days for hatching. 
 
ii) Broiler chicks  
Day-old commercial broiler chicks with IBV MDA were obtained from a local 
commercial hatchery
3
. 
 
iii) Housing and management  
Chicks were housed in the experimental poultry facility at Leahurst campus 
(University of Liverpool) equipped with a supply of filtered air under negative 
pressure. Footbaths with 2% Virkon
4
 disinfectant and protective clothing (including 
overalls, masks, latex gloves and boots) were used at all times when visiting the 
birds. Heat was supplied from an electrical heater which also served as a red light 
source when the main lighting was turned off. This form of lighting prevents any 
cannibalism amongst the birds. The chicks were placed on a wood shaving litter in 
the isolation pens; feed and water were provided ad libitum as shown in Figure 2. 2. 
The room temperatures (RT) and humidity were recorded daily. 
                                                          
3
 Frodsham Hatchery, Frodsham, UK 
4
 Antec International, Suffolk, UK 
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Figure 2.2. Chicks placed on a wood shaving litter in the isolation pens. Feed and 
water were provided, along with an electrical heater. 
iv) Handling of the birds  
Stringent precautions were taken when handling the birds in order to reduce the risk 
of cross contamination between different treatment groups. Disinfectant foot baths 
were placed both outside and inside each experimental room. Full body disposable 
gowns were used, and double gowning was operated in rooms when handling 
infected birds. Disposable gloves were worn and changed in between handling 
different groups of birds. Disposable face masks were used and also served as a 
protection for handlers. All used gowns, gloves and face masks were disposed of in 
disinfectant baths before incineration.   
2.4. Source of the viruses and vaccines  
 
Several field and vaccine strains of IBV, aMPV and NDV belonging to different 
serotype were used in this study; their details are given in respective chapter.    
 
 Chapter Three                                                                      Pathogenesis of IS/885                                                                                                                                        
                                                                                                                                                       
                                                                                                                           
47 
 
 
2.5. Examination of chickens 
 
i) Assessment of IBV clinical signs  
Chicks were inspected daily to record the clinical signs observed by two persons 
over a 3 minutes period. Clinical signs were scored as previously described (Grgic et 
al., 2008). Coughing, head shaking and depression of short during were considered 
mild signs, whereas gasping, coughing and depression, accompanied by ruffled 
feathers were scored as severe signs.  
ii) Assessment of aMPV clinical signs 
Following virulent aMPV challenge (Chapter 8), birds were monitored once a day 
during the course of infection to record the clinical signs. Chicks were examined 
individually; their beaks were squeezed gently behind the nostrils to show the 
presence of nasal exudate (Figure 2.3) and clinical signs were scored as previously 
described (Jones et al., 1992): no clinical signs = 0, clear nasal exudates = 1, turbid 
nasal exudates = 2, frothy eyes and/or swollen intraorbital sinuses in conjunction 
with nasal exudates = 3. Total clinical scores for each group were calculated based 
on the mean of scores observed per total number of chickens at each dpi. 
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Figure 2.3. Gently squeezing the beak to detect nasal exudates. 
 
iii) Necropsy examination for IBV  
 
Gross lesions were evaluated on all dead or scarified chicks individually and scored 
according to the following formula described in Table 2.1. 
 
Table 2.1. Shows the scoring system of gross lesions following IBV infection.  
Tissue Lesions Scores 
 
Trachea 
No lesions 0 
Congestion 1 
Mucoid exudate  2 
Caseous plug  or  airsacculitis, perihepatitis  and pericarditis 3 
 
Kidney 
 
No lesion 0 
Swelling and pale 1 
Swelling with visible urate 2 
Large swelling, pale with tubules and ureters distended with urates 3 
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iv) Euthanasia of birds 
Birds used for tissue sampling, severely affected challenged birds and all birds 
remaining at the end of each experiment were humanly killed by wing vein injection 
of 0.5-1 ml of Euthatal
5
.  
v) Ciliostasis test (IBV)  
Following euthanasia, the ciliostasis test was carried out on ten tracheal rings per 
bird to determine the level of vaccine protection in the trachea. The trachea was 
removed aseptically and immediately placed in warm (37
o
C) TOC medium 
(Appendix 1). Each trachea was cut (3 rings from the upper, 4 rings from the middle 
and 3 rings from the lower) using a tissue chopper
6
 and the trachea was placed in a 
petri dish
7
 containing warm TOC medium and examined under a low power 
microscope (100x magnification). Cilia beating in each ring was scored as 
previously described (Cook et al., 1999a): All cilia beating = 0, 75% cilia beating = 
1, 50% cilia beating = 2, 25% cilia beating = 3, 0% cilia beating = 4.  A ciliary 
activity score of 4 indicates 100% ciliostasis. According to the European 
Pharmacopoeia’s reference standards, individual birds yielding 80% or more 
tracheal explants with ciliary activity were considered to have been protected by the 
vaccine against the challenge virus (Council of Europe, 2007).  Protection scores 
were calculated according to the following formula: 
1 −  
(Mean score for vaccinated/Number birds challenged group )
(Mean score for unvaccinated Number birds unchallenged )
 ∗ 100 
 
                                                          
5
 Pentobarbitone sodium B.P., Rhone Merieux, Ireland 
6
 McILWAIN tissue chopper (The Mickle laboratory engineering. Co LTD) 
7
 Sterilin Ltd, Hounslow, UK 
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2.6. Sample collection  
 
i)  Blood  
 
Blood samples were obtained from the wing (brachial) vein of each bird using a 
23-gauge sterile needle
8
 and 2 ml syringe
8
 and placed in individually labelled bijou 
tubes without anticoagulant. The blood was kept in a slant position on a workbench 
overnight at RT to allow serum separation. Sera was removed the following day and 
then stored at -20
o
C until required. 
 
ii) Swabs and tissue  
Sterile cotton wool swabs
9
 were used throughout all experiments. Following 
euthanasia, tissues were collected aseptically from each bird and placed in labelled 
bijou tubes. These samples were securely transported to the laboratory and samples 
were processed as soon as possible.  
 
 
 
 
 
 
 
 
 
                                                          
8
 Becton, Dickinson and Co. Ltd 
9
 Medical wire and equipment Co. Ltd 
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2.8. Virological methods  
 
i) Virus propagation and isolation in ECE  
Fertile SPF eggs of 9-10 days incubation were used for the propagation and isolation 
of IBV strains. At the candling eggs were marked around the air space and also at a 
point on the periphery of the air sac where no blood vessels could be seen on the 
chorioallantoic membrane. This point was punctured using a pin disinfected with 
70% alcohol. The inoculum was introduced to the allantoic cavity by a syringe 
equipped with a 23-gauge needle. The site of inoculation was sealed with molten 
paraffin wax and eggs were incubated at 37
o
C in an incubator. Eggs were examined 
daily and embryos dying within 24 hours were discarded. End points were decided 
on the basis of embryo deaths (after 24 hours) and dwarfing of the embryos. 
ii) Virus propagation and isolation in TOC  
 
The method for the preparation of TOC has been previously described by (Cook et 
al., 1976). TOC medium in sterile tubes
10
 was used for the cultivation of TOC. The 
tubes were filled with 0.6 ml of medium and placed overnight in an incubator at 
37ºC before the preparation of TOC rings. Embryos were euthanised humanely at 18 
to 20 days old, and the entire trachea from the glottis to the syrinx was removed and 
placed in a petri dish containing warm (37
o
C) TOC medium. The extraneous 
tracheal tissue was removed using a small scalpel blade and forceps. The trachea 
was then placed on sterile filter paper
11
 and cut into rings of 0.6 to 0.8 mm thickness 
using a tissue chopper. Several rings from the upper and the bottom ends were 
discarded and the remaining rings were placed into the already prepared tubes, with 
one ring per tube. Tubes were placed in a rotating drum (8 rpm) in a 37ºC 
                                                          
10
 Nunclon™ culture tubes, sterile, Thermo Scientific, UK 
11
 Fisher scientific, UK 
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incubator
12
 overnight. The following day, TOC rings were examined 
microscopically under low magnification (100x) for ciliary activity. Rings with 75-
100% ciliary activity were used for virus propagation or titration. 
The medium was removed and each ring was inoculated with 0.1 ml of the sample 
or swab suspension. Three rings were inoculated for each sample. The virus was 
allowed to be adsorbed at 37
o
C for one hour, after which 0.6 ml TOC medium was 
added and tubes were maintained in the roller drum at 37
o
C. These were examined 
daily for 7 days for IBV and 10 days for aMPV. Each sample was passaged up to 
three times in TOC medium and complete ciliostasis on the third passage was taken 
to be indicative of virus presence. Supernatants were harvested from the three tubes, 
pooled, aliquoted and stored at -70ºC until required.  
iii) Virus titration  
 
Following virus propagation in TOC (for IBV or aMPV) or ECE (for IBV), the 
infectivity titre of the virus material needed to be determined. Replicates of three 
tubes of TOC or ECE were inoculated with a tenfold dilution of the virus stock.  For 
TOC, following incubation for up to 7 days (IBV) and for up to 10 days (aMPV) at 
37
o
C, complete ciliostasis was taken as the endpoint. For the ECE, embryo mortality 
or abnormalities were assessed five days post inoculation. For both TOC and ECE, 
titres were calculated according to the method established by (Reed and Muench, 
1938) and expressed as the median ciliostasis dose (log10 CD50/ml) or Egg infective 
dose (EID50/ml). 
 
 
                                                          
12
 Laboratory thermal equipment Ltd. Greenfield, NR Oldham   
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2.9. Sample processing 
 
i) Swabs for VI  
 
Virus isolation was attempted from either OP or CL swabs. After sampling, the 
cotton tips were dipped into 1 ml of TOC medium containing 10x the usual 
concentration of antibiotics (Appendix 1), shaken vigorously and stored at -70
o
C 
until required.  
 
ii) Swabs for RT-PCR 
Each swab was dipped into a labelled bijou containing 1.5 ml of guanidine 
thiocyanate (solution D, Appendix 1), then quickly returned to its sleeve. The first 
swab was dipped back into the guanidine thiocyanate and rotated 5 times. Excess 
guanidine thiocyanate was removed by rotating and pressing on the side of the tube. 
Fluid of swabs were then stored at -20
o
C until required. 
 
iii) Tissue samples for VI and RT-PCR 
Tissues were broken up by grinding in a sterile pestle and mortar using a small 
amount of sterile sand with 1 ml of TOC medium. This was freeze-thawed three 
times and then stored at -70
o
C until required. All tissue dilutions were centrifuged at 
3,000 g for 10 minutes before being used. 
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2.10. RT-PCR  
i)  Extraction of RNA using phenol chloroform method 
RNA was extracted using the guanidine thiocyanate-phenol chloroform method as 
described previously (Chomczynski and Sacchi, 2006). Three hundred microlitres of 
mixtures of swabs or processed tissue samples were treated with 300 μl of solution 
D and frozen at -20°C overnight. The mixture was then thawed and transferred into a 
screw capped Eppendorf tube
13
 to which 50 μl sodium acetate14 and 650 μl phenol 
chloroform 5:1
14
 were added. Tubes were inverted 12 times to mix and then 
centrifuged at 13,000 g for 5 minutes. The top layer was removed and mixed with 
500 μl isopropanol14 and then precipitated overnight at -20oC. Following this, the 
sample was immediately centrifuged at 13,000 g for 15 minutes. The supernatant 
was removed and the precipitate was carefully washed twice with 100% ethanol and 
then left to air dry. The precipitate was resuspended in 30 μl of resuspension (RS) 
water (Appendix 1) and left to stand at 4
o
C for at least 15 minutes. The samples 
were flick mixed and then quickly spun for 10 seconds before proceeding.  
ii) Extraction of RNA using a commercial kit 
Total viral RNA was extracted using the QIAamp viral RNA mini kit
15
 following 
manufacturer’s instructions. In brief, 140 µl of each virus sample was mixed with 
560 µl of lysis buffer, vortexed briefly, incubated for 10 minutes at RT, followed by 
the addition of 560 µl of 100% ethanol. Following this, the liquid was applied to a 
spin-column, followed by two steps washings with washing buffers (AW-1 and 
AW-2) (Appendix 1 for detailed protocol). The RNA was eluted in 60 µl RNase-free 
water, and used immediately or stored at -20
o
C for later use. 
                                                          
13
 Elkay laboratory products Ltd UK 
14
 Sigma-Aldrich, UK 
15
 QIAGEN, UK 
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iii) RT-PCR protocol  
The RT-PCR method used in this study was performed as previously described for 
IBV (Worthington et al., 2008), aMPV (Cavanagh et al., 1999) and NDV(Aldous 
and Alexander, 2001). 
Table 2.2. RT- PCR oligonucleotides. 
Virus Oligo Sequence (5’ to 3’) Gene 
Product 
size (bp) 
Position in 
sequences 
IBV 
 PCR 1 
SX1+ CACCTAGAGGTTTG T/C T A/T GCAT 
 
S1 
 
 
393 
677-698 
SX2- TCCACCTCTATAAACACC C/T TT 1148 -1168 
Nested PCR 2 
SX3+ TAATACTGG C/T AATTTTTCAGA 705 - 725 
SX4- AATACAGATTGCTTACAACCACC 1075-1097 
aMPV 
 PCR 1 
G6- CTGACAAATTGGTCCTGATT 
G 
 
422-441 
G1+ GGGACAAGTATC T/C C/A T/G AT 1- 17 
Nested PCR 2 
G5- CAAAGAAGCCAATAAGCCCA 401 to 419 
G8+A CACTCACTGTTAGCGTCATA 268 152-171 
G9+B TAGTCCTCAAGCAAGTCCTC 361 68 to 87 
NDV 
Single step 
PCR 
MSF-1R GACCGCTGACCACGAGGTTA 
F 182 
- 
MSF-2F AGTCGGAGGATGTTGGCAGC - 
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a) Reverse transcription (RT) reaction  
The PCR reaction mixture was prepared at a separate workstation and gloves were 
worn at all times to prevent contamination.  
The RT reaction mixture included superscript II RT and one of the outer (negative) 
oligonucleotides (Appendix 1). The mixtures were then taken to a separate 
workstation where 5 µl of the mixture was placed into a 0.5 ml pre-labelled clip top 
Eppendorf tube
16
, after which 2 drops of mineral oil
17
 were added. To this, 0.5 µl of 
RNA was placed under the oil. Positive and negative controls were included in each 
run. This was thoroughly mixed by vortexing and then centrifuged for 10 seconds at 
5000 rpm. The tubes were placed in a thermocycler 
18
 and run under the following 
conditions: 42
o
C for 1 hour, 72
o
C for 10 minutes and then held indefinitely at 8
o
C. 
Immediately after the RT mixture, the following was performed: 
b) Nested PCR 1  
The total volume mixture for PCR 1 reaction was 20 l (Appendix 1). Sufficient 
PCR reaction mixture was made for all the samples including a positive and negative 
control for a particular run in a 1.5 ml clip top Eppendorf tube.
19
 The PCR reaction 
mixture was thoroughly vortexed before dispensing 20 l aliquots beneath the oil 
layer in each tube containing the RT-PCR product. The tubes were placed in a 
thermocycler and run under the following conditions: 94
o
C for 15 seconds followed 
by 35 cycles of 94
o
C for 10 seconds, 50
o
C for 20 seconds, and 72
o
C for 40 seconds 
and then held indefinitely at 8
o
C. 
                                                          
16
 Elkay Laboratory Products UK (Ltd), Basingstoke, Hampshire, UK 
17
 Sigma-Aldrich, UK 
18
 GeneAmp PCR system 9700 
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c) Nested PCR 2  
The total volume of the reaction mixture for one PCR 2 reaction was 24.5 l 
(Appendix 1). Sufficient PCR reaction mixture was made for all the samples 
including a positive and negative control for a particular run in a 1.5 ml clip top 
Eppendorf tube. This The PCR mixture was thoroughly vortexed before dispensing 
24.5 l aliquots into labelled 0.5 ml clip top Eppendorf tubes, and overlaid with two 
drops of mineral oil. Then 0.5 l of the PCR 1 product was added beneath the oil 
layer, tubes were flick-mixed, quickly spun and finally placed in a thermocycler and 
run under the following conditions: 94
o
C for 15 seconds followed by 35 cycles of 
94
o
C for 10 seconds, 50
o
C for 20 seconds, and 72
o
C for 40 seconds and held 
indefinitely at 8
o
C. 
 
d) Gel electrophoresis   
Agarose gels (1.5%) were prepared by dissolving agarose in 1x TBE buffer 
(Tris-borate-EDTA) (Appendix 1). Once dissolved the agarose solution was cooled 
and stained with 2 µl nucleic acid solution (Redsafe
TM
).
20
 The solution was then 
poured into a gel mould (12cm x 9cm) Hybaid Electro-4 gel tank
 
.
21
  
 For each sample, 10 µl
 
 of reaction mix was added to 4 µl
 
of loading buffer. After 
mixing, the 14 l was added to each of the wells in the gel. A 100 bp ladder 
(Molecular marker) 
22
 was included for amplicon analysis.  Gels were run at 75V for 
55 minutes in 1x TBE buffer.  The gels were analysed using UV transillumination.  
                                                          
20
 iNtRON Biotechnology, Inc 
21
 Hybaid Ltd, Middlesex, UK 
22
 Amersham Pharmacia Biotech, UK 
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2.11. DNA sequencing  IBV 
For sequencing, positive nested PCR amplicons (393 bp)  were purified with 0.15 µl 
Exonuclease 1 (EXO)
 23
  and 0.99 µl shrimp alkaline phosphatase (SAP)
 23
 at 37
o
C 
for 30 minutes and then at 80
o
C for 10 minutes to remove any extraneous 
nucleotides. Purified products along with forward primer (SX3+) were submitted to 
external commercial laboratory 
24
 for sequencing. 
i) Phylogenetic analysis and nucleotide comparison  
Multiple sequence alignments were prepared with Clustal W (Thompson et al., 
1994), and phylogenic trees were constructed using MEGA 6 (Tamura et al., 2013) 
using the Neighbor-joining method with 1000 bootstrap replicates to assign 
confidence levels to branches. The IBV sequences were aligned and compared with 
IBV references available in GenBank (National Centre of Biotechnology 
Information; http://www.ncbi.nlm.nih.gov/) and BLAST searches were conducted to 
confirm sample identification. 
 
 
 
 
 
 
                                                          
23
 78250, Affymetrix 
24
 Source bioscience sequencing, Nottingham, UK 
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2.12. Serological tests 
 
i) ELISA 
Serum samples were analysed using BioChek 
25
 or IDEXX 
26
 commercial ELISA 
kits.  
a)  ELISA BioChek protocol 
All steps were carried out at RT. The ELISA plates were adapted to RT for 30 
minutes before use. In brief, serum samples were heat treated at 56
o
C for 30 minutes 
and each sample was diluted 1:500 by adding 1 μl of sample to 0.5 ml of sample 
diluent and mixed well by vortexing. After the addition of 100 μl positive and 
negative control samples to the indicated wells of the ELISA plate, 100 μl of diluted 
sample were added to the appropriate well of the plate. The plate was covered with a 
plastic cover and incubated at RT (20-25
o
C) for 30 minutes for IBV and 60 minutes 
for aMPV. After incubation, the contents of the plate were aspirated and the plate 
was washed four times with 300 μl/well of wash buffer. After addition of 
100-μl/well of conjugate reagent (Anti-chicken IgG labelled with the enzyme 
alkaline phosphatase), the plate was covered again and incubated at RT for 30 
minutes for IBV and 60 minutes for aMPV. Following four washing steps with 300 
μl/well of wash buffer to remove unreacted conjugate, 100 μl/well of substrate 
reagent in the form of PNPP chromogen was added and the plate was incubated at 
RT for 15 minutes for IBV and 30 minutes for aMPV. A yellow colour was 
developed if anti-IBV or aMPV antibodies were present and the intensity was 
directly related to the amount of antibody present in the sample. The reaction was 
halted with stop solution (100 μl/well) (sodium hydroxide in diethanolamine buffer). 
                                                          
25
 Gouda, The Netherlands 
26
 Hoofddorp, The Netherlands 
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Optical density (ODs) was determined by measuring absorbance at 405 nm with a 
microplate reader.
27
 Based on the ODs, the sample to positive (S/P) ratios were 
calculated and used to express the mean (S/P) ratio per group. For the results to be 
valid the mean of the negative control should be less than 0.30 and the difference 
between the positive control mean and negative control mean should be greater than 
0.15, S/P ratio values greater than 0.2 were considered as positive.  
b) ELISA IDEXX protocol 
The ELISAs were performed according to the manufacturer’s instructions. Briefly, 
serum samples were diluted 1:500 with sample diluent provided by the 
manufacturers, and 100 µl of the diluted samples were dispensed into the antigen 
coated test plates. Samples were incubated for 30 minutes at 25°C and washed 3-5 
times with approximately 350 µl of distilled water, per well. Following this, 100 µl 
of conjugate was added to each well and plates were incubated for 30 minutes at 
25°C. Each well was washed again 3-5 times, as described above, and 100 µl of 
substrate solution was added to each well, and plates were incubated at 25°C in the 
dark for 15 minutes. A blue colour developed if anti IBV or aMPV antibodies were 
present. The reactions were halted by adding 100 µl stop solution per well. Sample 
absorbance was measured at 650 nm with a microplate reader. For both kits, for the 
results to be valid the mean of the negative control should be less than 0.150 and the 
difference between the positive control mean and negative control mean should be 
0.075. Samples with S/P ratio value greater than 0.2 were considered positive. 
 
 
                                                          
27
 Thermo Scientific, Multiskan FC, Finland 
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ii) IBV HA antigen preparation and HI test 
a) IBV antigen preparation 
Reference antigens for IBV serotypes M41 and 793B (4/91) were obtained from a 
commercial source.
28
 Previously described methods (King and Hopkins, 1983; 
Alexander and Chettle, 1977) were used for preparing IS/885/00-like and 
IS/1494/06-like HA antigens. Ten-day ECEs were inoculated via the allantoic cavity 
with a 0.1 ml volume of the respective virus stock (10
6 
EID50/ml). Following 
72-hours incubation at 37
o
C, the inoculated eggs were chilled overnight at 4
o
C. The 
following day, allantoic fluid (AF) was harvested, pooled and then clarified by 
centrifugation at 1000 g for 30 minutes. The titre of the virus was determined by 
using TOC. The virus was concentrated from the supernatant by ultracentrifugation
29
 
at 30,000 g (Rotor SW 41 Ti) for 90 minutes. All centrifugations were carried out at 
4
o
C. The virus pellet was resuspended to 1/100 original AF volume in 
2-hydroxy-ethyl-piperazine-N2-ethane sulphonic acid (HEPES) buffer (Appendix 1). 
The concentrated virus was treated with enzyme phospholipase C, Type 1, from 
Clostridium perfringens
30
 by mixing equal parts of enzyme (1 unit/ml) and virus 
concentrate, and incubating the virus/enzyme mixture at 37
o
C for 2 hours. The 
virus/enzyme mixture was tested for HA activity and stored at 4
o
C for the same day 
use 
 
 
                                                          
28
 Animal Health Service, Deventer, The Netherlands 
29
 Beckman Coulter, USA 
30
 Sigma-Aldrich, UK 
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b) Chicken red blood cells  
A total of 2 ml of blood was collected from SPF chicks via the wing vein using a 
sterile syringe, and added to the same volume of Alsever’s solution.31 This was then 
gently mixed and centrifuged at 1200 g for 5 minutes. The plasma layer was 
removed by pipetting. After washing three times with phosphate buffered saline 
(PBS) (Appendix 1) a 1% RBC suspension was prepared in PBS for HA and 
subsequent HI testing. 
c) HA and HI test procedure 
HI tests were carried out in microtiter "U" shaped plates.
32
 Twenty five µl of antigen 
suspension was serially diluted in 25 µl PBS (pH 7.5) and an equal amount of 1% 
RBC suspension was added to each well. All procedures were performed at RT. The 
test plates were incubated for 45 minutes before the results were recorded. HA is 
determined by tilting the plate and observing the presence or absence of tear-shaped 
streaming of the RBCs. The titration should be read to the highest dilution giving 
complete HA (no streaming). The reproducibility of the HA titre for each IBV type 
was examined twice. End point dilutions for each virus were as follows: M41 
(1:1024), 793B (1:512), IS/885/00-like (1:32) and IS/1494/06-like (1:8).  
HI was used to assess antibody level in samples (Chapter 3 and 4). The test was 
carried out as described by Alexander and Chettle (1977). Prior to conducting the HI 
test, serum samples were thawed and placed in a water bath at 56°C for 30 minutes 
to destroy heat labile non-specific agglutinins. Two fold serial dilutions of 25 μl 
serum were made with PBS in U-bottomed microtiter plates up to the 10
th
 well. 
Twenty five μl of 4 HA units (U) of IBV antigen were added up to the 11th well. 
                                                          
31
 Sigma-Aldrich, UK 
32
 Thermo Fisher Scientific, Denmark 
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Plates were kept at RT for 30 minutes to allow antigen antibody reaction. After this, 
25 μl of 1% RBC suspension was added to each well. The 11th well contained 
antigen and RBCs as the positive control, with the 12
th
 well containing only RBCs 
as the negative control. After gentle mixing for up to 10 seconds, RBCs were 
allowed to settle at RT for 45 minutes and agglutination was assessed by tilting the 
plates. The HI titre is the highest dilution of serum causing complete inhibition of 4 
HAU of antigen. The agglutination is assessed by tilting the plates. Only those wells 
in which the RBCs stream at the same rate as the control wells (containing 0.025 ml 
RBCs and 0.05 ml PBS only) should be considered as showing inhibition.  Prior to 
the HI test, back-titration of the antigen was carried out to ascertain the 4 HAU. The 
HI was performed using positive control antisera against the M41, 793B, 
IS/885/00-like and IS1494/06-like antigens.  
 
2.13. Immunohistochemistry  
 
i) Tissue sections/cryostat 
At post-mortem the trachea (approximately 1cm/length) was collected from each 
bird, immediately placed in aluminium foil cups containing cryo embedding 
compound (OCT) 
33
 and frozen in liquid nitrogen (-190°C). When needed, each 
sample was retrieved in a self-sealing polyether bag and stored at -70
o
C until used 
for sectioning. Frozen tissue blocks were sectioned at 5μm using a pre-
cooled cryostat,
34
 mounted on glass slides
35
 and then kept overnight away from 
                                                          
33
 Solmedia laboratory, Shrewsbury, UK  
34
 LEICA CM 1900, Germany 
35
 Thermo Scientific, UK 
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direct light. These were then fixed in pre-cooled  (-20ºC) acetone 
36
 for 10 minutes, 
air dried at RT for 10 minutes and then stored at -70ºC until stained.  
ii) IHC staining  
Monoclonal antibodies against chickens IgA were used as a marker for B cells and 
CD4+ and CD8+ 
37
 specific monoclonals were used to identify T-helper and T- 
cytotoxic cells respectively. Staining was carried out as described by Rautenschlein 
et al. (2011), with some modification. Briefly, slides were incubated for 20 minutes 
in 0.03% hydrogen peroxide (H2O2) diluted in PBS, washed three times in PBS for 2 
minutes and incubated with horse serum for 20 minutes. Tissue sections were 
incubated with primary antibodies [mouse anti CD4+ chickens at 0.5 µg/ml; 1:1000 
(clone CT-4), CD8 alpha+ at 0. 25 µg/ml, 1:2000 (clone CT-8), IgA (clone  A-1) at 
0.5 µg/ml, 1:1000]. Slides were then incubated overnight at 4ºC. After monoclonal 
antibody incubation, sections were washed in PBS for 2 minutes and incubated with 
the secondary antibody (goat anti-mouse IgG) for 30 minutes.  After washing three 
times with PBS, sections were incubated with 1% Avidin DH and 1% biotinylated 
horseradish peroxidase H reagents (ABC reagent).
38
 After a further three washes 
with PBS, colour development was achieved by addition of 4% 
3,3-diaminobenzidine (DAB) 
38
 substrate containing 2% hydrogen peroxide and 2% 
buffer stock solution. Slides were then washed in super quality water, and tissue 
sections were counter stained with hematoxylin for 1 minute, followed by washing 
in tap water for 5 minutes. Finally, sections were dehydrated for 1 minute in 96% 
ethanol, 2 minutes in 100% ethanol, 3 minutes in 100% ethanol, 2 minutes in 100% 
xylene, 3 minutes in 100% xylene, 3 minutes 100% xylene and later mounted with 
                                                          
36
 Fisher Scientific, UK 
37
 Southern Biotech, Birmingham, USA 
38
 VECTOR Laboratories, Burlingame, USA 
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aquatic mounting medium and covered with a coverslip. All antibodies used for 
immunohistochemical studies were diluted in PBS and all incubation steps were 
carried out at RT. The immunostained sections were evaluated using Nikon 
ECLIPSE 80i microscope.
39
 For each sample and each cell surface determinant 
(CD4+, CD8+ and IgA), immunostained cells were counted in 5 selected 
microscopic fields at a 400x magnification (fields/trachea). The average number of 
positive cells per 400x microscopic field was calculated for each sample. Figure 4 
shows the immunostaining of the tracheal tissue of birds infected with virulent IBV 
QX that used for of the standardisation immunohistochemistry assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
39
 Nikon-corporation, Japan 
Figure 2.4a.Microscopic image tracheal 
tissue of control birds 
Figure 2.4c.Microscopic image of CD4 
cells in vaccinated tracheal tissue 
Figure 2.4d. Microscopic image of IgA 
cells in vaccinated tracheal tissue 
Figure 2.4b.Microscopic image of CD4+ 
cells in vaccinated tracheal tissue 
100 µm 
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Chapter 3: Pathogenesis of IS/885/00-like infectious 
bronchitis virus in specific pathogen-free and 
commercial broiler chicks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Three                                                                      Pathogenesis of IS/885                                                                                                                                        
                                                                                                                                                       
                                                                                                                           
67 
 
3.1 Abstract  
 
The pathogenesis of an IS/885/00-like (IS/885) strain of IBV isolates was examined 
in one day old SPF and commercial broiler chicks. Following infection at one 
day-old, chicks were monitored for clinical signs and antibody responses by ELISA 
and HI. In addition, five chicks were humanely killed at 3, 6, 9, 12, 15, 21 and 28 
dpi, lesions were scored, and tissues were collected for histopathology and virus 
detection by RT-PCR. The IS/885 strain caused respiratory distress, depression and 
diarrhoea in both SPF and broiler chicks. Mild head swelling was observed in one 
infected broiler chick at 15 dpi and a virus with 100% nucleotide level similarity to 
the IS/885 inoculum was detected by RT-PCR and VI. Tracheal and kidney lesions 
were observed in both types of bird but lesions were more severe in SPF than the 
broiler chicks. In the IS/885-infected SPF chicks, cystic oviducts were found in two 
female chicks at 28dpi. IBV with 99% nucleotide level similarity to the initial 
inoculum was isolated from the cystic fluid aspirated from these oviducts. The SPF 
showed a higher severity of microscopic lesions and they persisted for longer than in 
the broiler chicks. The virus was consistently detected in the tissue and swabs 
throughout the observation period. Increase in antibody titres were found at 21 dpi in 
both types of birds. The IS/885 strain examined in this study was pathogenic for 
both SPF and broiler chicks, however the onset of disease was delayed and of lesser 
severity in the latter.  
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3.2. Introduction 
In the winter of 2000, a severe outbreak of renal disease occurred in several broiler 
farms in Israel. An IBV, designated IS/885/00, was isolated from the kidneys of 
these flocks (Meir et al., 2004).  
In the Middle East and North Africa, in addition to the circulation of Massachusetts, 
793B, QX and Dutch strains (Abdel-Moneim et al., 2006; Bourogaa et al., 2009; 
Amin et al., 2012; Boroomand et al., 2012), genetically similar strains  to IS/885/00 
have been reported in Egypt (Abdel-Moneim et al., 2012), Iraq (Mahmood et al., 
2011) and Libya (Awad et al., 2014). These strains were isolated from broiler and 
layer flocks experiencing respiratory distress, renal lesions and high mortality (Selim 
et al., 2013; Awad et al., 2014). In addition, the IBV IS/885/00 and IS/885/00-like 
isolates were distantly related to other genotypes reported in both this region and 
elsewhere (Meir et al., 2004; Abdel-Moneim et al., 2012; Awad et al., 2014).  
The pathogenesis and host immune responses of common IBV variants are known, 
such as M41 (Crinion and Hofstad, 1972a; Jones and Jordan, 1972; Butcher et al., 
1990), Beaudette (Geilhausen et al., 1973), Australian T-strain (Chong and 
Apostolov, 1982; Ignjatovic et al., 2002), Moroccan G strain (El-Houadfi et al., 
1986; Ambali and Jones, 1990), 793B (Dhinakar Raj and Jones, 1996a; Boroomand 
et al., 2012), QX (Terregino et al., 2008; Ganapathy et al., 2012), It-02 (Dolz et al., 
2012), Q1 (Toffan et al., 2013) and more recently Brazilian IBV variant (USP-10 
and USP-50) (Chacón et al., 2014). 
Despite the IS/885/00 strain being one of the predominant IBV strains in the Middle 
East and North Africa, no published information is available on 
immunopathogenesis of this increasingly important IBV variant. Furthermore, tissue 
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tropism and pathogenesis of this novel genotype remain unknown. To better 
understand the IS/885 strain, an experiment was performed to investigate the 
pathogenesis in SPF and commercial broiler chicks. Clinical signs, gross and 
microscopic lesions, virus detection and humoral antibody responses were evaluated. 
3.3. Materials and methods 
 
3.3. 1. Virus 
The virus used throughout this study (referred here as IBV IS/885) was received as 
third passage AF from the Istituto Zooprofilattico Sperimentale delle Venezie, 
Padova, Italy. The virus had been isolated from a recent outbreak of high mortality 
and respiratory disease complex in broiler flocks in Egypt. Initial isolation was 
carried out in the virology laboratory at Cairo University, Egypt, and the AF was 
submitted to the Italian laboratory. There, the AF went through three further 
passages in ECEs and was shown to be negative for avian influenza virus (AIV) and 
NDV and positive for IBV by RT-PCR. DNA sequences of the S1 gene showed 99% 
nucleotide level similarity to the Israeli strain IS/885/00 (Meir et al., 2004).  
At the University of Liverpool, the virus received a further passage in 9 to 11 
day-old SPF ECE (Chapter 2.1). The viral titre was determined by titration in ECE 
as 10
4.66 
EID50/ml. The AF was free of AIV, NDV, aMPV, ILTV, infectious bursal 
disease virus (IBDV) and fowl adenovirus (FAdV) by RT-PCR, and free of bacterial 
or fungal contaminations. 
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3.3. 2. Eggs and chicks 
Fertile eggs from SPF White Leghorn chickens were used (Chapter 2.3.i). Day-old 
commercial broiler chicks with IBV MDA were obtained from a commercial 
hatchery (Chapter 2.3.ii). 
 
3.4. Experimental design 
 
3.4. 1. Experiment 1. Infection of SPF chicks 
Seventy one-day-old SPF chicks were randomly divided into two groups, consisting 
of 45 and 25 chicks in the infected and control group respectively. The chicks in the 
infected group were inoculated oculonasally with 0.1 ml of the virus and those in the 
control group with virus-free AF.   
 
3.4. 2. Experiment 2. Infection of commercial broiler chicks 
 
Seventy one-day-old commercial broiler chicks were divided into two groups and 
inoculated as per Experiment 1 described above.  
For both experiments, clinical signs were observed daily throughout the 
experimental period (Chapter 2.5.i). At 3, 6, 9, 12, 15, 21 and 28 dpi, five infected 
and three control chicks were randomly selected and euthanised to evaluate the gross 
lesions. OP and CL swabs and tissue samples of trachea, lung, caecal tonsils and 
kidney were collected individually and frozen at -70
o
C for virus detection by 
RT-PCR. In addition, pieces of trachea and kidney were fixed in 10% buffered 
formalin for histopathology. Blood samples were collected from 8 randomly selected 
chicks at 0, 15, 21and 28 dpi from the SPF chicks and at 0, 3, 6, 9, 15, 21 and 28 dpi 
from the broiler chicks to monitor antibody responses. 
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3.4. 3. Gross and microscopic lesions  
All euthanised and found dead chicks were necropsied and examined for gross 
lesions. The trachea and kidney were scored individually according to the criteria 
described in Chapter 2.5.iii.  
For histopathological examination, the upper part of the trachea and anterior kidney 
tissues were fixed in 10% buffered formalin, embedded in paraffin and sections were 
cut for hematoxylin and eosin (H&E) staining. Trachea and kidney lesions were 
examined and scored as follows: 0 = no change, 1= mild, 2 = moderate, 3 = severe 
(Chen et al., 1996).  
 
3.4.4. Swab and tissue sample processing for RT-PCR 
Each set of swabs (either OP or CL) were dipped and pooled as a single sample in 
1.5 ml of TOC medium (Appendix 1). Individual tissue samples of tracheal, lung, 
kidney and caecal tonsils were ground up using a pestle and mortar (Chapter 2.9.iii). 
RNA for the two experiments was extracted from swab and tissue samples using the 
QIAamp viral RNA mini kit following manufacturer’s instructions (Chapter 2.10.ii). 
RT-PCR was carried out as described in Chapter 2.10.iii.  
3.4.5. Serological assay 
Sera were tested using commercial ELISA kits (IDEXX) according to the 
manufacturer's instructions (Chapter 2.12.i.b). HI testing was performed using 4 
HAU as described in Chapter 2.12.ii. The virus strains used as antigens for the HI 
test were IBV M41, 793B and IS/885. IBV HI titres were expressed as log2 values of 
the highest reciprocal of the dilution that showed HI.  
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3.4.6. Statistical analysis 
Data for gross and histopathological lesions and ELISA were analysed using the 
Mann-Whitney U test. The mean HI antibody titres of infected SPF and broiler 
chicks sera tested with different IBV antigens were compared and analysed using 
one way ANOVA to test for a significant overall effect, followed by Tukey’s test to 
identify which means were significantly different from each other. All analysis were 
conducted using GraphPad Prism, 6.0.1 
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3.5. Results 
 
3.5. 1. Clinical signs  
No clinical signs or mortalities were observed in the control groups of either 
experiment. 
In the SPF chicks, clinical signs were first observed at 1 dpi, which included mild 
tracheal râles, sneezing, coughing, head shaking and eye scratching. Gasping, 
wheezing and open mouth breathing were seen in some cases (4-5 birds) between 4 
to 13 dpi (Figure 3.1 A) and wet dropping (white or milky faeces) were also 
observed. All clinical signs disappeared completely by 18 dpi. Of 45 chicks, one 
bird died at 8 dpi (2.2%).  
 
For the commercial broiler chicks, the clinical signs were similar to those observed 
in SPF chicks but with a lower severity and lasting for a longer period. Clinical signs 
were first observed at 3 dpi and the last at 22 dpi. Of the 45 birds, three died; one at 
12 dpi and two at 19 dpi (6.6%). Apart from respiratory signs, one bird showed 
swelling of the head, foamy eyes and nasal discharge at 14 dpi. The 
swelling increased at 15 dpi, with the periocular tissues particularly affected (Figure 
3.1, B). For welfare reasons, this bird was euthanized for necropsy and sampling was 
carried out. 
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Figure 3.1. A, Respiratory distress, gasping and open-mouth breathing of an 
infected SPF chick (Arrow). B, Periocular swelling of an infected broiler chick at 15 
dpi ( Arrow). 
 
3.5. 2. Gross necropsy findings  
No detectable gross lesions were witnessed in the two control groups. A summary of 
all gross lesions seen in the infected SPF and broiler chicks is presented in Table 3.1. 
In the SPF chicks (Expt 1), tracheal lesions mostly comprised congestion and 
presence of excess mucus (observed from 3 dpi onward). Pale kidneys with swelling 
and large amounts of urate deposits were observed at 6 dpi (Figure 3.2, B). These 
lesions were not seen after 12 dpi (Table 3.1). At 28 dpi, (during the post mortem 
examination) water-like fluid accumulation was found in the oviduct of two female 
SPF chicks (Figure 3.2, C). Samples of the fluid and tissues of the cystic oviduct 
were collected for virus detection. In addition, tissue sample from the cystic oviduct 
was collected for histopathology. The fluid was positive for IBV by RT-PCR and 
VI, while the tissue was negative. Part-sequencing of the hypervariable region of the 
S1 gene of this isolate revealed 99% homology with the challenge virus of IS/885 
 A  B 
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that was used for infection. Necropsy of the dead bird at 8 dpi showed large swollen, 
pale kidneys with tubules and ureters distended with urates.  
In the broiler chicks (Expt 2), the gross lesions of the trachea and kidney were 
similar to those observed in Expt 1 but with lower severity. However, the lesions 
persisted for a longer time than in the SPF chicks (Table 3.1). Severe tracheal 
lesions such as plugs of yellow caseous were observed at 15 dpi (Figure 3.2, A). 
Paleness and swelling of kidneys were observed from 6 to 21 dpi. However, there 
was no significant difference regarding the extent and severity of the kidney lesions 
between the two infected groups. The only exception was at 6 dpi, where the 
severity of kidney lesions of the SPF chicks was significantly higher (P = 0.03) than 
those in the broilers.  
The chick with swelling of the head was euthanized at 15 dpi. Subcutaneous swabs 
were taken for virus detection (IBV and aMPV) by RT-PCR, VI and for bacterial 
culture (E. coli). Clear positive signal was obtained for IB virus. DNA sequence of 
the par-S1 gene fragment obtained was 100 % identical with the IS/885 strain (the 
inoculum). Isolation in SPF ECEs yielded a positive result at the third passages, with 
typical lesions including dwarfing and curling of the embryos. Neither aMPV nor 
E. coli was detected in the swabs. Necropsy of birds that died showed emaciation, 
dehydration, cheesy exudate plugs in the upper trachea and pale, swollen kidneys. In 
addition they had fibrinous pericarditis, fibrinous perihepatitis, airsacculitis and 
peritonitis (Figure 3.2, D).  
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Table 3.1.  Gross lesions of the trachea and kidney of SPF or broiler chicks infected 
with IBV IS/885 strain. 
dpi 
SPF Broiler 
Trachea Kidney Trachea Kidney 
3 0.4±0.2 (2) 0.0±0.0 0.4±0.2 (2) 0.0±0.0 
6 0.6±0.2 (3) 1.6±0.4
a 
(5) 0.6±0.2 (3) 0.4±0.2
b 
(3) 
9 1.2±0.2 (5) 0.8±0.3 (3) 0.6±0.2 (3) 0.6±0.2 (3) 
12 1.4±0.4 (4) 0.4±0.2 (2) 1.0 ±0.3 (4) 0.8±0.2 (4) 
15 0.0±0.0 0.0±0.0 1.2±0.5 (3) 0.6±0.2 (3) 
21 0.0±0.0 0.0±0.0 0.4±0.2 (2) 0.4±0.2 (2) 
28 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 
Data are expressed as the mean gross lesion score ± SEM. For each time point and tissue, different 
superscript letters for SPF and broiler indicate they are significantly different (p < 0.05). Absence of 
letter indicates that there were no significant differences between the lesions of infected groups 
(p > 0.05). Numbers in parenthesis are number of chicks with gross lesion, out of five examined. 
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Figure 3. 2. A, Mucoid exudate and caseous plug in the trachea of an infected 
broiler chick at 15 dpi. B, large swelling of kidneys, pale tubules and ureters 
distended with urates of an infected SPF chick at 6 dpi. C, Cystic dilation of the 
oviduct of an SPF female chick at 28 dpi. D, Fibrinous pericarditis, fibrinous 
perihepatitis and peritonitis in an infected broiler chick which died at 12 dpi.  
 
 
 
 
 
 
 
 
 
 
 
 A  B 
 D  C 
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3.5. 3. Histopathology  
 
No histological abnormalities were observed in the trachea (Figure 3.3, A), kidneys 
(Figure 3.3, D) or oviduct of the control groups in either experiment.  
 
3.5. 3.1. Trachea of infected chicks  
Details of histological lesions in the tracheas in both experiments are summarised in 
Table 3.2. In both lines of chicks (SPF and broiler) they were essentially the same; 
however the severity differed throughout study period.  
In the SPF chicks, severe changes in the trachea were observed at 3 dpi. The most 
consistent lesions in the SPF chick were loss of cilia (Figure 3.3, B) and heterophil 
infiltration, decreased mucous cells, and occasional heterophilic exudate in the 
tracheal lumen. Mild to moderate lesions were witnessed until 15dpi. Ciliated 
epithelium redeveloped at 21dpi. Areas of severe lymphoid infiltration in the lamina 
propria or submucosa persisted until the end of the experiment (Table 3.2).  
In the broilers chicks, at early stage of infection, each lesion type was less severe 
than those observed in the SPF chicks but persisted for longer (Figure 3.3, C). At 21 
dpi, the histopathological changes were significantly greater (p < 0.05) than those 
observed in the SPF chicks (Table 3.2).   
 
3.5. 3.2. Kidney of the infected chicks 
A summary of the histopathological changes in the kidneys during both experiments 
is given in Table 3.3. 
In the SPF chicks, kidney lesions developed by 3 dpi, which included ducto-tubular 
dilation, interstitial heterophilic infiltration and epithelial hyperplasia. The main 
histological lesions consisted of interstitial lymphoid infiltration with mild lymphoid 
nodules observed throughout the study. Most of the kidney lesions had cleared by 21 
A 
C 
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dpi, apart from mild lymphoid infiltration and lymphoid nodules that were present 
until the end of the experiment (Table 3.3).  
In the broiler chicks, kidney lesions were first observed at 6 dpi, which included 
tubular degeneration and hyperplasia of the epithelium. Lymphoid infiltration was 
the main lesion observed throughout the observation period. No significant 
differences were observed among the histological changes regarding the extent and 
severity of the lesions between the SPF and broiler chicks.  
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Figure 3.3. Hematoxylin and eosin stains of the trachea and kidney (magnification 
at 400x). Panels A (trachea) and D (kidney) correspond to control chick tissue taken 
at 3 and 9 days of age respectively. B, Extensive epithelial deciliation, with severe 
lymphocyte and heterophil infiltration of trachea of SPF chicks at 3 dpi. C, Mild 
epithelial deciliation, with moderate lymphocyte and heterophil and mild epithelial 
hyperplasia of broiler chicks at 3 dpi. E, Moderate to severe lymphocyte and mild 
heterophil interstitial infiltration in kidney of SPF chicks at 9 dpi. F, Mild to 
moderate lymphocyte and heterophil interstitial infiltration in kidney of broiler chick 
at 9dpi. 
 A  B 
 C  D 
 E  F 
100 µm 
 Chapter Three                                                                                                                                          Pathogenesis of IS/885                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                   
81 
 
Table 3.2. Histopathology of the trachea in SPF or broiler chicks infected with IBV IS/885 strain.  
 
Tracheal 
lesions 
SPF  (dpi) Broiler (dpi) 
3 6 9 12 15 21 28 3 6 9 12 15 21 28 
Epithelial 
deciliation 
3.0±0.0a ND 3.0±0.0 2.8±0.2 0.5±0.2 0.0±0.0a 0.0±0.0 1.6±0.4b 2.8±0.2 2.4±0.2 2.4±0.4 2.2±0.4 2.0±0.3 b 0.0±0.0 
Epithelial 
degeneration 
0.5±0.2 ND 1.2±0.2 1.0±0.3 1.0±0.4 0.5±0.2 0.5±0.5 0.8±0.2 1.2±0.2 1.4±0.2 1.8±0.3 1.0±0.0 1.4±0.2 0.2±0.2 
Decrease 
mucous cells 
1.2±0.2 a ND 2.2±0.2 2.6±0.2 2.0±0.4 1.2±0.5 1.5±0.5 0.2±0.2 b 1.8±0.5 1.8±0.2 2.0±0.3 2.8±0.2 2.2±0.3 0.5±0.2 
Heterophil 
infiltration 
2.0±0.0 a ND 0.5±0.2 0.8±0.3 0.0±0.0 0.0±0.0 a 0.0±0.0 0.8±0.3 b 0.8±0.3 1.6±0.5 1.0±0.3 0.6±0.2 1.2±0.3 b 0.2±0.2 
Epithelial 
hyperplasia 
1.7±0.2 ND 2.7±0.2 a 2.6±0.2 a 1.2±0.2 1.0±0.0 a 1.5±0.5 1.2±0.2 1.4±0.2 1.6±0.2 b 1.0±0.0 b 1.0±0.4 2.0±0.0 b 1.5±0.2 
Lymphoid 
infiltration 
2.0±0.0 a ND 1.5±0.2 1.4±0.2 2.0±0.0 1.7±0.2 2.0±0.0 1.0±0.0 b 1.2±0.2 1.8±0.2 1.6±0.2 1.6±0.4 2.2±0.2 1.5±0.2 
 
ND: not done; Data are expressed as the mean histopathological lesion score ± SEM (n = 5). Tracheal lesions scores as follows: no change (0), mild (1), moderate (2) or 
severe (3). For each time point and lesions, different superscripts for SPF and broiler chicks indicate significant differences between them (p < 0.05). Absence of a letter 
indicates that there were no significant differences (p > 0.05). 
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Table 3.3. Histopathology of the kidney in SPF or broiler chicks infected with IBV IS/885 strain.  
 
Kidney lesions 
SPF  (dpi) Broiler (dpi) 
3 6 9 12 15 21 28 3 6 9 12 15 21 28 
Epithelial 
degeneration 
0.0±0.0 0.0±0.0 0.6±0.2 0.2±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.4±0.2 0.0±0.0 0.0±0.0 0.2±0.2 0.2±0.2 0.0±0.0 
Ducto-tubular 
dilation 
0.4±0.2 0.4±0.2 0.2±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.2 0.2±0.2 0.0±0.0 0.0±0.0 0.0±0.0 
Heterophil 
infiltration 
0.2±0.2 1.0±0.0a 0.2±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0b 0.2±0.2 0.0±0.0 0.2±0.2 0.0±0.0 0.4±0.2 
Lymphoid 
infiltration 
0.0±0.0 0.0±0.0 1.0±0.0 1.6±0.2 1.0±0.0 0.6±0.2 0.4±0.2 0.0±0.0 0.0±0.0 1.0±0.0 1.2±0.2 0.6±0.2 0.6±0.2 0.0±0.0 
Epithelial 
regeneration 
0.0±0.0 0.0±0.0 0.2±0.2 0.2±0.2 0.8±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.8±0.3 0.2±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
Epithelial 
hyperplasia 
0.2±.02 0.0±0.0 0.6±0.2 0.2±0.2 1.0±0.0a 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.2 0.0±0.0 0.0±0.0 0.2±0.2b 0.2±0.2 0.0±0.0 
Lymphoid  
nodules 
0.0±0.0 0.0±0.0 0.6±0.2 0.8±0.2 1.0±0.0a 0.4±0.2 0.8±0.2 0.0±0.0 0.0±0.0 0.0±0.0 0.6±0.4 0.0±0.0b 0.4±0.4 1.0±0.0 
 
Data are expressed as the mean histopathological lesion score ± SEM (n = 5). Kidney lesions scores as follows: no change (0), mild (1), moderate (2) or severe (3). For each 
time point and lesions, different superscripts for SPF and broiler chicks indicate significant differences between them (p < 0.05). Absence of a letter indicates that there were 
no significant differences (p > 0.05).
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3.5. 3.3. Oviduct of infected SPF chicks 
 
The oviduct lumen is multifocally partially lined by compact epithelial cells which 
have entirely lost their cilia (Figure 3.4). Many epithelial cells are shed into the 
lumen leaving sections devoid of mucosa. The underlying submucosa is multifocally 
infiltrated by both moderate numbers of degenerate and viable lymphocytes and 
plasma cells with lesser numbers of macrophages.    
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Hematoxylin and eosin stains of the cystic oviduct of infected female 
SPF chicks at 28dpi (magnification at 400x). Multifocal moderate chronic 
lymphocytic salpingitis with cystic dilation. Diffuse loss in the cilia (Black arrow) 
and infiltration of lymphocytes and plasma cells (Blue arrow). 
 
 
 
 
 
100 µm 
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3.5.4. IBV RT-PCR 
 
No virus was detected in the control groups of either experiment throughout the 
study. The viral genome was detected in pooled OP and CL swabs (Table 3.4) from 
both infected groups for the duration of the study (28 dpi).  
In the SPF chicks, the virus was detected in the trachea, lung, caecal tonsil and 
kidney in most of the tested samples for up to 15 dpi. Beyond that, the virus was 
infrequently detected in tissues (Table 3.5).   
In the broiler chicks, detection of the virus was lower than observed in the SPF 
chicks throughout the observation period. It was found most frequently in the caecal 
tonsil, followed by trachea (Table 3.5).  
 
Table 3.4. Virus detection by RT-PCR in swabs of SPF or broiler chicks infected 
with IBV IS/885 strain. 
 
dpi 
  
SPF Broiler 
OP CL OP CL 
3 + + + + 
6 + + + + 
9 + + + + 
12 + + + + 
15 + + + + 
21 + + - + 
28 + + + + 
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Table 3.5. Virus detection by RT-PCR in tissue of SPF or broiler chicks infected 
with IBV IS/885 strain. 
 
dpi 
SPF Broiler 
Tr L CT kid Tr L CT kid 
3 5 ⃰ 5 4 4 3 1 5 5 
6 5 5 5 5 5 2 5 2 
9 5 5 5 5 2 0 4 0 
12 5 5 4 5 4 1 2 1 
15 5 5 5 5 4 2 4 1 
21 2 3 4 3 0 0 3 1 
28 1 3 3 0 1 0 5 2 
Total
≠
 28 31 30 27 19 6 28 12 
 
* Values presented are number of IBV-positive cases out of five birds examined. Tr= Trachea, L= 
lung, CT= caecal tonsil, Kid= kidney.
 ≠ 
Total number of tissues that was positive for IBV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Three                                                                          Pathogenesis of IS/885                                                                                                                                         
                                                                                                                                                        
86 
 
3.5.5. Serology  
3.5.5. 1. ELISA 
 
Analysis of the antibody titres of both experiments using ELISA is summarised in 
Table 3.6.  
In the SPF chicks, sera collected prior to experimental infection were free of IBV 
antibodies. Chicks which received virus-free AF had ELISA titres lower than the 
detectable level throughout the experimental period. In the IS/885-infected chicks, 
an increase of antibody titres occurred at 21 dpi which decreased by 28 dpi (Table 
3.6).  
In broiler chicks, high levels of IBV MDA were detected in all birds at 1-day-old. 
By 3 dpi, the MDA had declined in the control and infected groups and showed no 
significant differences (Table 3.6). At 9 and 15 dpi, neither the infected nor control 
group had antibody titres above the cut-off point. However, at 21 and 28 dpi, highly 
significant antibody titres were observed in the infected group compared to the 
control group (Table 3.6).  
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Table 3.6. Mean ELISA antibody titres in the SPF and broiler chicks infected with 
IBV IS/885 strain.  
 
dpi 
SPF Broiler 
Infected Control Infected Control 
0 21±9.0 21±9.0 2867±229 2867±229 
3 ND ND 1813±343 1809±544 
6 ND ND 531±153
 
501±64 
9 ND ND 311±85 282±75 
15 160±64
a
 4.0±2.0
b
 378±175 75±19 
21 551±146
a
 12±5.0
 b
 1116±129
 a
 19±8.0
 b
 
28 481±194
a
 7.0±4.0
b
 623±35
 a
 10±8.0
 b
 
 
ND: test not done. Data are expressed as the mean values ± SEM (n = 8). Data in the same row with 
different superscript letters are significantly different in antibody titres (p < 0.05). Absence of a letter 
indicates that there were no significant differences (p > 0.05) between any of the time points. The 
cut-off point = 396. 
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3.5.5. 2. HI  
 
Analysis of the HI antibody titres of both experiments using different IBV antigens 
are summarised in Tables 3.7 and 3.8. 
In the SPF chicks, all sera collected prior to experimental infection and from the 
control group were free of IBV HI antibodies (Table 3.7). At 15 dpi, the HI titres 
against the heterologous antigens of M41 and 793B were low (<3 log2) compared to 
the homologous antigen (3.8 log2). At 21 dpi, chicks showed high antibody titres 
(≥3 log2) compared to control birds. The birds showed high significant level (p 
<0.05) of IBV HI antibody titres when IS/885 was used as antigen throughout the 
sampling time (Table 3.7).  
In the broiler chicks, sera collected at one day old showed a high, significant 
antibody titre when either M41 or 793B were used as the antigen (Table 3.8). Titres 
had started to decline significantly by 3 dpi in both the infected and control groups. 
At 6 and 9 dpi, there were no detectable titres in either (<3 log2). When all IBV 
antigens were compared, higher levels of IBV antibody titres were seen when IS/885 
used as the antigen from 15 dpi onwards.  
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Table 3.7. Mean HI antibody titres in the SPF chicks infected with IS/885 strain 
using homologous and heterologous antigens.   
 
dpi 
Infected Control 
M41 793B IS/885 M41 793B IS/885 
0 
0.6±0.2 1.1±0.2 0.7±0.2 0.6±0.2 1.1±0.2 0.6±0.2 
3 
ND ND ND ND ND ND 
6 
ND ND ND ND ND ND 
9 
ND ND ND ND ND ND 
15 
1.5±0.3
a
 0.6±0.1
a
 3.8±0.2
b*
 1.1±0.1 0.6±0.1 0.6±0.1 
21 4.0±0.2
a*
 3.6±0.3
a*
 5.1±0.3
b*
 0.8±0.3 0.7±0.2 0.3±0.1 
28 2.5±0.4
a*
 2.6±0.1
a*
 3.9±0.2
b*
 0.6±0.1 0.2±0.1 0.3±0.2 
 
ND: test not done. Data are expressed as the mean values ± SEM (n = 8). Data in the same row 
across with different superscript letters are significantly different (p < 0.05). Absence of a letter 
indicates that there were no significant differences (p > 0.05) between the IBV antigens at any of the 
time points.
 *
Values differed significantly from each representative control group. 
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Table 3.8. Mean HI antibody titres in the broiler chicks infected with IS/885 strain 
using IBV homologous and heterologous antigens.     
 
dpi 
Infected group Control 
M41 793B IS/885 M41 793B IS/885 
0 
6.2±0.6
 a
 5.8±0.5
a
 3.5±0.2
b
 6.2±0.6
a
 5.8±0.5
a
 3.5±0.2
 b
 
3 
5.1±0.7
a
 5.0±0.2
a
 2.6±0.1
b
 5.1±1.1
a
 5.5±0.8
a
 3.1±0.1
b
 
6 
2.4±0.6 1.3±0.3 2.1±0.2 3.0±0.3
 a
 3.3±0.5
b
 1.7±0.3
a
 
9 
1.6±0.8 1.4±0.2 1.8±0.2 1.6±0.8 2.3±0.6 1.1±0.2 
15 3.5±0.1
a*
 3.3±0.1
a*
 4.0±0.2
a*
 1.3±0.4 0.7±0.1 1.0 ±0.0 
21 5.0±0.0
 a*
 4.2±0.4
a*
 5.8±0.2
b*
 1.1±0.3 0.6±0.1 0.3±0.2 
28 3.7±0.1
a*
 3.5±0.1
a*
 4.5±0.1
b*
 0.7±0.2 0.4±0.1 0.1±0.1 
 
Data are expressed as the mean values ± SEM (n = 8). Data in the same row across with different 
superscript letters are significantly different (p < 0.05). Absence of a letter indicates that there were 
no significant differences (p > 0.05) between the IBV antigens at any of the time points.
 *
Values 
differed significantly from each representative control group.   
 
 
 
 
 
 
 
 
 
 
 Chapter Three                                                                          Pathogenesis of IS/885                                                                                                                                         
                                                                                                                                                        
91 
 
3.6. Discussion  
 
The results presented in this study demonstrate that IS/885/00 is a virulent IBV, as 
extensive disease was produced following infection in both types of chicks. In 
addition to the respiratory signs, gross lesions comprising tracheal caseous exudate 
and plugs, and swollen kidneys with (or without) urate deposits were observed. Such 
clinical signs have been observed following infection with virulent IBV 
M41(Butcher et al., 1990), Moroccan G strain (Ambali and Jones, 1990),793B 
(Boroomand et al., 2012), It-02 (Dolz et al., 2012) and QX (Ganapathy et al., 2012). 
These clinical signs and lesions were more severe in SPF than in the broiler chicks, 
indicating differences in the susceptibility to IBV infection in these different types of 
birds. Such differences could be contributed to the genetic line of the birds or the 
IBV MDAs in the broiler chicks (Ignjatovic et al., 2003). Previous studies using 
virulent IBV M41 demonstrated a considerable difference between two white 
leghorn chick lines in term of the severity and duration of respiratory signs (Otsuki 
et al., 1990). Another study compared mortalities in several inbred lines of chickens 
following inoculation with a pool of strains of IBV and/or E.coli and found marked 
differences among them (Bumstead et al., 1989).   
It has been reported that chicks with high antibody titres had excellent protection 
against infection by IBV M41 at one day old but not at seven days old (Mondal and 
Naqi, 2001) and that MDA does not prevent the viral infection but does reduce the 
pathogenic effects of the IBV infection in young chicks (Klieve and Cumming, 
1988). Our findings suggest that MDA is an important factor in determining the 
severity of the disease caused by IBV IS/885 strain at a young age. 
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Following IS/885 infection of the broiler chicks, clear periorbital swelling was noted 
in one bird at 15 dpi. The swab collected from this site was positive for IBV by 
RT-PCR and VI, and sequencing demonstrated 100% nucleotide level similarity to 
IS/885. Neither aMPV nor bacteria were detected or cultured from swabbing, 
suggesting that mild head swelling was due to the IBV infection. This finding is 
similar to the first  report of SHS where untyped coronavirus  and E.coli were 
isolated from a broiler chickens in Southern Africa (Morley and Thomson, 1984). 
IBV M41 and E.coli were isolated from broiler flock in the USA that experienced 
SHS (Droual and Woolcock, 1994). Apart from IBV, aMPV (Picault et al., 1987; 
Aung et al., 2008), FAdV (Droual and Woolcock, 1994; Georgiades et al., 2001) and 
the presence of a secondary infection (such as E.coli) have been implicated as the 
cause of SHS (Nakamura et al., 1997; Nakamura et al., 1998).   
In the IS/885-infected SPF chicks, necropsy examination at 28 dpi revealed dilation 
of the oviduct with fluid content (cystic oviduct) in two female chicks. Cystic 
oviduct formation following infection of virulent IBVs at a young age has been 
reported for IBV variants M41 (Crinion et al., 1971; Crinion and Hofstad, 1972a; 
Jones and Jordan, 1972) and recently, QX (Benyeda et al., 2009; de Wit et al., 
2011b; Ganapathy et al., 2012). We report, for the first time, similar pathological 
development in SPF chicks that received the IS/885 virus at 1-day-old. In addition, 
the virus with 99% part-S1 sequence similarity to IS/885 was isolated from the 
cystic fluid. The epithelial cells of the oviduct are the primary cells attacked by the 
IBV (Crinion and Hofstad, 1972a). From this evidence, the IS/885 has caused a 
diffuse loss in the cilia, epithelial necrosis and infiltration of lymphocytes and 
plasma cells into the oviduct which indicates that the virus has replicated in the 
epithelial cells lining the oviduct.  
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The pathogenicity of IBV strain for the oviduct varies as some do not replicate in the 
oviduct neither causing lesions nor showing significant amounts of viral antigen in 
the epithelial cells (Crinion and Hofstad, 1972a). For instance, IBV Conn and Iowa 
failed to produce any gross or histopathological change in the oviduct which 
involved incidence of microscopic cystic oviduct and cellular infiltration and 
oedema in the oviduct wall. In contrast, IBV M41 produced the greatest number of 
changes, followed by Australian T which both  showed significant amounts of IBV 
antigen by immunofluorescence in epithelial cells lining the oviduct (Crinion and 
Hofstad, 1972a). Benyeda et al. (2009) also did not detect any abnormalities in the 
oviducts of 793B infected 1-day-old SPF chicks, whereas a variable percentage of 
oviduct dilatations were detected following inoculation with five different QX-like 
strains. It appears that along with M41 and QX, IS/885 should be considered as a 
potential cause of cystic oviducts in chickens. 
The microscopic findings in the SPF and broiler chicks following IS/885 infection 
were similar to previous reports (Albassam et al., 1986; Nakamura et al., 1991; Chen 
et al., 1996; Benyeda et al., 2010). In this work, the SPF chicks had greater 
degeneration in the trachea, indicating a more extensive virus replication than broiler 
chicks, which may have been due to extravasation of circulating maternal antibody 
in the latter. In both types of birds, severe and early onset of histopathological 
lesions was seen in the trachea, compared to mild lesions in the kidney. 
Nephropathogenic IBVs have shown tropism for respiratory and kidney tissues 
although kidney lesions are more apparent (Albassam et al., 1986; Butcher et al., 
1989). Based on our findings, the IS/885 strain appears to have an affinity for both 
respiratory and renal tissues.  
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In the current study, persistence of the viral genome was observed in the selected 
tissues and swabs until the end of all experiments (28 dpi). Previous studies have 
reported the detection of virulent IBV It-02 in the trachea and kidney of infected 
SPF chicks by RT-PCR for up to 21 dpi (Dolz et al., 2012). For other pathogenicity 
studies conducted in broiler chicks free of MDA, the viral genome of virulent IBV 
793B was detected in the trachea for up to 13 dpi and in the kidney for up to 15 dpi 
(Boroomand et al., 2012). Discrepancies in these findings could be due to individual 
IBV strain differences. The viral genome could be detected in the kidney as early as 
3 dpi. Such observations are supported by several other studies in which virulent 
IBV 793B (Boroomand et al., 2012) and It-02 (Dolz et al., 2012) were detected by 
RT-PCR from the kidney of infected SPF chicks from 1 dpi. Dhinakar Raj and Jones 
(1996a) reported the isolation of 793B from the kidney of infected SPF chicks at 
1 dpi and from broiler chicks at 3 dpi.  
Our findings showed that the total amount of positive tissue in the SPF chicks was 
greater than in the broilers. This may relate to the extensive virus replication in fully 
susceptible chicks. This is similar to the finding of Dhinakar Raj and Jones (1996a), 
where virulent 793B was recovered from respiratory tissues (trachea and lung) for 
7 to 10 dpi in SPF chicks but only 3 dpi in broilers.  
Virus shedding in both OP and CL was investigated by RT-PCR and the viral 
genome was consistently detected until the end of the experiment. A similar 
observation was reported, in which IBV It-02 was detected by RT-PCR in nasal and 
CL swabs for up to 27 dpi (Dolz et al., 2012). Previously, El Houadfi et al. (1986) 
reported the isolation of the Moroccan G strain from CL swabs for up to 28 dpi. 
These observations indicate the virus persisted for longer period in the OP and CL 
swabs.  
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The immune response after infection with IBV was measured by ELISA and HI. 
High level of maternal antibodies at 0, 3 and 6 days old for IBV could be detected by 
HI when IBV M41 and 793B were used as antigens compared to IS/885. These 
findings may due to the parent flock of the broiler chicks having been vaccinated 
with Mass or/and 793B types. 
ELISA detected low to moderate levels of the antibody to IBV in the infected SPF 
chicks, compared to infected broilers. This discrepancy could be related to different 
types of birds. However, significant levels of HI antibodies against the IS/885 
antigen were witnessed when compared to the level of antibody response against 
M41 and 793B antigens. This finding may reflect the use of the homologous virus as 
an antigen in the HI test, as it is well known that the HI test is strain specific 
(Monreal et al., 1985; de Wit et al., 1997).   
In conclusion, this study showed that IBV IS/885 is pathogenic for both SPF and 
broiler chicks under experimental conditions. The virus affected epithelium of the 
trachea and produced severe kidney lesions; however, the disease was more severe 
in SPF than in the broiler chicks. Our study suggests the IS/885 has tropism for both 
respiratory and renal tissues. In addition, it could be implicated in the pathology of 
head-swelling and cystic oviduct development in young chicks.  
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Chapter 4: Protection conferred by live infectious 
bronchitis vaccine viruses against variant Middle East 
IS/885/00-like and IS/1494/06-like isolates in commercial 
broiler chicks 
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4.1. Abstract 
 
The ability of the IB H120 (a Massachusetts strain) and CR88 (a 793B strain) live 
attenuated vaccine viruses to protect against two Middle East isolates IS/885 and 
IS/1494/06-like (IS/1494) in broiler chicks was investigated. Day-old chicks were 
separated into three groups, I) vaccinated with H120 at day-old followed by CR88 at 
14 days-old, II) vaccinated with H120 and CR88 simultaneously at day-old and 
again with CR88 at 14 days-old, III) control unvaccinated. At 30 days-old, each of 
the groups was challenged with virulent IS/885 or IS/1494. Protection was evaluated 
based on the clinical signs, tracheal and kidney gross lesions, tracheal ciliary scores 
and virus detection by RT-PCR. Results showed that administering combined live 
H120 and CR88 vaccines simultaneously at day old followed by CR88 vaccine at 14 
days-old gave more than 80% cilliary protection against both of the Middle East 
isolates. In addition, this programme conferred 100% protection against clinical 
signs and tracheal/kidney lesions. The other vaccination programme, H120 at 
day-old followed by CR88 at 14 days-old, provided somewhat lower protection, in 
particular against IS/885.   
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4.2. Introduction 
 
IB  is a ubiquitous virus with a high mutation rate, and a large number of serotypes 
or genotypes of IBV strains have been reported worldwide (de Wit et al., 2011a). 
Variant strains emerge due to changes in the IBV genome through point mutations, 
deletions, insertions or RNA recombination and these variants are often responsible 
for IB outbreaks in vaccinated chicken flocks (Cavanagh et al., 1988; Jia et al., 1995; 
Liu et al., 2007). Many countries have shown that multiple variant IBV strains are 
circulating in their poultry flocks (de Wit et al., 2011a). 
IS/885/00 and IS/1494/06 or those with high similarities to these strains of  IBVs 
have been reported throughout the Middle East and North Africa (Meir et al., 2004; 
Mahmood et al., 2011; Abdel-Moneim et al., 2012; Kahya et al., 2013; Awad et al., 
2014). In most cases, severe respiratory distress and renal lesions with high mortality 
were observed in vaccinated flocks affected by these strains. It appears that the 
conventional H120 vaccines alone do not provide sufficient protection against these 
strains (Meir et al., 2004; Kahya et al., 2013). However, development of vaccines 
against each of these new variants is not generally an option due to the high cost and 
time required for product registration (Jackwood et al., 2003; Bijlenga et al., 2004). 
Furthermore, it could be a never-ending race as new variant IBVs are constantly 
emerging in major poultry producing countries. Instead, it has been recommended 
that protection conferred by available live IBV vaccines against new variants should 
be constantly evaluated (Alvarado et al., 2003). Vaccination with one serotype does 
not ensure complete protection against heterologous strains (Cook et al., 1999a) but 
the use of different combinations of live IBV vaccines has been shown to be able to 
induce high and broad protection against challenges with several heterologous 
Chapter Four                                                    IBV Vaccine Protection
                                                                                                   
                                                                                                                                                           
   
99 
 
virulent IBV variants (Gelb et al., 1991; Cook et al., 1999a; Cook et al., 2001a; 
Alvarado et al., 2003; Martin et al., 2007; Terregino et al., 2008). 
The objective of this study is to evaluate the protection conferred by available live 
IBV vaccines when used in strategic manner against the two prominent Middle East 
variant IBVs that are related to IS/885/00 and IS/1494/06. In addition to the 
conventional vaccination programme (Mass at day-old followed by variant at 
14 days-old); we also evaluated another vaccination programme where the Mass and 
variant live vaccines were given simultaneously at day-old followed by a variant 
vaccine at 14 days-old. Following challenge, the protection was assessed based on 
ciliostasis assay as recommended by European Pharmacopoeia. In addition, clinical 
signs, gross lesions and presence of the viral genome in the trachea and kidney were 
evaluated. 
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4.3. Materials and methods 
 
4.3.1. Chicks 
 Day-old commercial broiler chicks with IBV MDA were used in this study (Chapter 
2.3.ii). Chicks were kept in an isolation unit throughout the experiment (Chapter 
2.3.iii). 
 
4.3.2. IBV vaccines 
Two different commercial live vaccines were used in this study; i) H120, vaccine 
belonging to Mass serotype (Merial S.A.S, Lyon, France) and (ii) 793B-type 
vaccine, strain CR88 (Merial S.A.S, Lyon, France). The vaccines were kept at 
+4-8
o
C until used. Each vaccine was dissolved in chilled SDW as follows: H120 
vaccine alone, CR88 vaccine alone, or H120 plus CR88 vaccines.  
4.3.3. IBV challenge strains 
Virulent strains of IBV IS/885 and IS/1494/06-like (referred here as IS/1494) were 
used as challenge viruses. These viruses had been isolated from a recent outbreak of 
high mortality and respiratory disease complex in broiler flocks in Egypt (Details 
source of the viruses described in Chapter 3.3. 1). The IS/885 strain was identified 
by RT-PCR and sequencing (Chapter 3.3. 1). The IS/1494 strain showed a high 
sequence 99% nucleotide level similarity to Israel strain IS/1494/06 (GenBank 
Accesion number: EU780077). The titre of the isolates were determined in SPF 
ECE, and expressed as 50% EID50 (Chapter 2.8.iii). 
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4.4. Experimental design 
 
Ninety one-day old commercial broiler chicks were divided into three groups of 
thirty chicks and housed in different isolation rooms. At 1 and 14 days-old, chicks 
were vaccinated oculonasally with 0.1 ml of vaccine according to the programme 
described in Table 4.1. Following the vaccinations, the birds were observed daily for 
clinical signs. Blood was collected prior to vaccination (1 day-old) and at 30 days 
old from eight chicks in each group for antibody responses. On the same day, ten 
chicks from each group (vaccinated and control groups) were transferred to another 
isolation room and challenged by the oculonasal route with 0.1 ml of virulent IS/885 
to provide 10
4.66 
EID50/chick. Another 10 chicks from each group were similarly 
transferred and challenged with 0.1 ml of virulent IS/1494 to provide 
10
5.00 
EID50/chick. The remaining 10 chicks (vaccinated or unvaccinated control) in 
each group were left as unchallenged controls. The birds were observed daily for 
clinical signs during the post-challenge period. Five days after challenge, all ten 
chicks in each unchallenged and challenged group were humanely euthanized 
(Chapter 2.5.iv). Vaccine protection was evaluated by ciliostasis test, examination of 
trachea and kidney for gross lesions, and virus detection by RT-PCR.  
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Table 4.1. Experimental design used to study the protection conferred by two 
different IBV vaccination programmes against the Middle East isolates of IS/885 
and IS/1494.  
 
Group 
Age and vaccination programmes ( Oculonasally) 
Day old 14 days-old 
I H120 CR88 
II H120+CR88 CR88 
III SW SW 
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4.4.1. Detection of antibody responses 
Sera collected prior to vaccination (1 day-old) and at 30 days old of age were tested 
using commercial ELISA (BioChek) following the protocols recommended by the 
manufacturer (Chapter 2.12.i.a). The HI test was carried out as described in Chapter 
2.12.ii.a. The IBV antigens used for the HI assay were M41, 793B, IS/885 and 
IS/1494 (Chapter 2.12.ii.a).  
4.4.2. Ciliostasis test 
Tracheas were removed from each chick and processed for ciliary assessment 
(Chapter 2.5.v). According to the European Pharmacopoeia’s, individual birds 
yielding 80% or more tracheal explants with ciliary activity were considered to have 
been protected by the vaccine against the challenge virus (Council of Europe, 2007).   
4.4.3. Gross lesions  
All chicks that were sacrificed at 5 day post challenge (dpc) were examined 
individually for gross tracheal and kidney lesions and scored following the criteria 
described in Chapter 2.5.ii. Total gross lesions scores for each group were calculated 
based on the mean of scores observed per total number of chicks.  
4.4.3. RT- PCR and DNA Sequencing 
Individual tissue samples of trachea and kidney were ground up using a pestle and 
mortar (Chapter 2.9.iii). RNA was extracted using QIAamp viral RNA mini kit 
following the manufacturer’s instructions (Chapter 2.10.ii). RT-PCR was carried out 
as described in Chapter 2.10.iii.  
Samples positive for IBV were processed for sequencing using EXO-SAP according 
to manufacturer’s instructions and were sequenced using the SX3+ primers (Chapter 
2.11).   
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4.4.4. Statistical analysis 
 
The ELISA, HI antibody titres and gross lesion between groups were analysed 
statistically using one way ANOVA, followed by Tukey’s test for comparison of 
means. Differences were considered to be significant when p ≤ 0.05. All analysis 
were conducted using the GraphPad Prism, 6.0.1. 
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4.5. Results 
 
4.5. 1. Clinical signs post vaccination 
There were no clinical signs found in the unvaccinated control chicks. In both 
vaccinated groups, mild clinical respiratory signs began to appear at 6 dpv. The 
signs included head shaking, tracheal râles and sneezes. These signs subsided by 
12 dpv.   
 
4.5. 2. Serology  
The mean ELISA antibody titre prior to vaccination (1 day-old, MDA) was 
4174±225. The means of IBV HI titres against IBV M41, 793B, IS/885 and IS/1494 
prior to vaccination were log2 6.3, 5.6, 3.5 and 3.1 respectively. 
At 30 days of age (on the day of challenge), vaccinated groups showed significantly 
higher levels of IBV ELISA antibody titre than the unvaccinated control group. 
Chicks of group II (d0:H120+CR88, d14:CR88) exhibited significantly higher 
antibody titre (P<0.05) than group I (d0:H120, d14:CR88) (Figure 4.1). The HI 
response to M41 and 793B were higher than the heterologous antigens (IS/885 and 
IS/1494) (Figure 4.2). Using the M41 as antigen, the vaccinated chickens showed 
high level of HI antibody titre compared to the control group (Group III). The 
antibody titre against 793B antigen in group II was significantly higher than group I 
(Figure 4. 2). 
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Figure 4.1. Mean ELISA antibody titres at 30 days of age. Group I= d0:H120, 
d14:CR88; group II= d0:H120+CR88, d14CR88; group; III= control. Bars represent 
the mean ± SEM (n=8). Different superscripts lowercases letters in the bar indicate 
significant difference (P<0.05), while data with same letters indicates that there were 
no significant differences (p > 0.05). The cut-off titre= 834. 
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Figure 4.2. HI antibody titres log2 against IBV antigens at 30 days of age. Group I= 
d0:H120, d14:CR88; group II= d0:H120+CR88, d14CR88; group III= control. Bars 
represent the mean ± SEM (n=8). Different superscripts lowercases letters in the bar 
indicate significant difference (P<0.05), while data with same letters indicates that 
there were no significant differences (p > 0.05) (within same antigen). 
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4.5. 3. Clinical signs post challenge 
The unvaccinated and vaccinated-unchallenged groups were remained free of 
clinical signs. All the ten chicks of  unvaccinated-challenged chicks showed signs of 
typical IBV infection at 1 dpc which including depression with ruffled feathers, 
listlessness and huddling, head shaking, tracheal râles, sneezing and coughing. These 
signs were continued up to 5 dpc. In contrast, no clinical signs were observed in both 
of the vaccinated-challenged groups. 
4.5. 4. Ciliostasis test 
The percentage ciliostasis protection was calculated for each group. The 
unvaccinated and vaccinated-unchallenged groups had greater than 98% ciliary 
activity. The unvaccinated (group III) birds challenged with either IS/885 or IS/1494 
viruses had protection scores of 0% (Table 4.2). Group II (d0:H120+CR88, 
d14:CR88) and group I (d0:H120, d14:CR88) showed 83% and 60% ciliary 
protection against IS/885 challenge respectively (Table 2). Following challenge with 
IS/1494, the group I and II gave 80% and 94 % protection respectively (Table 4.2). 
4.5. 5. Gross lesions 
The unvaccinated and vaccinated-unchallenged control groups remained free of 
gross lesions. Five days after the IS/885 challenge, congestion of the trachea and 
pale swollen kidneys were observed in all chicks in group III (unvaccinated 
challenged). These lesions were also found in group I (Table 4.2). However, birds in 
group II were free of these gross lesions. Following the IS/1494 challenge, 
congestion of trachea and pale swollen of kidney was observed in one bird in group 
I, while it appeared normal in the rest of the birds (Table 4.2). Chicks in group II 
showed no tracheal or kidney lesions. 
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Table 4.2. Ciliostasis test and gross lesions of IBV-vaccinated and unvaccinated chicks following challenge with IS/885 or IS/1494 isolates. 
 
Groups 
IS/885 IS/1494 
Ciliostasis test Gross lesions 
*
 Ciliostasis test
 
Gross lesions 
% Protection scores Trachea Kidney % Protection  scores Trachea Kidney 
I 
60 0.3±0.1
a
 0.6±0.1
b
 80 0.1±0.1
 a
 0.1±0.1
 a
 
II 
83 0.0±0.0
 a
 0.0±0.0
 a
 94 0.0±0.0
 a
 0.0±0.0
 a
 
III 0 0.9±0.1
b
 0.9±0.1
b
 0 0.8±0.1
b
 0.8±0.1
b
 
 
Group I= d0:H120, d14:CR88; group II= d0:H120+CR88, d14CR88; group III= unvaccinated control. 
* 
Severity of gross lesions induced by virulent IBV infection and data 
are expressed as the mean gross lesion score ± SEM (n=10).  Different superscripts lowercases letters within same columns indicate significant difference (P<0.05), while 
data with same letters indicates that there were no significant differences (p > 0.05).
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4.5. 6. Post challenge virus detection 
 
The number of birds positive for detection of IBV genome in the trachea or kidney, 
five days after the virulent IS/885 or IS/1494 challenges, are presented in the Table 
4.3 and Table 4.4 respectively. In the unvaccinated-challenged groups, either 
challenged by IS/885 or IS/1494, the challenge virus was detected in the trachea and 
kidney of all 10 chicks. Following the IS/885 challenge, for group I (d0:H120; 
d14:CR88), 9 tracheas and two kidneys were positive for the challenge virus. In 
contrast, in group II, no challenge virus was detected in kidney but four tracheas 
were positive for IBV (two vaccinal and the other two challenge viruses). When the 
groups were challenged with IS/1494, in group I, two of 10 and 6 of 10 kidney and 
trachea respectively were positive for the challenge virus.  For the trachea, one of 10 
tracheas was positive for the CR88 and the rest were negative for viruses. In 
group II, no virus was detected in trachea but one of 10 kidneys was positive for 
CR88. 
 
 
 
 
 
 
 
 
 
 
Chapter Four                                                                          IBV Vaccines Protection
                                                                                                                                          
110 
 
 
Table 4.3. Detection of the vaccine or challenge virus of IS/885 by RT-PCR in the 
trachea and kidney at 5 dpc. 
 
Groups 
Tissue 
samples 
Number of birds 
1 2 3 4 5 6 7 8 9 10 
 
I 
Trachea Ch
* Ch Ch - Ch Ch Ch Ch Ch Ch 
Kidney - - - - Ch Ch - - - - 
 
II 
Trachea CR88 - CR88 - Ch - - Ch - - 
Kidney - - - - - - - - - - 
 
III 
Trachea Ch
 
Ch Ch Ch Ch Ch Ch Ch Ch Ch 
Kidney Ch
 
Ch Ch Ch Ch Ch Ch Ch Ch Ch 
 
*
Challenge virus (99 to100% part-S1 sequence similarity to the initial inoculum of IS/885). Group I= 
d0:H120, d14:CR88; group II= d0:H120+CR88, d14CR88; group III= unvaccinated control. 
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Table 4.4. Detection of the vaccines or challenge virus of IS/1494 by RT-PCR in the 
trachea and kidney at 5 dpc. 
Groups 
Tissue 
samples 
Number of birds 
1 2 3 4 5 6 7 8 9 10 
 
I 
Trachea - Ch
*
 Ch - - Ch Ch Ch CR88 Ch 
Kidney - - - - Ch - - - - Ch 
 
II 
Trachea - - - - - - - - - - 
Kidney - CR88 - - - - - - - - 
 
III 
Trachea Ch Ch Ch Ch Ch Ch Ch Ch Ch Ch 
Kidney Ch Ch Ch Ch Ch Ch Ch Ch Ch Ch 
 
*  
Challenge virus (99 to100% part-S1 sequence similarity to the initial inoculum of IS/1494). Group 
I= d0:H120, d14:CR88; group II= d0:H120+CR88, d14CR88; group III= unvaccinated control. 
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4.6. Discussion 
 
The evaluation of protection conferred by live vaccines against the virulent IS/885 
and IS/1494 isolates was assessed based on ciliary activity in the tracheal explants 
prepared from vaccinated-challenged chicks (Darbyshire, 1980; Marquardt et al., 
1982; Andrade et al., 1982; Snyder et al., 1983; Cook et al., 1999a), gross lesions 
and virus detection in the trachea and kidneys following the challenge with the 
respective viruses. The combined vaccination programme where both live H120 and 
CR88 vaccines were simultaneously given at one day-old followed by CR88 vaccine 
two weeks later (Group II) provided an excellent protection against both isolates. 
Following the challenges, there were no clinical signs or tracheal/kidney lesions and 
the ciliary protection was high (83% to 94%). While 100% of the unvaccinated 
challenged birds were positive for IBV RNA in the trachea and kidney, in group II, 
no RNA was detected in kidneys and only 20% of the trachea was positive for the 
challenge virus.   
Live H120 vaccine alone at day old followed by CR88 vaccine two weeks later 
(group I) conferred somewhat poorer protection against IS/885 than group II. 
Protection was much improved when the CR88 was given together with the H120 at 
day-old in contrast to H120 given alone. It must be noted that the vaccine 
programme given to group II also offered 100% kidney protection against both 
isolates. In a previous study performed in SPF chicks, live H120 vaccination 
afforded protection of the trachea (92%) and the kidney (25%) on the basis of virus 
isolation when the birds were challenged with IS/885/00 (Meir et al., 2004). 
Moreover, immunization with live H120, H52, and D274 given singly was reported 
to produce little cross protection against challenge with other nephropathogenic IBV 
strains (Lambrechts et al., 1993; Pensaert and Lambrechts, 1994). Our study shows 
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that the vaccination programme of group II has further boosted the ciliary and 
tracheal/kidney protection against IS/885 compared to that of group I.   
Both vaccination programmes used in this experiment provided excellent protection 
against the virulent IS/1494 challenge. A better protection observed in group II 
(d0:H120+CR88, d14CR88) as compared to group I (d0:H120, d14CR88), could be 
due to the higher levels of local and cellular immunity at the tracheal site which may 
have prevented the virulent virus from reaching the kidneys (Lambrechts et al., 
1993). In an another experiment, cellular and local immunity induced by 
administration of combined live Massachusetts and 793B-type vaccines at day old 
showed a significant increase in the expression of CD4+, CD8+ and IgA-bearing B 
cells in the trachea compared to single H120 alone or unvaccinated groups (Chapter 
5). These results reinforce the importance of optimising local and cell-mediated 
mucosal immunity at the respiratory lining through strategic heterologous day-old 
vaccination for enhanced protection against variant viruses. 
As the challenge virus could be differentiated from the vaccinal strains by part-S1 
sequencing in this study, the trachea and kidney were examined for the presence of 
the respective challenge viruses following the challenge. Upon excluding birds with 
vaccine virus detection, group II displayed 80% or more tracheal protection and no 
virus (100% protection) in the kidney, following the IS/885 or IS/494 challenges. 
This demonstrates excellent protection by this vaccination programme and this 
supports the other findings (eg. clinical signs, gross lesions and ciliary scores). In 
contrast, group I showed poorer protection, particularly in the trachea. While the 
tracheal protection was only 10% and 40% against IS/885 and IS/1494 challenge 
viruses respectively, the kidney of 80% of the birds were protected. This shows that 
vaccination programme in group 1 (d0:H120; d14:CR88) provides lower protection 
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against these challenge viruses, particularly against IS/885. In some cases, where the 
challenge virus can be differentiated from vaccinal IBV strains, redetection of the 
challenge virus in trachea and kidney can be used as part of protection studies. 
Humoral antibody responses following vaccination as measured by ELISA and HI 
are often used for monitoring vaccine-take (Dhinakar Raj and Jones, 1997). In this 
study, at 30 days of age (challenge day) the mean ELISA titre and the mean 793B HI 
titre in group II were significantly higher than the other vaccinated group. This 
reflects that combined live IBV vaccination at day-old and re-vaccination at 
14 days-old has provided an immunological boost compare to the other vaccination 
schedule (group I). Although it has been demonstrated before that circulating 
humoral antibody levels are of minor importance in the protection against IBV 
infection (Raggi and Lee, 1965; Darbyshire and Peters, 1985; Endo-Munoz and 
Faragher, 1989; Pensaert and Lambrechts, 1994), in our study the group with higher 
levels of humoral antibodies had better protection against both of the Middle East 
isolates. Cytotoxic T cell plays a vital anti-viral activity during early stages of IBV 
infection while serum IgG is critical at the late stage of IBV infection (Collisson et 
al., 2000). 
Despite the low level of genetic homology in the S1 protein between the vaccine and 
challenge strains used in this study, the protection achieved with the vaccination 
programme employed in the present study was high. The genetic relationship of the 
hypervariable region of the S1 gene between IS/885 and H120 or CR88 was 80% 
and 79% respectively, while the genetic relationship between the IS/1494 and H120 
or CR88 was 81% and 80% respectively. Despite the 19-21% variation in the S1 
gene, the successful protection conferred by vaccination programmes employed in 
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this study may be attributable to the shared characteristics of the S1 protein of the 
vaccine and the challenge IBVs (Cavanagh et al., 1986a).  
Based on the data presented in this study, it appears that a combination of live H120 
and CR88 vaccines given at day old followed by CR88 vaccine at day 14 of age 
confer an excellent protection against virulent variant IS/885 and IS/1494 viruses. 
More work is needed to establish the underlying immune mechanisms for such 
higher and broader protection conferred by these distant vaccine viruses. 
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Chapter 5: Effects of homologous and heterologous live 
IBV vaccination in day-old commercial broiler chicks: 
tracheal health, immune responses and protection 
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5.1. Abstract 
 
Group of commercial broiler chicks were vaccinated at one day-old with seven live 
IBV vaccines which included two different Mass-type and two different 793B-type 
vaccines. Five chicks were humanly killed at intervals and tracheal samples were 
collected for ciliary activity assessment and for the detection of CD4+, CD8+ and 
IgA-bearing B cells by IHC. Blood samples were collected regularly for the 
detection of IBV antibody responses by ELISA. Protection studies were conducted 
to evaluate immunity conferred by different vaccination regimes against virulent 
IBV M41, QX and 793B strain challenges. Chicks receiving two vaccines showed 
substantial damage to the trachea epithelium at 10 and 14 dpv compared to those 
given single vaccines. All vaccine viruses were able to induce measurable levels of 
CD4+, CD8+ and IgA-bearing B cells in the trachea following vaccination when 
compared to unvaccinated birds. At peak time, significantly higher levels of CD4+ 
(6 dpv), CD8+ (14 dpv) expression were observed in the dual vaccinated groups 
when compared to single vaccine groups. These results indicate variations in the 
development of CMI following live IBV vaccinations at day-old. At the time of 
challenge there were low levels or no circulating antibodies against IBV detected by 
ELISA. Protection studies indicated that the group of chicks vaccinated with 
Mass2+793B2 produced good cross protection against challenge with IBV QX when 
compared to Mass1+D274 or 793B1. All vaccines produced solid immunity (>80% 
protection) against homologous challenge from IBV M41 and 793B.    
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5.2. Introduction 
 
Infectious bronchitis is controlled by the administration of live, IBV attenuated 
vaccines and it has been suggested that mucosal immunity is essential for effective 
protection against the virus (Gomez and Raggi, 1974). The development of local 
immunity may rely on the direct interaction between mucosal immune system 
elements and IBV itself (Toro et al., 1997; Guo et al., 2008). Previous studies have 
reported the development of humoral immune responses following live IBV 
vaccination (Cook et al., 1999a; Terregino et al., 2008). However, conflicting studies 
demonstrate that humoral responses have a low correlation with protection against 
IBV infection (Raggi and Lee, 1965; Roh et al., 2013). Instead, they highlighted the 
importance of the local and CMI in IBV infections.  
Trachea being a main target of IBV, cellular and local immunity in that organ has 
been demonstrated (Nakamura et al., 1991; Dhinakar Raj and Jones, 1996a; Kotani 
et al., 2000). It has been shown that IgA and CD8+ T cell responses which  develop 
at tracheal sites following IBV vaccination could be taken as a good indicator of 
protection against the virus (Okino et al., 2013). Local anti-IBV antibodies, 
particularly IgA and cytotoxic T cells, have been shown as crucial for restricting or 
eliminating IBV from the host (Gillette, 1981; Collisson et al., 2000; Mondal and 
Naqi, 2001). It has been demonstrated that lachrymal fluid IgA levels of chickens 
are associated with resistance against IBV infection (Toro and Fernandez, 1994). 
However, little information is available regarding the evaluation of cellular and local 
immune responses elicited by different live IBV vaccination programmes. 
It well recognized that IBV consists of more than one serotype. Mass 41 and 793B 
serotypes have spread worldwide and commercial vaccines are available (Bijlenga et 
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al., 2004; Jones, 2010). Despite vaccination, different and novel serotypes continue 
to be a major concern in poultry of all ages in many parts of the world (de Wit et al., 
2011a). In addition, the continuous emergence of novel antigenic variants makes 
prevention of IBV infections challenging. The QX serotype was first isolated in 
China in 1996 from birds with proventriculitis (Wang et al., 1998), and later reported 
in Europe (Beato et al., 2005; Worthington et al., 2008), Middle East (Amin et al., 
2012), Africa (Toffan et al., 2011a), and rapidly spread to become the most 
widespread serotype of non-vaccine origin (Worthington et al., 2008). 
To achieve broad protection against challenge from IBV variants, the use of 
combinations of  different  live IBV vaccines has been shown to induce a wide of 
protection against challenge from several heterologous strains (Cook et al., 1999a; 
Gelb et al., 2005). The phenomenon of IBV cross-protection has been recognized for 
many years (Hofstad, 1981; Cook et al., 1999a), and has been attributed to the host 
immune response towards several IBV gene epitopes, especially the S1 sub-unit 
(Cavanagh et al., 1997).  
This study aimed to evaluate the tracheal health of chicks following vaccination with 
a number IBV strains belonging to serotypes Mass, D274 and 793B, or Ark using 
ciliary activity assessment. The cellular and local immune responses in trachea were 
assessed using IHC. The humoral antibody responses against IBV were also 
evaluated using a commercial ELISA kit. Furthermore, the protection conferred by 
different vaccine programmes against virulent IBV M41, QX and 793B was 
evaluated. Following challenge, clinical signs, ciliary activity and virus detection by 
RT-PCR were carried out.  
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5.3. Materials and methods 
 
5.3.1. Chicks 
 
Day-old commercial broiler chicks with IBV MDA were obtained from a 
commercial hatchery (Chapter 2.3.ii). 
 
5.3.2. IBV vaccines 
Seven commercially available live IBV vaccines were used. They belong to four 
different serotypes, namely Mass, 793B, D274 and Ark. Vaccines ‘Mass1’ and 
‘Mass2’ contained two different strains of the Mass serotypes. Two commonly used 
793B vaccines, referred here as 793B1 and 793B2 were used in combination with the 
Mass vaccines. The mixtures of Mass1+793B1 and Mass2+793B2 were prepared in 
our laboratory. Vaccine ‘Mass1+D274’ is a commercial combined live vaccine 
containing both a Mass and D274-type strain.  Vaccine ‘Mass3+Ark’ contained a 
manufactured combination of a Mass and Ark-type strain. All vaccines were 
prepared prior administration and to provide the dosages per chick as recommended 
by the manufacturers.   
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5.3.3. IBV challenge strains 
Virulent IBV challenge viruses belonging to three different serotypes were used.  
M41 has been maintained in our laboratory for several years (Dhinakar Raj and 
Jones, 1996b). QX (KG3P) strain was first isolated from the proventriculus of a 
flock of broilers in England (Ganapathy et al., 2012). The 793B (KG12/11) strain 
was isolated from caecal tonsil that came from a flock of layers suffering from a 
drop in egg production (Ganapathy, unpublished data). All viruses were grown in 
ECE and titrated in TOC as described in Chapter 2.8. 
5.4. Experimental design 
 
Three hundred and eighty five, day-old chicks were randomly divided into seven 
groups and kept in separate isolation units, with 55 chicks per group. Each group 
was inoculated with one of the following, Mass1 (group 1), Mass2 (group 2), 
Mass1+D274 (group 3), Mass1+793B1 (group 4), Mass2+793B2 (group 5), 
Mass3+Ark (group 6) and SW (group 7, control). Each chick was inoculated via 
oculo (50 µl) and nasal (50 µl) routes. Dosages were given as recommended by the 
manufacturer. Following vaccination, chicks were observed daily for clinical signs 
as described in Chapter 2.5.i. 
5.4.1. Study 1. Evaluation of tracheal health of chicks following live IBV 
vaccinations 
At 3, 6, 10, 14, 18 and 25 dpv, five chicks from each group were humanely killed. 
Tracheas were removed from each chick and processed for ciliostasis test as 
described in Chapter 2.5.v. 
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5.4.2. Study 2. Evaluation of tracheal immunity induced by live IBV vaccines 
 
During necropsy, pieces of the trachea were collected at 3, 6, 10, 14, 18 and 25 dpv 
from five chicks in each group. Pieces of trachea were used for the detection of 
CD4+, CD8+ and IgA-bearing B cells by IHC as described in Chapter 2.13. 
 5.4.3. Study 3. Evaluation of humoral antibody response induced by live IBV 
vaccines 
 
IBV antibodies were detected using a commercial ELISA kit (BioChek) following 
the protocols recommended by the manufacturer (Chapter 2.12.i.a). Serum was 
collected prior to vaccination and then at 3, 6, 10, 14, 18 and 25 dpv from eight 
chicks per group to evaluate the antibody response against IBV.   
5.4.4. Study 4. Assessment of protection induced by homologous or heterologous 
vaccination against virulent IBVs 
At 21 days of age, five chicks were taken from each group and challenged 
oculonasally with 10
5.00 
CD50 M41 per dose of 0.1 ml. The same number from each 
group was challenged with 10
5.00
 CD50/ml QX per dose of 0.1 ml, and a further five 
birds from the combined vaccine groups were challenged with 10
4.50
 CD50/ml 793B 
per dose of 0.1 ml via the same route. The remaining chicks in each group were left 
unchallenged in control groups. Following challenge, all birds were observed daily 
for clinical signs attributable to IBV infection (Chapter 2.5.i). Five dpc, the ciliary 
activity (Chapter 2.5.v) of tracheal explants was examined in both the challenged 
and unchallenged chicks. To evaluate the effect of vaccines on the prevention of 
shedding of the challenge virus, trachea and kidney tissue samples were collected 
and processed for virus detection by RT-PCR (Chapter 2.10). PCR positive products 
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corresponding to the S1 were purified with EXO-SAP for partial DNA sequencing 
(Chapter 2.11).   
5.5. Statistical analysis 
Statistical analysis of cellular, local and humoral antibody responses data was 
conducted using one way ANOVA, followed by Tukey’s test. Differences were 
considered to be significant when p ≤ 0.05. All analysis was conducted using 
GraphPad Prism, 6.0.1. 
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5.6. Results 
 
5.6.1. Clinical signs following vaccination 
A summary of the onset and duration of the clinical signs following vaccination for 
each vaccine group is shown in Figure 5.1. Control birds (group 7) remained free of 
clinical signs throughout the experiment. For groups that received single Mass strain 
vaccines (group 1 or 2), mild respiratory clinical signs of short duration such as head 
shaking, tracheal râles, sneezing and coughing appeared from 6 dpv and continued 
until 10 dpv. Groups 3 and 4 that were vaccinated with Mass1 combined with either 
D274 or 793B1 showed mild clinical signs starting at 5 dpv and subsiding by 14 dpv. 
Group 5 (Mass2+793B2), mild clinical signs were first observed at 2dpv, starting 
with coughing and sneezing. At 4 dpv some of the chicks were showing depression, 
ruffled feathers, coughing, gasping and up to 10 dpv, but thereafter the chicks 
showed mild respiratory signs and ultimately all signs disappeared at 14dpv. For 
group 6 (Mass3+Ark), signs of mild respiratory distress started at 2 dpv and 
continued up to 10 dpv.  
Despite showing only mild clinical signs, two birds in group 1 were dead at 6 and 8 
dpv, one bird died in group 2 at 2 dpv, two birds died in group 3 at 8 and 14 dpv and 
one bird died in group 4 at 14 dpv. No gross lesions were observed during post 
mortem examination. In group 5, during the stage when severe clinical signs were 
seen, three birds died at 6, 9 and 10 dpv. Post-mortem examination showed fibrinous 
pericarditis, peritonitis and perihepatitis in all birds. No deaths were recorded in 
group 6 or 7 (control). 
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Figure 5.1. Onset and duration of clinical signs and mortality within each of the 
seven vaccine groups. Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, 
Group 4 = Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and  
Group 7 = SW.   
 
5.6.2. Study 1. Tracheal health of chicks following live IBV vaccinations 
Results of the ciliary activity assessment are presented in Figure 5.2. Chicks 
vaccinated with a single live IBV vaccine (groups 1 and 2) showed no effect on 
trachea epithelium activity when compared to the unvaccinated birds. Between 
dually-vaccinated groups, the pattern of damage to the ciliary activities differed. 
Severe damage to the tracheal epithelium was seen in both groups 3 and 4 at 10 and 
14 dpv respectively compared to group 1 vaccinated solely with Mass1. Similarly, 
groups 5 and 6 demonstrated severe damage at 10 dpv when compared to group 2. 
Tracheal epithelium cells of the vaccinated groups were fully (≥ 80% protection) 
recovered at 18-25 dpv. 
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Figure 5.2. Comparison of ciliary activity in chicks receiving either one or two 
vaccines. Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, Group 4 = 
Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and  Group 7 = SW.   
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5.6.3. Study 2. Tracheal immunity induced by live IBV vaccinations 
 
All vaccine viruses induced measurable levels of CD4+, CD8+ (Table 5.1) and 
IgA-bearing B (Table 5.2) cells in the trachea following vaccination when compared 
to unvaccinated birds. CD4+ and CD8+ cell counts varied between each vaccinated 
group throughout sampling time. However, in all vaccinated groups the expression 
levels of CD4+ increased from 3 dpv, peaked at day 6 and then decreased 
dramatically after 10 dpv. One exception was a significantly high expression 
(p < 0.05) of CD4+ cells at 3 dpv for groups 2, 5 and 6. At 6 dpv a significantly high 
level of CD4+ cells was observed in the dual vaccinated groups (group 3, 4, 5 and 6) 
when compared to the single vaccine groups (group 1 and 2). At 10 dpv, group 5 and 
6 showed a significantly high level of CD4+ compared to all other vaccinated 
groups. However levels diminished by 25 dpv and no significant differences were 
seen between vaccinated and control groups.  
For CD8+ cell counts, no significant differences were observed at 3 dpv in 
vaccinated groups when compared to the control group. The average number CD8+ 
cells increased after 6 dpv and peaked by 14-18 dpv. At 10 dpv, high significantly 
levels of CD8+ were observed in combined vaccine groups (group 3, 4, 5 and 6) 
when compared to the single vaccine groups (group 1 and 2). By 14 dpv, no 
significant differences were observed between any of the vaccinated groups. The 
average number of CD8+ cells subsided by 25 dpv. The decline of CD4+ cells 
corresponded with an increase of CD8+ cells.   
All vaccinated groups demonstrated a significantly higher IgA-bearing B cell count 
when compared to the unvaccinated group throughout sampling time. Local 
IgA-bearing B cells levels peaked at 10 dpv, and in addition, the level of 
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IgA-bearing B cells was significantly higher (p < 0.05) in dual vaccinated groups 
(group 3, 4, 5 and 6) than single vaccinated groups (group 1 and 2). 
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  Table 5.1. Immunohistochemical detection of CD4+ and CD8+ cells in the trachea of chickens receiving IBV vaccinations. 
Vaccine 
Groups 
CD4+ 
 
CD8+ 
dpv 
 
dpv 
3 6 10 14 18 25 
 
3 6 10 14 18 25 
1 36±0.3
a
 46±4.8
a
 52±4.3
a
 37±4.3
ab
 17±0.8
a
 12±0.3 
 
11±0.1 22±1.7
a
 38±11
ab
 53±7.4
a
 66±0.6
a
 31±0.7 
2 71±0.4
b
 48±2.8
a
 34±4.7
ac
 11±1.3
a
 22±0.5
a
 9.0±0.2 
 
14±0.3 24±4.9
a
 27±5.1
a
 54±4.4
a
 48±14
a
 14±0.3 
3 35±0.3
a
 79±8.7
b
 34±3.7
c
 58±0.6
b
 37±10
ab
 13±0.2 
 
16±4.5 14.±1.3
ab
 43±7.1
b
 80±10
a
 51±0.3
a
 21±12 
4 50±4.5
a
 70±5.1
b
 29±3.7
c
 44±0.2
ab
 52±16
b
 25±0.6 
 
25±0.6 21±0.2
a
 49±7.1
ab
 57±0.4
a
 59±0.4
a
 25±11 
5 79±0.6
b
 93±7.5
b
 81±0.6
b
 35±0.3
ab
 17±0.3
a
 15±0.4 
 
24±0.8 19±2.4
ab
 87±18
b
 77±2.9
a
 58±2.7
a
 18±0.2 
6 76±0.6
b
 70±0.7
b
 62±5.6
b
 68±21
b
 27±0.7
a
 14±0.3 
 
28±10 29±2.4
a
 12±0.7
a
 68±21
a
 56±0.6
a
 12±0.7 
7 8±0.1
c
 13±0.2
c
 10±0.1
d
 6.0±0.5
a
 8.0±0.2
a
 4.0±0.1 
 
6.0±0.3 9.2±0.2
b
 7.0±0.1
a
 5.6±0.6
b
 8.2±0.2
b
 12±0.1 
 
 Data is expressed as mean values ± SEM. Significant differences within each column (dpv) are labelled with either a, b or ab. Groups with no significant difference     
between  them are labelled with the same letter, whereas groups with a significant difference are labelled with a different letter (p < 0.05). Time points with no significant 
differences are not labelled. Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, Group 4 = Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and  
Group 7 = SW.   
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Table 5.2. Immunohistochemical detection of IgA-bearing B cells in the trachea of 
chickens receiving IBV vaccinations. 
Vaccine 
Groups 
 
dpv 
3 6 10 14 18* 25* 
1 29±0.6
a
 40±0.6
a
 70±0.4
a
 66±0.4
a
   
2 31±11
a
 60±12
a
 84±0.9
ab
 77±0.5
ab
   
3 58±0.9
a
 50±0.9
a
 72±21
a
 59±20
a
   
4 52±0.8
a
 60±10
a
 96±15
ab
 70±13
ab
   
5 40±13
a
 68±19
a
 122±15
b
 102±22
b
   
6 42±14
a
 70±15
a
 88±14
ab
 78±0.5
ab
   
7 5.0±0.1
b
 4.0±0.5
b
 10±0.4
c
 10±0.4
c
   
 
*
No data were obtained for 18 or 25 dpv. Data is expressed as mean values ± SEM. Significant 
differences within each column (dpv) are labelled with either a, b or ab. Groups with no significant 
difference between them are labelled with the same letter, whereas groups with a significant 
difference are labelled with a different letter (p < 0.05). Time points with no significant differences 
are not labelled. Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, Group 4 = 
Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and Group 7 = SW.   
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5.6.4. Study 3. Humoral antibody response induced by live IBV vaccinations  
 
The mean ELISA antibody titre in the chicks at day-old was 5702±324. Mean titres 
of each group following vaccination are shown in Table 5.3. At 3 dpv, MDA levels 
began to decline in all groups, although group 5 (Mass2+793B2) had a significant 
reduction in antibody titre (p < 0.05) when compared to the other groups. At 6 dpv, 
no significant differences were seen between the vaccinated and control groups. By 
10 dpv, all groups had no detectable antibody titres, except for group 6 (Mass3+Ark) 
which was above the detectable titre level (Table 5.3). Despite an increase in 
antibody titres in four vaccinated groups at 18 dpv, all groups remained below 
detectable levels until end of the experiment. 
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Table 5.3. Mean ELISA antibody titres for each group receiving either single or 
combined vaccinations. 
Group 
dpv 
3 6 10 14 18 25 
1 3463±583
a
 1421±236 570±78
ab
 205±30
a
 401±57 314±57
ab
 
2 2466±380
a
 2128±314 675±75
ab
 385±60
ab
 209±45 431±93
ab
 
3 2324±254
a
 2108±380 440±94
a
 328±77
ab
 406±72 391±77
ab
 
4 2374±334
a
 1788±355 748±101
ab
 291±41
ab
 404±178 639±97
a
 
5 1846±199
b
 1911±208 501±49
ab
 216±47
ab
 238±56 512±47
a
 
6 3094±379
a
 2049±205 881±75
b
 578±96
b
 461±57 444±41
a
 
7 2253±392
a
 1728±183 695±107
ab
 290±28
ab
 241±29 128±21
b
 
 
Data is expressed as mean values ± SEM. Significant differences within each column (dpv) are 
labelled with either a, b or ab.  Groups with no significant difference between them are labelled with 
the same letter, whereas groups with a significant titre difference are labelled with a different letter 
(p < 0.05).  Time points with no significant differences are not labelled. Cut-off point titre = 834. 
Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, Group 4 = Mass1+793B1, Group 5 = 
Mass2+793B2, Group 6 = Mass3+Ark and Group 7 = SW.   
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5.6.5. Study 4. Protection induced by homologous or heterologous vaccination 
against virulent IBVs 
Following challenge with virulent M41, QX and 793B strains, clinical signs such as 
head shacking, sneezing, tracheal râles and coughing were observed in the 
unvaccinated control group. No clinical signs were observed in vaccinated birds.  
Challenge by M41, QX or 793B caused severe damage to the tracheal epithelium of 
unvaccinated birds (Table 5.4). The results of the ciliary scores show that all the 
vaccination programmes gave excellent protection against challenge with 
homologous M41. Group 5 (Mass2+793B2) was the only group protected against 
challenge from QX, whereas the rest of the groups provided poor protection against 
challenge.  
Only groups receiving a combined vaccine (groups 3, 4, 5 and 6) were challenged 
with IBV 793B, with all combined vaccines providing good levels of protection 
(>85% protection). All non-challenged groups retained 100% ciliary beating. 
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Table 5.4. Homologous and heterologous protection induced by IBV vaccination 
programmes against virulent IBV challenges at 21 dpv. 
Vaccine 
Group 
% Protection scores (ciliostasis test) 
M41 QX 793B 
1 88 54 ND 
2 94 42 ND 
3 90 53 90 
4 96 68 93 
5 90 92 93 
6 98 73 85 
7 0 15 0 
 
ND= Challenge not done. Group 1 = Mass1, Group 2 = Mass2, Group 3 = Mass1+D274, Group 4 = 
Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and  Group 7 = SW.   
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5.6.5.1. RT-PCR detection and genotyping of IBVs in trachea and kidney 
following virulent IBV challenge 
The viral genome of each challenge virus was detected in both the trachea and 
kidney of the control chicks at 5 dpc (Table 5.5). Virulent M41 and 793B were not 
detected by RT-PCR in any of the vaccinated groups, however the viral genome of 
the virulent QX was detected in four groups (groups 4 and 5 were negative). 
Table 5.5. IBV detection by RT-PCR at 5 dpc in each vaccine group following 
challenge at 21 dpv. 
Vaccine 
Group 
M41 QX 793B 
Trachea Kidney Trachea Kidney Trachea Kidney 
1 - - QX* QX* ND** ND** 
2 - - QX* Mass2 ND** ND** 
3 Mass1 - QX* QX* - - 
4 - 793B1 Mass1 793B1 793B1 Mass1 
5 - 793B2 793B2 - - - 
6 - - QX* - - Ark 
7 M41* M41* QX* QX* 793B* 793B* 
 
*Challenge strain; **ND = Challenge not done. Group 1 = Mass1, Group 2 = Mass2, Group 3 = 
Mass1+D274, Group 4 = Mass1+793B1, Group 5 = Mass2+793B2, Group 6 = Mass3+Ark and Group 7 
= SW.   
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5.7. Discussion 
 
The ciliostasis test was used in the initial study to determine the effect of 
administration of live IBV vaccines alone or in combination. To our knowledge this 
is the first report on such findings over an extended period. Our findings show that 
application of single Mass vaccination causes little detrimental effect on the tracheal 
ciliary activity compared to that caused by the combined vaccination. One possible 
explanation is that the combined vaccines contained a higher overall dose than the 
single vaccines, which may be the cause of the greater damage, because IBV tends 
to localize subepithelially after initial infection of the surface tracheal epithelial cells 
(Geilhausen et al., 1973). It has been previously shown that exposure to a higher titre 
of live attenuated virus results in mild inflammation of the trachea (Gillette, 1981).  
 
Between the combined vaccination groups, the pattern of damage to the ciliary 
activities differed. For example, group 4 (Mass1+793B1), the tracheal protection fell 
within 10 days with later recovery compared to group 5 (Mass2+793B2) where the 
ciliary protection was lowest at first sampling (3 dpv) following vaccination and but 
showed a slow recovery thereafter. Even though Mass1 and Mass2 or 793B1 and 
793B2 vaccines belong to the Mass or 793B serotypes respectively, when they were 
used in combination, they showed a high variation on their effect on the tracheal 
health. Differences in the virulence of IBV strains may have played a role in the 
tracheal damage. It has been found that unvaccinated chicks challenged with four 
IBV isolates (one belonging to the Mass serotype and three variants) the tracheal 
damage in term of ciliary activity was variable (Cubillos et al., 1991). The severity 
of the ciliostasis caused by virulent 793B strain proved to be the mild, while the 
effect of  M41 was more severe (Benyeda et al., 2009). The results from this study 
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suggest that such differential effects of different vaccine or vaccination regimes on 
tracheal health should be utilized in designing proper vaccination programmes. 
Relatively little research exists regarding cellular and local immune responses 
induced by IBV vaccination. To further our understanding, we evaluated CD4+, 
CD8+ and IgA-bearing B cell expression in the trachea following vaccination 
regimes used in this study. It is known that presence of CD4+ and CD8+ cells in 
large numbers in IBV vaccinated or infected birds have a protective role against 
viral infections (Kotani et al., 2000). Our study reported detection of both types of 
T cells as early as 3 dpv, which then peaked at 6 dpv (CD4+) and 14 dpv (CD8+). 
These findings are similar to those by Kotani et al. (2000) who identified that CD4+ 
and CD8+ cell numbers peaked at five days following infection with virulent IBV. 
Moreover, the present study revealed that CD4+ cells were recruited into the trachea 
earlier than CD8+. This observation was in accordance with a previous study using a 
nephropathogenic IBV strain, which observed that on day 5 post infection, CD4+ 
cells outnumbered CD8+ cell (Janse et al., 1994). In contrast, Dhinakar Raj and 
Jones (1996a) reported that CD8+ cells were recruited into the trachea earlier than 
CD4+ cells after infection with virulent 793B. Whether this discrepancy relates to 
the virulence of the different IBV strains requires further investigation, as attenuated 
live IBV vaccines were used in the current study. 
A greater expression in the levels of CD4+ (6dpv) and CD8+ (10 dpv) were 
observed in groups receiving the combined vaccines compared to the single 
vaccines. It is possible that local inflammation and trachea damage caused by a 
greater vaccination dosage or heterogeneity of vaccines promoted an enhanced 
response in the respiratory tract. Further to this, a stronger cellular immunity was 
observed in the group given Mass2+793B2 (group 5) and Mass3+Ark (group 6).  
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Nakamura et al. (1991) observed IgA cells in the trachea from 7-12 days following 
infection with virulent IBV M41. We observed in all vaccinated groups that 
IgA-bearing B cells in the trachea appeared at 3 dpv and peaked at 10 dpv. In our 
study, the highest level of IgA-bearing B cells was observed in the group given 
Mass2+793B2. It suggests that an increase in the number of this cells at the tracheal 
site as a result of  greater tracheal damage (Nakamura et al., 1991).  
Cellular and local immunity was generated at an earlier stage of infection (3-10 dpv) 
than humoral immunity (25dpv and thereafter). This is in agreement with previous 
work that alluded to cytotoxic T cells acting as a vital component for anti-viral 
activity during the early stage of IBV infection, whereas serum IgG was critical at a 
later stage (Seo and Collisson, 1997; Collisson et al., 2000). 
Following live IBV vaccination, no significant increases in serum antibody titres 
were found. It is well documented that low or undetectable antibody titres in young 
chicks following IBV vaccination is attributed to interference of active antibody 
production by IBV MDA (Raggi and Lee, 1965; Davelaar and Kouwenhoven, 1977) 
and in this study broilers with IBV MDA were used. Based on our results, it seems 
that low levels of humoral antibodies did not indicate a lack of protection against 
IBV. In a previous study, vaccination with live H120 conferred protection against 
homologous challenge, although it induced low IBV antibody levels (Meir et al., 
2012). Inefficient induction of antibody by live attenuated IBV vaccines has been 
demonstrated before (Cook et al., 1991a; Roh et al., 2013). This indicates that the 
resistance against IBV was due to a cellular and local tracheal immunity.  
We also evaluated the effectiveness of different vaccination programmes against 
challenge with virulent M41, QX or 793B. Groups vaccinated with single Mass type 
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strains (group1 or group 2) were not challenged with virulent 793B, as it has been 
previously reported that Mass based vaccines did not offer protection against 
virulent 793B strains (Parsons et al., 1992). There was a strong degree of protection 
induced by the homologous and heterologous vaccination programmes against 
challenge with M41 or 793B. In addition, birds vaccinated with Mass1+D274 (group 
3) or Mass3+Ark (group 6) induced full protection against the challenge with 
heterologous virus of 793B. It is reported that immunization with a bivalent vaccine 
containing Mass and Ark-type strains provided cross-protection against challenge 
with many field strains (Gelb et al., 1991; Martin et al., 2007), including 793B 
(Unpublished data cited in Jones, 2010). TOC prepared from birds vaccinated with 
D274 gave 93% protection against virulent 793B (Dhinakar Raj and Jones, 1996d). 
The combined vaccine programme of Mass2+793B2 (group 5) provided high 
protection against the heterologous challenge with virulent IBV QX. It was 
previously proposed that vaccination with a live Mass-type vaccine at 1 day of age 
followed by a 793B vaccine two weeks later provided good protection against many 
heterologous IBV viruses including virulent QX (Cook et al., 1999a; Terregino et 
al., 2008; de Wit et al., 2011b). Despite an excellent protection against M41, QX and 
793B, most early and high ciliary damages, mortality with lesions and high CD4+, 
CD8+ and IgA-bearing B cells were found in this group. This shows that the high 
degree of protection conferred against all three challenge viruses were likely due the 
intense cellular and local immune responses. A careful judgement between the need 
for a stronger protection induced by stronger immune responses against losses due to 
excessive clinical reactions and mortality should be considered. 
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Despite the low level of protection (ciliostasis test) in groups that received Mass 
type strains either alone or in combination with 793B1, D274 or Ark, the birds were 
fully protected against the respiratory signs caused by QX. This could be due to 
induction of the cellular and local immunity. To ensure effective vaccination, when 
developing vaccine strategies, mechanisms for inducing CTL immunity should be 
considered (Collisson et al., 2000). 
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Chapter 6: Detection of variant infectious bronchitis 
viruses in broiler flocks in Libya 
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6.1. Abstract  
A number of broiler flocks with respiratory disease and high mortality in five broiler 
farms in Libya were sampled for detection of IBV. Twelve IBV strains from these 
farms were detected by RT-PCR and differentiated by nucleotide sequencing of the 
hypervariable region of the S1 gene. A pair-wise comparison of the sequences 
showed two distinctive patterns. Those from farms 1, 2, 4 and 5, formed a separate 
cluster with 94-99% relatedness to the Egyptian IBV strains CK/Eg/BSU-2/2011, 
CK/Eg/BSU-3/2011 and Eg/1212B. Sequences from the farm 3 formed another 
cluster with 100% relatedness to Eg/CLEVB-2/IBV/012 and IS/1494/06. This 
appears to be the first report on the co-circulation of variant IBVs in Libya.  
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6.2. Introduction 
 
A number of IBV variant genotypes have been reported in the Middle East, 
including Iran/793B/19/08, Iraq /Sul/01/09, Israel/ 720/99, Israel /885/00, 
IS/1494/06, Egypt/ Beni-Seuf/01, Egypt/ F/03, Egypt/ D/89, CK/CH/LDL/97I, and 
CK/CH/SCYA/10I  (Meir et al., 2004; Gelb et al., 2005; Abdel-Moneim et al., 2006; 
Jackwood, 2012; Ababneh et al., 2012; Kahya et al., 2013). Some of these genotypes 
in particular IS/885/00 and IS/1494/06 have become dominant in the majority of 
farms in the Middle East countries, causing respiratory and renal diseases (Meir et 
al., 2004; Abdel-Moneim et al., 2012; Selim et al., 2013). To date, there is no 
information available on the circulation of variant IBVs in Libya. In the Middle 
East, the vaccination against IBV is performed with vaccines that contain live 
attenuated belonging to the Mass serotype (Meir et al., 2004). In the past few years, 
vaccine strains belonging to 793B and D274 serotypes are also widely used. In spite 
of this, IBV infection is considered endemic and widely spread both in vaccinated 
and unvaccinated poultry farms generally associated with kidney damages (Meir et 
al., 2004; Gelb et al., 2005; Abdel-Moneim et al., 2006; Kahya et al., 2013). The aim 
of this study is to provide information on the molecular characteristic and the 
phylogenetic relationship of strains in Libya in comparison to other strains reported 
in the Middle East. 
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6.3. Materials and methods 
 
6.3. 1. Case history and clinical samples  
In July 2012, a number of broiler flocks in five different farms with respiratory 
disease and high mortality at East Libya were visited. The flocks had no vaccination 
against IBV but were vaccinated against NDV and IBD (Table 6.1). All flocks 
showed clinical signs of respiratory distress, manifested by sneezing, tracheal râles, 
gasping, nasal discharge, head swelling, conjunctival congestion and frothy eyes. 
Post-mortem examination revealed lesions of inflamed trachea, cheesy exudate in 
airsacs and swelling of the kidneys. Mortality on the day of sampling ranged from 
1.4% to 3.7% (Table 6.1).   
From each of the farms, OP swabs were collected from a total of 40 chicks. These 
swabs were divided into sets of 10 and were dipped into bijou tubes containing 2 ml 
of sterile water.  After vigorous shaking, 100 µl of the mixture was spotted onto the 
FTA cards. Ten to twenty diseased birds per farm were killed and samples of 
turbinates, tracheas, lungs and kidneys were collected. The like-tissues were rubbed 
gently onto matrix areas of the FTA cards. These cards were air-dried and 
transported to our laboratory for RT-PCR. 
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6.3. 2. RNA extraction 
The FTA cards were processed as described by the manufacturer. Briefly, the 
spotted or imprint area of the FTA card were cut using sterile scissors and forceps, 
each sample was placed into bijou tubes containing 2 ml of solution D (Appendix 1) 
and stored at -20
o
C until required. RNA was extracted using phenol-chloroform 
method as described in Chapter 2.10.i.  
6.3. 3. RT-PCR and Sequencing  
The RT-PCR procedure and sequences was performed as described in 
Chapter 2.10iii.  
6.3. 3.1.  Phylogenetic analysis and nucleotide comparison 
Multiple sequence alignments were carried out with Clustal W, and phylogenic trees 
were constructed with MEGA 6 software as described in Chapter 2.11. The IBV 
sequences were aligned and compared with reference and vaccine strains that were 
used in the Middle East. The sequences were retrieved from GenBank and BLAST 
search was carried out. The other S1 gene sequences used for comparison or 
phylogenetic analysis were CK/Eg/BSU-2/2011 (JX174185), CK/Eg/BSU-3/2011 
(JX174186), Eg/1212B (JQ839287), Eg/CLEVB-2/IBV/012 (JX173488), IS/885/00 
(AY279533) and IS/1494/06 (EU780077), M41 (GQ219712), H120 (GU393335), 
D274 (X15832), 4/91 (JN600614), CR88 (JN542567 ) and 793B(Z83979 ).  
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6.4. Results  
 
The daily mortality on the day sampling is given in the Table 6.1. At necropsy, the 
main lesions found were tracheitis, lung congestion, air-sacculitis and enlarged 
kidneys. IBV was detected in samples obtained from all the farms. The nucleotide 
sequences of these IBVs were submitted to the GenBank and the assigned accession 
numbers are shown in the Table 6.1. Figure 6.1and Table 6.2 shows the relatedness 
between the Libyan IBV sequences in comparison to those found in the Middle East 
and the reference IBVs. A pair-wise comparison of the IBVs, showed two distinctive 
patterns. The Libyan IBVs, from farm 1, 2, 4, and 5, formed a separate cluster, with 
94-99% homology to CK/Eg/BSU-2/2011, CK/Eg/BSU-3/2011 and Eg/1212B.  
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         Table 6.1. Flock details, RT-PCR and virus genotype results. 
Farm 
Number 
chicks 
Age/day 
Vaccination 
programme 
Mortality/ 
day of 
sampling 
RT-PCR (Laboratory sequence No, Genebank accession No) 
OP Turbinate Trachea Lung Kidney 
1 6000 32 None 2% - - +,01,KF007922 +,02,KF007923 +,03,KF007924 
2 5000 22 IBD 3% +,04,KF007924 - - - - 
3 9000 40 NDV/IBD 3.7% - - +,05,KF007926 - +,06,KF007927 
4 10000 26 IBD 2% - - - - +,07,KF007928 
5 7500 16 NDV 1.4% +,08,KF007929 +,09,KF007930 +,10,KF007930 +,11,KF007932 +,12,KF007933 
  
           * For details, see Figure 6.1 
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 Figure 6.1. Phylogenetic tree based on a partial sequence of the S1 gene, showing 
the relationship between the Libyan and other IBV strains. 
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Table 6.2. Nucleotide and amino acid identity of the part-S1 glycoprotein gene of the Libyan in comparison to other IBV strains  
% Amino acid identities   
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20   
1  96 100 90 83 84 98 100 97 99 97 100 99 98 85 96 88 85 75 79 1 IBV/Chicken/Libya/01/12 
2 99  96 94 78 79 94 96 97 95 97 96 95 94 81 91 83 81 73 74 2 IBV/Chicken/Libya/02/12 
3 100 99  90 83 84 98 100 97 99 97 100 99 98 85 96 88 85 75 79 3 IBV/Chicken/Libya/03/12 
4 99 98 98  74 73 88 90 91 90 91 90 89 88 74 85 77 74 68 67 4 IBV/Chicken/Libya/04/12 
5 83 81 82 82  97 84 83 79 82 79 83 84 83 98 82 84 98 70 78 5 IBV/Chicken/Libya/05/12 
6 83 81 82 82 100  85 84 81 83 81 84 85 84 99 83 85 99 74 79 6 IBV/Chicken/Libya/06/12 
7 99 97 98 98 84 84  98 95 97 95 98 99 98 87 98 89 87 75 79 7 IBV/Chicken/Libya/07/12 
8 100 99 100 98 83 83 98  97 99 97 100 99 98 85 96 88 85 75 79 8 IBV/Chicken/Libya/08/12 
9 98 98 98 97 80 80 97 98  96 98 97 96 95 82 92 84 82 73 75 9 IBV/Chicken/Libya/09/12 
10 100 99 100 99 83 83 99 100 98  96 99 98 97 84 95 87 84 74 78 10 IBV/Chicken/Libya/10/12 
11 98 98 98 97 79 79 97 98 99 98  97 96 95 82 92 84 82 73 75 11 IBV/Chicken/Libya/11/12 
12 100 99 100 99 83 83 99 100 98 100 98  99 98 85 96 88 85 75 79 12 IBV/Chicken/Libya/12/12 
13 100 98 99 99 83 83 99 99 100 100 97 100  99 87 97 88 87 77 79 13 Ck/Eg/BSU-2/2011 
14 99 98 99 99 83 83 99 99 99 99 97 99 100  85 97 87 85 75 78 14 Ck/Eg/BSU-3/2011 
15 83 81 82 82 100 100 84 82 83 83 79 83 99 83  84 87 100 73 81 15 Eg/CLEVB-2/IBV/012 
16 98 97 98 98 82 82 99 98 98 98 96 98 81 99 82  87 84 74 78 16 Eg/1212B 
17 85 83 84 84 84 84 86 84 82 85 82 85 85 84 84 84  87 70 78 17 IS/885/00 
18 83 81 82 82 100 100 84 82 80 83 79 83 83 83 100 82 84  73 81 18 IS/1494/06 
19 70 69 70 96 73 73 71 70 69 70 68 70 73 83 73 69 72 73  68 19 Mass (H120) 
20 74 72 74 71 77 77 72 73 70 74 68 74 76 77 77 73 75 77 63  20 793 B(4/91) 
% Nucleotide identities  
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6.4. Discussion  
 
The similarity to another regionally important IBV, IS/885/00, first detected in 
Israel, ranged from 85% to 89%. The Egyptian IBV strains CK/Eg/BSU-2 (also 3) 
/2011 were associated with high mortality, respiratory and renal pathology  (Abdel-
Moneim et al., 2012). The IS/885/00 strain was isolated in 2000 from broiler 
chickens in Israel. This strain was reported to cause acute renal disease, severe 
morbidity and high mortality ranging from 15% to 25% (Meir et al., 2004). 
Those IBVs detected in farm 3 (IBV/Chicken/Libya/05/2012 and 
IBV/Chicken/Libya/06/2012) formed another cluster, with 100% relatedness to 
Eg/CLEVB-2/IBV/012 and IS/1494/06. The IS/1494/06 was first identified in Israel 
in 2006, was recognised as a nephropathogenic IBV, and later classified as variant 2 
(R. Meir, personal communication, 2012). It has been reported that birds vaccinated 
with H120 were poorly protected when challenged with these strains (Meir et al., 
2004; Kahya et al., 2013). 
These findings show both, IS/885/00-like and IS/1494/06-like IBVs, are now 
circulating in Libya. Not much is known about the mode of IBV spread between the 
countries in the Middle East, however, cross-border movements of poultry and 
poultry-related products is likely an important factor. These finding shows that high 
mortality and severe respiratory diseases in Libyan chicken farms is likely 
contributed by these variant IBVs. The role of other co-infections and other 
exacerbating factors (eg. immunosuppression, poor ventilation, stocking density, 
poor management) need to be examined.  In North Africa, both classical and variant 
IBVs have been reported in Egypt (Abdel-Moneim et al., 2006; Abdel-Moneim et 
al., 2012), Tunisia (Bourogaa et al., 2009) and Morocco (El-Houadfi et al., 1986). In 
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this study, even though only small numbers of farms were sampled, our findings 
have highlighted the circulation of variant IBVs in Eastern part of Libya for the first 
time. Further studies should include sero-surveillance, isolation and 
serotyping/genotyping of IBVs in the region.   
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Chapter 7: Immune responses and interactions following 
simultaneous application of live Newcastle disease, avian 
metapneumovirus and infectious bronchitis vaccines in 
specific-pathogen-free chicks 
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7.1. Abstract 
 
Interactions between live NDV, aMPV and IBV vaccines following simultaneous 
vaccination of one-day old SPF chicks were evaluated. The chicks were divided into 
eight groups. One group served as unvaccinated controls, whereas the other seven 
groups were vaccinated against NDV, aMPV and IBV (single, dual or triple). HI 
NDV antibody titres were similar in single, dual or triple-vaccinated groups. Levels 
of aMPV ELISA antibodies were suppressed when the aMPV vaccine was given 
with other live vaccines. The cellular and local immunity induced by administration 
of live NDV, aMPV or IBV vaccines (individually or together) showed a significant 
increase in the expression of CD4+, CD8+ and IgA-bearing B cells in the trachea 
compared to the unvaccinated group. There were no significant differences between 
the vaccinated groups. Despite lowering the serological antibody response to aMPV, 
simultaneous vaccination with live NDV (VG/GA strain), aMPV (subtype B), and 
IBV (H120) did not affect protection against aMPV or IBV. NDV challenge was not 
included due to local restrictions; however, HI titres in the NDV vaccinated groups 
reached above the protective titre. It appears that the efficacy of each of the live 
vaccines was not compromised when given simultaneously (dual or triple) in young 
SPF chicks. 
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7.2. Introduction  
 
NDV, aMPV and IBV are important and common causes of respiratory diseases in 
chickens. The losses due to these pathogens are significantly reduced by the use of 
live and inactivated vaccines worldwide, including the use of combined live 
vaccines. All three viruses initially replicate in the epithelium of the respiratory tract 
(Alexander, 2000; Jackwood and de Wit, 2013; Jones and Rautenschlein, 2013), and 
their ability to induce protective immunity may therefore be reduced if it is necessary 
to apply all three live vaccines simultaneously.  
Previous in vivo studies, demonstrated that IBV interfered with the replication of 
virulent NDV (Hanson et al., 1956), live NDV vaccines (Bracewell et al., 1972; 
Thornton and Muskett, 1975) and aMPV vaccines in chickens (Cook et al., 2001b). 
Ganapathy et al. (2005a) demonstrated that NDV vaccination delayed the replication 
of the live aMPV vaccine, and also reduced the humoral antibody responses. These 
studies relied on serum antibody titres, either measured by ELISA or HI test to 
demonstrate the impact of simultaneous vaccine application in chicks. Systemic 
antibody responses have been shown to have a poor correlation with protection 
against IBV (Pensaert and Lambrechts, 1994) and aMPV infections (Cook et al., 
1989b). Working with live NDV, IBV and aMPV vaccine viruses (Cook et al., 
2001b; Ganapathy et al., 2005a; Tarpey et al., 2007), the authors suggested that the 
protection against these viruses was likely induced by cell-mediated and local 
immune responses, however this was not investigated.   
It is established that cellular and local immunity plays a critical role in the protection 
of chicks from NDV, aMPV and IBV infections (Takada and Kida, 1996; Seo and 
Collisson, 1997; Rautenschlein et al., 2011). A number of studies have examined the 
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induction and role of CMI after vaccination with live NDV (Russell et al., 1997; 
Rauw et al., 2009) or IBV vaccines (Okino et al., 2013) alone. In a simultaneous 
vaccination study, Ganapathy et al. (2005a) reported that IgA levels in the tears of 
chicks that were given NDV alone or dually with aMPV were not affected. Despite 
the widespread application of combined live respiratory viral vaccines in young 
chicks, very little is known about the cellular and local immune responses following 
simultaneous application of live NDV, aMPV or IBV vaccine viruses. The objective 
of this study was to evaluate the interactions between live NDV, aMPV and IBV 
vaccine viruses in young SPF chicks. In addition to humoral antibody responses, the 
cell-mediated and local antibody responses in the trachea were also assessed. 
Furthermore, the protection conferred against virulent IBV and aMPV was 
evaluated. 
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7.3. Materials and methods 
 
7.3.1. Eggs and chicks 
Fertile eggs from SPF White Leghorn chickens were incubated and hatched in our 
facilities (Chapter 2.3.i). Chicks were placed in separate isolation units 
(Chapter 2.3.iii). 
7.3.2. Vaccines 
NDV vaccine (strain VG/GA), aMPV vaccine (subtype B), IBV vaccine (strain 
H120) were kindly provided by Merial SAS (Lyon France). Vaccines were 
reconstituted as recommended by the manufacturer and the titres are estimated from 
data provided by the manufacturer. For NDV and aMPV vaccines, each 1,000 dose 
vial was reconstituted in 2 ml of chilled SW and thoroughly mixed with 100 ml of 
SW.  For IBV vaccine, a 5,000 dose vial was reconstituted in 5 ml of SW and then 
1 ml was mixed with 100 ml of SW. For dual-vaccination, NDV vaccine was first 
reconstituted and then followed by aMPV or IBV vials as previously described. Each 
pair was then mixed in 100 ml SW. For triple vaccination, NDV, aMPV and IBV 
were reconstituted as above and all three were diluted in 100 ml of SW.   
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7.3.3. Challenge viruses  
7.3.3. 1. IBV  
IBV M41 strain was grown in ECE and titrated in TOC as described (Chapter 2.8). 
The titre obtained was 10
5.00 
CD50/ml.   
7.3.3. 2. aMPV  
aMPV subtype B  virus  was propagated and titrated in TOC (Chapter 2.8). The titre 
obtained was 10
4.51
 CD50/ml. 
7.4. Experimental design  
 
Three hundred and twenty 1-day old chicks were randomly distributed in 8 groups, 
each group consisting of 40 chicks per isolation unit. The vaccination treatments 
consisted of a single dose of NDV, aMPV or IBV vaccines, or dual or triple 
combinations of these vaccines (Table 7.1). Each chick was vaccinated via oculo 
(50 µl) nasal (50 µl) route. Dosages received by each bird were as recommended by 
the manufacturers (Table 7.1). Following the vaccination, the chicks were observed 
daily for the clinical signs. OP swabs were randomly collected prior to vaccination 
and from 10 chicks in each group at 3, 7, 14, 21, 26 and 35 dpv for RT-PCR. For 
serology, blood was collected prior to vaccination and at 21 and 35 dpv from eight 
chicks in each group. At 21 dpv, five chicks from each group were humanely killed 
and trachea samples were collected from each bird, immediately placed in 
aluminium foil cups containing OCT medium and frozen in liquid nitrogen (-190°C). 
These tracheas were used for detection of CD4+, CD8+ and IgA-bearing B cells by 
IHC. All samples were stored at -70 
o
C until processing. At 21 dpv, 10 birds from 
each group were transferred to a different isolation room and one was challenged 
with 0.1 ml virulent aMPV subtype B by the oculonasal routes. An additional 10 
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birds from each group were challenged with 0.1 ml virulent IBV M41 via the same 
route. The remaining 15 chickens in each group were left as unchallenged.  
Table 7.1.  Experimental design for the single and simultaneous application of dual 
or triple live NDV, aMPV and IBV vaccines in SPF chicks.  
Groups Vaccines Oculo-nasal  dose 
1 NDV 5.5 log10 EID50/chick 
2 aMPV 2.3 log10 TCID50/chick 
3 IBV 3.5-5.0 log10 EID50/chick 
4 NDV+aMPV 5.5 log10 EID50/chick+2.3 log10 TCID50/chick 
5 NDV+IBV 5.5 log10 EID50/chick+3.5-5.0 log10 EID50/chick 
6 aMPV+IBV 2.3 log10 TCID50/chick3.5-5.0 log10 EID50/chick 
7 NDV+aMPV+ IBV 5.5 log10 EID50/chick+2.3 log10 
TCID50/chick+3.5-5.0 log10 EID50/chick 
8 Unvaccinated control SW 
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7.4.1. Detection of vaccine viruses by RT-PCR  
Pooled daily swabs were dipped as a single sample per group, per day in a labelled 
bijou that contained 1.5 ml of solution D (Appendix 1). RNA was extracted using the 
phenol-chloroform method (Chapter 2.10.i). RT-PCR was performed for NDV, 
aMPV and IBV as described in Chapter 2.10.iii.  
7.4.2. Serology 
NDV antibodies were detected by HI (This was done in commercial laboratory, 
SciTech laboratories, The Grove, Craven Arms, Shropshire SY7 8DA). For aMPV 
and IBV, sera were tested by commercial ELISA (BioChek) (Chapter 2.12.i.a). 
7.4.3. Immunohistochemical analysis of cell-mediated responses in tracheal 
sections 
Indirect immunohistochemical staining was conducted to quantify immune cell 
populations of CD4+, CD8+ or IgA-bearing B cells (Chapter 2.13). 
7.4.4. Assessment of protection against aMPV challenge 
Following aMPV challenge, chicks were observed daily up to 13 dpc to record the 
clinical signs. Ten chicks from each group were examined individually as described 
in Chapter 2.5.ii. 
7.4.5. Assessment of protection against IBV challenge 
Following IBV challenge, all chicks were observed daily for clinical signs 
attributable to IBV infection. At 5dpc, the chicks were humanely killed for gross 
lesions (Chapter 2.5.iii) and determine level of protection of the trachea using the 
ciliostasis test (Chapter 2.5.v).  
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7.4.6. Statistical analysis 
The data of the serological responses, CMI and aMPV clinical signs were analysed 
by one way ANOVA followed by Tukey’s test. Differences were considered to be 
significant when P≤0.05. All analysis were conducted using the GraphPad Prism, 
6.0.1. 
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7.5. Results 
 
7.5.1. Clinical signs post-vaccination 
No clinical signs were observed in any of the vaccinated groups.  
7.5.2. Detection of vaccine viruses by RT-PCR 
None of the viruses was detected in pooled swabs from any group prior to the 
vaccination. 
NDV was detected at 3 dpv only in the single and dual-vaccinated NDV groups, and 
up to 7 dpv in the triple vaccinated group (Table 7.2). aMPV was detected up to 
7 dpv in birds that received single vaccine and 14 dpv in those given NDV and 
aMPV vaccines. In contrast, aMPV was detected for a much longer duration (up to 
21 dpv) when administered with IBV or with NDV and IBV vaccines. In all 
IBV-vaccinated groups, IBV was detected to the end of the experiment.  
7.5.3. Detection of viruses after challenge 
Virulent aMPV subtype B was detected at 6 but not at 13 dpc in groups that were not 
vaccinated against aMPV (Table 7.2). aMPV was not detected in groups that 
received aMPV vaccine, whether singly or in dual or triple combinations. 
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Table 7.2. RT-PCR detection of vaccine viruses following vaccination of chickens 
with NDV, aMPV and IBV vaccines. 
Vaccines dpv dpc 
NDV aMPV IBV 3 7 14 21 26 35 6
≠
 13
≠
 
+   N
*
 - - - - - + - 
 +  M M - - - - - - 
  
+ 
B B B B B B + - 
+ + 
 NM -M -M -- -- -- - - 
+  
+ 
NB -B -B -B -B -B + - 
 + 
+ 
MB -B -B MB -B -B - - 
+ + + 
NMB NMB --B -MB --B --B - - 
Unvaccinated Control 
--- --- --- --- --- --- + - 
 
N: Positive for NDV vaccine; M: Positive for aMPV vaccine; B: Positive for IBV vaccine;
 *
 Ten OP 
swabs pooled as single sample; 
≠
 OP swabs collected following aMPV challenge.  
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7.5.4. Detection of NDV HI antibodies 
HI titres in groups not vaccinated with NDV vaccine remained below the detectable 
levels. At 21 and 35 dpv, chicks vaccinated with NDV vaccine either alone or in 
combination had significantly higher antibody titres than chicks that did not 
vaccinated with NDV vaccine (Figure 7.1). There were no significant differences in 
the level of HI antibody titres between the groups that received NDV vaccine.  
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Figure 7.1. NDV HI antibody titres in chicks administered with live NDV vaccine 
alone or with other live vaccines. Vertical bars represent SEM (n= 8). Different 
superscripts letters represent significant differences in the antibody response, while 
bars with the same superscript letters are not significantly different.   
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7.5.5. Detection of aMPV antibodies by ELISA  
Sera collected prior to vaccination or from the aMPV unvaccinated groups did not 
have detectable of level aMPV antibodies. At 21dpv, chicks vaccinated with aMPV 
vaccine singly showed significantly higher levels of antibody titre than chicks 
vaccinated with aMPV vaccine either with NDV and/or IBV (Figure 7.2). At 35 dpv, 
antibody titres in the single aMPV vaccinated chickens remained higher than in the 
dual or triple vaccinated chicks (Figure 7.2).  
At 21 and 35 dpv chicks vaccinated with aMPV vaccine either alone or in 
combination had significantly higher antibody titres than chicks that did not 
vaccinate with aMPV vaccine. 
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Figure 7.2.  aMPV ELISA antibodies in chicks vaccinated with aMPV or with NDV 
and/or  IBV. Vertical bars represent SEM (n= 8). Different superscripts represent 
significant differences in the antibody response, while bars with the same superscript 
letters are not significantly different. The cut-off titre=1656. 
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7.5.6. Detection of IBV antibodies by ELISA 
There were no IBV antibodies detected in sera collected prior to vaccination or from 
those groups not vaccinated with IBV vaccine. Chicks vaccinated with H120 vaccine 
alone or in combination with other vaccines showed high levels of antibody titre 
against IBV compared to unvaccinated groups (Figure 7.3). However, there were no 
significant differences in the level of antibody titres between the groups that received 
H120 vaccine.  
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Figure 7.3. IBV ELISA antibodies in chicks vaccinated with IBV alone or with 
NDV and/or aMPV. Vertical bars represent SEM (n= 8). Different superscripts 
represent significant differences in the antibody response, while bars with the same 
superscript letters are not significantly different. The cut-off titre= 834. 
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7.5.7. CD4+, CD8+ and IgA-bearing B cells in the trachea 
The average numbers of CD4+, CD8+ and IgA bearing B-cells in the trachea were 
evaluated by IHC. Single, dual or triple vaccinated groups showed significantly 
greater expression of CD4+, CD8+ (Figure 7.5) and IgA bearing B-cells 
(Figure 7. 6) in tracheal tissue compared to the unvaccinated control groups. 
However, there were no significant differences between the vaccinated groups at 
21dpv. Figure 7.8 shows the immunostaining of trachea sections of unvaccinated 
control birds whereas Figure 7.9 shows immunostaining of trachea sections of 
vaccinated birds.  
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Figure 7.5. Immunostaining of trachea sections following vaccination using Mabs 
for presence of CD4+ and CD8+ T-cells. Vertical bars represent SEM (n= 5). 
Different superscripts represent significant differences in the antibody response, 
while bars with the same superscript letters are not significantly different.  
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Figure 7.6. Immunostaining of trachea sections following vaccination using Mabs 
for presence of IgA-bearing B cells. Vertical bars represent SEM (n= 5). Different 
superscripts represent significant differences in the antibody response, while bars 
with the same superscript letters are not significantly different. 
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Figure 7.8. Immunostaining of trachea sections of unvaccinated control birds  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9. Immunostaining of trachea sections following single or triple vaccination 
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7.5.8. Effects of NDV and IBV vaccinations on protection against aMPV 
challenge 
7.5.8. 1. Clinical signs  
Following virulent aMPV challenge, no clinical signs were observed in the groups 
vaccinated with aMPV alone or co-delivered with NDV or IBV, or both (Figure 
7.10). In contrast, chicks not vaccinated against aMPV showed clinical signs such as 
clear to turbid nasal discharges at 3 dpc and completely recovered by 11 dpc. No 
significant differences in clinical signs were seen in the groups that did not receive 
aMPV vaccine.  
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Figure 7.10.  Mean clinical scores in the vaccinated and unvaccinated chickens after 
aMPV challenge. No clinical signs were observed in the chickens vaccinated with 
aMPV vaccine alone or together with NDV or IBV or both.  
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7.5.9. Effect of NDV and aMPV vaccination on protection against IBV challenge 
 
7.5.9.1. Clinical signs and gross lesions 
Following IBV challenge, no clinical signs were observed in the group vaccinated 
with H120 vaccine alone or in combination with the other vaccines. Chicks not 
vaccinated with H120 vaccine showed mild respiratory signs at 1dpc which included 
tracheal râles, coughing, sneezing and head shaking. At necropsy at 5 dpc, chicks 
vaccinated with H120 vaccine were found to be free of lesions, while unvaccinated 
chicks had slight congestion in the trachea and pale and mild swelling of kidneys.   
 
7.5.9.2. TOC assessment for protection against IBV challenge 
Virulent IBV M41 caused substantial damage to the tracheal epithelium of the chicks 
not vaccinated with H120 vaccine. Groups that were given H120 vaccine showed 
95-98% protection against IBV M41 (Figure 7.11). In the vaccinated/unvaccinated 
unchallenged groups, almost 100% the ciliary protection were recorded. 
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Figure 7.11. Protection against IBV M41challenge of chicks vaccinated with IBV 
H120 vaccine alone or together with NDV and/ or aMPV. 
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7.6. Discussion   
 
We evaluated the effect of co-delivering live NDV, aMPV and IBV vaccine viruses 
in combination in SPF chicks. Previous studies have reported the simultaneous 
application of NDV and aMPV (Ganapathy et al., 2005a; Ganapathy et al., 2006), 
aMPV and IBV (Cook et al., 2001b), or NDV, aMPV and IBV (Tarpey et al., 2007) 
in chicks. Those studies reported that simultaneous application of live NDV or IBV 
vaccines reduces humoral antibody responses to virulent aMPV, but the chicks were 
protected against disease. The authors strongly suggested that CMI may have played 
an important role in conferring the protection against challenge viruses of NDV, 
aMPV or IBV but this was not investigated. In the current comprehensive study, in 
order to generate comparative data, the same strains of live NDV, aMPV and IBV 
vaccine viruses were given to young SPF chicks in single, dual or triple 
combinations. In addition to humoral antibody responses, we monitored the 
cell-mediated and local immune responses in the trachea of the birds using IHC. 
 
Following single and simultaneous (dual and triple) application of the live vaccine 
viruses, to one day old SPF chicks no respiratory or any other clinical signs were 
found. Similar observations were reported when live NDV and aMPV (Ganapathy et 
al., 2007), aMPV and IBV (Cook et al., 2001b) and NDV+IBV and aMPV (Tarpey 
et al., 2007) were concurrently administered to SPF chicks. In the previous studies 
(Cavanagh et al., 1999; Cook et al., 2001b; Ganapathy et al., 2005a; Ganapathy et 
al., 2006) the distribution and persistence of the live vaccine viruses in various 
tissues and OP swabs were monitored. In our study, we used RT-PCR to trace the 
vaccine viruses in OP swabs and it was noted that the live IBV vaccine virus was 
detected throughout the experimental duration. This demonstrates the persistence of 
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IBV, which also could be related to its ability to dominate the other live respiratory 
vaccines. Cook et al. (2001b) reported that this is likely due the rapid replication of 
IBV. In our experience, under experimental and field conditions, we are able to 
detect IBV vaccine viruses by RT-PCR for many weeks following vaccination 
(Cavanagh et al., 1999; De Wit et al., 2010a).  
For the NDV vaccine, it appears that the virus is cleared rapidly when given alone or 
simultaneously with IBV or aMPV, but lasted slightly longer (up to 7 dpv) when all 
three vaccine viruses were given together. The aMPV vaccine virus could be 
detected in OP swabs for a much longer (up to 21 dpv) duration when administered 
with IBV or in combination with IBV and NDV. Prolonged detection of aMPV after 
dual vaccination with NDV has been reported before (Ganapathy et al., 2005a). 
There appears to be a delayed detection of NDV or aMPV when co-delivered with 
live IBV vaccine virus, potentially indicating the dominance of IBV virus. Despite 
this, it is evident that the NDV or IBV vaccine viruses are not completely eliminated, 
and instead allowed to replicate at a later time when co-administered with IBV. 
 
An important indication of successful vaccine-take is a serological response, as this 
indicates the ability of the vaccine to attach, replicate and induce immune responses, 
including humoral antibodies. In this study, IBV and aMPV humoral antibodies were 
measured using commercial ELISA kits and HI was used for detection of NDV 
antibodies. For IBV and NDV, the results demonstrate that simultaneous dual or 
triple vaccinations did not affect the levels of the antibodies induced. This is 
particularly important for NDV, as HI antibody levels are commonly used as an 
indicator of protection (Goddard et al., 1988; Reynolds and Maraqa, 2000; Carrasco 
et al., 2009; Ezema et al., 2009). For aMPV, the lower humoral antibody titres in 
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groups that were given dual or triple vaccinations were at the same level as 
previously reported (Cook et al., 2001b; Ganapathy et al., 2005a; Tarpey et al., 
2007). 
There are currently no published data on the cell-mediated responses to dual or triple 
vaccinations, even though such programmes are increasingly practiced in the poultry 
industry worldwide. We attempted to measure the CD4+ and CD8+ responses in the 
trachea following single, dual or triple vaccinations. In addition, the trachea was also 
assessed for IgA-bearing B-cells as an indicator of the local immune response. 
Responses were evaluated at 21 dpv before the flocks were separated for challenge 
against IBV or aMPV. Our findings showed significant increases in the expression of 
CD4+, CD8+ or IgA-bearing B-cell in the trachea from vaccinated compared to 
unvaccinated groups. The absence of significant differences between the vaccinated 
groups demonstrates that at the tracheal level, similar intensities of cell-mediated and 
local immune responses were induced by the single, dual and triple vaccinations.  In 
contrast, as previously discussed, there was suppression in the serological response 
to aMPV but not for IBV or NDV. 
As part of the study, the efficacy of live vaccines when given simultaneously (dual 
or triple) against single application were compared. For IBV and aMPV, the 
protections conferred against challenge viruses were evaluated. For NDV, due to 
local regulations, no challenge was carried out; instead NDV HI titres following 
vaccination were used. Our results showed that irrespective of live vaccine 
combinations, protection against IBV was not affected, as ciliary protection of 
95-98% was achieved in all IBV-vaccinated groups. Similar findings have 
previously been shown in other in vivo studies (Cook et al., 2001b; Gelb et al., 
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2007). For NDV, mean HI titres of 2-5 log
2
 and above were considered to provide 
clinical protection (Reynolds and Maraqa, 2000; Ganapathy et al., 2007; van Boven 
et al., 2008; Shim et al., 2011; Jeong et al., 2013). In this study, it appears that 
simultaneous application of live NDV vaccine with aMPV, IBV or both does not 
compromise the immune response or protection conferred against NDV.   
With increasing losses due to aMPV infection in broiler, layer and breeder chickens, 
live vaccines against aMPV are applied, often along with live IBV, NDV or both.  
Previous work has shown that protection against aMPV was not compromised when 
the live aMPV vaccine was given with live IBV (Cook et al., 2001b), NDV 
(Ganapathy et al., 2005a) and NDV+IBV combined vaccine (Tarpey et al., 2007). 
Results from this study demonstrate no loss of protection when the aMPV vaccine 
was given either alone, or in combination. Such protection was achieved irrespective 
of the humoral antibody levels. This finding supports previous reports contending 
that humoral antibodies do not have a major role in protection against aMPV 
challenge (Jones et al., 1992; Naylor et al., 1997b). In a long-term experimental 
study, turkey hens given a live aMPV vaccine at 12 days of age were protected 
against challenge at 22 weeks, even with no significant levels of ELISA antibody at 
the time of challenge (Williams et al., 1991). This demonstrates that antibody 
detection is an insufficient parameter for estimating the degree of protection in 
aMPV vaccinated poultry flocks (Rubbenstroth and Rautenschlein, 2009). Our study 
confirms previous suggestions that the protection against aMPV was due to cell 
mediated and local immune responses, as the levels of CD4+, CD8+ and 
IgA-bearing B-cells were similar in all aMPV-vaccinated groups.  
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Based on the findings presented in this study, it appears that the efficacy of the live 
NDV, aMPV and IBV vaccine viruses were not compromised when given 
simultaneously in dual or triple combinations to young SPF chicks. There was a 
suppression of humoral antibody responses to aMPV, but responses to IBV and 
NDV were not affected. At the tracheal level, no variations in the levels of cell 
mediated or IgA-bearing B-cells were seen between vaccinated groups. 
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Chapter 8: Comparative pathogenesis of avian 
metapneumovirus subtypes in specific pathogen-free 
chicks 
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8.1. Abstract 
 
Most aMPV infection studies have been done with a single subtype, using either A 
or B in turkeys or chickens. Little is known about co-infection of these two subtypes 
in SPF chicks. In this study, virulent subtypes A and B were used to infect SPF 
chicks, either singly or in combination (A+B). Clinical signs, virus distribution in 
tissues and sero-conversion were examined. There were significant differences in the 
degree of the clinical signs induced by the single subtypes A, B or A+B given 
together, with most severe signs observed in the latter two groups. By RT-PCR or 
VI, subtype B virus persisted longer than the subtype A. Tissue samples were 
positive for subtype A and B for up to 5 and 14 dpi respectively by RT-PCR and 3 
and 7 days respectively by VI. OP and CL swabs were positive for subtype A for up 
to 5 dpi but up to 9 dpi for B. Even though similar titres of the viruses were used, 
birds given subtype B alone or in combination showed a greater increase in ELISA 
antibody titres than those given A. These findings demonstrate that for the two 
strains used, subtype B was more pathogenic than A and was excreted and persisted 
in the tissues for longer.   
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8.2. Introduction  
 
Avian metapneumovirus, also known as turkey rhinotracheitis virus, causes a 
widespread disease of turkeys, chickens and few other avian species (Cook and 
Cavanagh, 2002), characterized by an upper respiratory tract infection. aMPV is also 
associated with SHS in broilers and broilers breeders (Cook et al., 1988; Jones et al., 
1991; Gough et al., 1994) and egg production losses in layers turkeys and chickens 
(Hafez et al., 1990; Cook et al., 1996b; Sugiyama et al., 2006). aMPV was first 
described in turkey in South Africa in 1978 (Buys et al., 1989), and since then the 
virus has been reported in Europe, United States, Middle East, Asia and Africa and 
is now considered to be a major disease threat in both turkeys and chickens in many 
parts of the world (Collins et al., 1993; Seal, 1998; Cook et al., 1999b; Bäyon-
Auboyer et al., 2000; Hafez et al., 2000; Mase et al., 2003; Banet-Noach et al., 2005; 
Chacón et al., 2011).  
Several pathogenesis studies have been reported with aMPV subtype A or B in 
turkeys or chickens (Jones et al., 1988; Cook et al., 1993; Majó et al., 1995; Liman 
and Rautenschlein, 2007; Aung et al., 2008). To the best of our knowledge, there are 
no comparative studies in SPF chicks using both aMPV subtype A or B, separately 
and in combination. The objective of the present study was to compare the 
development of the disease caused by aMPV A, and B or mixture of A and B in SPF 
chicks. Clinical signs, virus detection and antibody responses were examined. 
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8.3. Materials and methods 
 
8.3.1. Eggs and chicks 
 Fertile eggs from SPF White Leghorn chicken were incubated and hatched at our 
facilities (Chapter 2.3.i).   
8.3.2. Viruses 
 
aMPV subtypes A and B. Both were propagated and titrated in TOC (Chapter 2.8.ii). 
The median ciliostasis doses for subtypes A and B were 10
4.56
 CD50/ml and 
10
4.51
 CD50/ml respectively. 
 
8.4. Experimental design 
 
One hundred and sixty, seven-day old SPF chicks were randomly divided into four 
groups with 40 birds in each group. Group A birds were inoculated oculonasally 
with 0.1ml of subtype A virus. Group B birds were inoculated with 0.1ml of subtype 
B in the same manner. Group A+B birds were inoculated with 0.1 ml of subtype A 
via the left nostril and left eye, and 0.1 ml of subtype B via the right nostril and right 
eye. Group C (the control group) birds were inoculated with 0.1 ml virus-free TOC 
medium. At 1, 3, 5, 7, 9 and 14 dpi, five chicks from each group were swabbed (OP 
and CL) and then were humanely killed to allow collection of tissue samples 
(turbinate, trachea, lung and spleen) for virus detection by RT-PCR and VI. Serum 
samples were collected from ten birds per group before inoculation and at 14 dpi to 
detect antibodies against aMPV infection by two different commercial ELISA kits.   
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8.4.1. Assessment of clinical signs 
Following aMPV infection, birds were observed once daily up to 14 dpi to record 
clinical signs. Ten birds from each group were examined individually described in 
Chapter 2.5.ii.  
 
8.4.2. Sample collection for RT-PCR and VI 
Samples of turbinate, trachea, lung and spleen were collected aseptically and then 
were pooled per organ, per group and ground up using a pestle and mortar 
(Chapter 2.9.iii). 
 
8.4.3. OP and CL swabs for RT-PCR and VI 
Like swabs were dipped together as a single sample in 1.5 ml of TOC medium 
(Chapter 2.9.ii) and then supernatants were stored at -70
o
C until required.  
8.4.4. Detection of aMPV by RT-PCR 
RNA was extracted using phenol-chloroform method as described in Chapter 2.10i. 
The aMPV genome was detected by RT-PCR based on the attachment protein gene 
(G) (Chapter 2.10.iii). Using subtype specific PCRs whereby common primer G5- is 
paired with G8+A for subtype A specificity and G9+B for subtype B specificity. 
Subtype A and B viruses result in bands of 268 bp and 361 bp respectively and are 
readily distinguished on agarose gels. 
8.4.5. VI 
Virus isolation was performed in chicken embryo TOC (Chapter 2.8.ii); using three 
replicate cultures per sample and up to three 10-day passages. Ciliostasis was taken 
as indicator of aMPV detection (Chapter 2.5.v). aMPV identification and subtyping 
were determined by RT- PCR (Chapter 2.10.iii).  
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8.4.6. Detection of aMPV ELISA antibodies 
Two commercial ELISA kits (referred here as Kit 1 and Kit 2) were used to detect 
antibodies against aMPV as recommended by the respective manufacturers of the 
kits.  
8.4.7. Statistical analysis 
The mean antibody titres of the infected and clinical scores were analysed by one 
way ANOVA followed by Tukey’s test, using GraphPad Prism, 6.01.  
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8.5. Results 
 
8.5. 1. Clinical signs 
During the experiment, the control group inoculated with TOC medium only 
remained free of clinical signs (Figure 8.1). The clinical sign recorded was the 
presence of clear to turbid nasal exudates in some birds. Groups B and A+B both 
showed signs as soon as 2 dpi with similar peaks around 4 and 5 dpi. However, for 
group A+B recovery was by 12 dpi, which was two days longer than group B. 
Clinical signs in groups A did not appear until day 3 and they subsided sooner than 
A+B (Figure 8.1). The birds inoculated with subtype B either alone or with subtype 
A, produced significantly higher clinical sign scores than birds inoculated only with 
subtype A on days 1, 2, 3, 4, 6 and 7 post-infection but none thereafter. However, 
there was no significant difference between groups given subtype B alone or 
together with A except on day 6 (Figure 8.1). There was no significant difference on 
day 8, 9 (aMPV A), day 9 (aMPV B) and day 11 (aMPV A+B) with control group. 
Chicks in all groups were fully recovered by 12 dpi. No mortalities were recorded in 
any of the infected groups throughout the experiment.  
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Figure 8.1. Mean clinical sign scores following aMPV subtype A, subtype B or 
combination of A+B infection in SPF chicks. 
 
8.5. 2. Detection of aMPV by RT-PCR and VI 
 
8.5. 2. 1. Swabs 
No viruses were detected in the control birds throughout the experimental period. 
Table 8.1 shows the results of the detection of viral shedding using OP and CL 
swabs. In group A, viral genome was detected up to 5 and 7 dpi in OP and CL swabs 
respectively but virus was isolated only on day 3 in CL swabs. In group B, viral 
RNA was detected in both sets of swabs though intermittently from the CL, for up to 
9 dpi but isolated in only from that site on day 5. In group A+B only virus B was 
detected and then only in OP swabs on 3 dpi by PCR only.    
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Table 8.1.  Detection of aMPV in swabs by RT-PCR and VI in TOC. 
 
Swabs 
 
Groups 
dpi 
1 3 5 7 9 14 
 
OP 
A + +
VI 
+ - - - 
B + + + + +  
A+B - /-
*
 -/+ -/- -/- -/- -/- 
 
CL 
A - - + + - - 
B - - +
VI 
- + - 
A+B - /- -/- -/- -/- -/- -/- 
Control chicks free of aMPV throughout the experimental period; + aMPV positive by RT-PCR; 
- aMPV negative by RT-PCR; 
VI
 Positive for VI; 
*
= aMPV A/ aMPV B.  
 
8.5. 2. 2. Tissues 
 
The distribution of aMPV in different tissue samples is shown in Table 8.2. For 
group A, virus was detected by RT-PCR up to day 5 consistently from turbinate and 
trachea but only less so from lung and spleen. None was isolated at any time. In 
group B, the virus was consistently detected in the trachea for up to 5 dpi. However, 
in the turbinate, lung and spleen, subtype B was still being detected up to 14 dpi. 
The virus was only isolated from the lungs at 1 dpi and the turbinate at 3 dpi. In 
group A+B, only subtype B was detected in the tissues, but not in spleen. The 
turbinate was positive up to 9 dpi whereas the trachea and lung were positive until 5 
and 3 dpi respectively. VI of B was successful in six samples taken from the birds 
infected with both subtypes with virus isolated as long as 7 dpi in the turbinate of 
these birds. 
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Table 8.2. Detection of aMPV in tissue by RT-PCR and VI in TOC. 
 
Tissue 
samples 
 
Groups 
dpi 
1 3 5 7 9 14 
 
Turbinate 
A + + + - - - 
B - +
VI
 - + + + 
A+B - /+
*
 -/+ -/- -/+
 VI
 -/+ -/- 
 
Trachea 
A + + + - - - 
B + + + - - - 
A+B -/+
 VI
 -/+
 VI
 -/+
 VI
 -/- -/- -/- 
 
Lung 
A - + + - - - 
B +
VI 
+
 
+ - + + 
A+B -/+ -/+
 VI
 -/- -/- -/- -/- 
 
Spleen 
A - - + - - - 
B - + + - + + 
A+B -/- -/- -/- -/- -/- -/- 
Control chicks free of aMPV throughout the experimental period. + aMPV positive by RT-PCR; 
- aMPV negative by RT-PCR; 
VI
 Positive for VI; 
*
 aMPV A/ aMPV B.  
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8.5.3. aMPV ELISA antibodies detection 
 
Mean ELISA titres at 14dpi using two different ELISA kits from two different 
manufacturers is shown in Figure 8.2 (Kit 1) and Figure 8.3 (Kit 2). In both ELISA 
kits, serum samples collected prior to infections and control birds were free of the 
aMPV antibodies. In both ELISA kits, all infected birds, either singly (A or B) or in 
combination (A+B) showed high significant antibody titres against aMPV compared 
to control birds. Groups of birds that infected with subtype B either singly or as part 
of a co-infection with subtype A showed high antibody titres compared to the birds 
infected with subtype A alone. The highest titres were seen in both subtype infected 
birds and there were significant differences (P > 0.05) between subtype B-infected 
birds and the group of birds infected with both subtypes A+B. In ELISA kit 1, based 
on the recommended cut-off value, subtype A infected birds had a low mean 
antibody titres (Figure 8.2) when compared to kit 2 which had antibody titres above 
the detectable level (Figure 8.3). 
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Figure 8.2. Kit 1. Mean of antibody titres against aMPV at 14dpi. Data presented as 
SEM (n= 10). Different letters demonstrate significant differences in response 
(P< 0.05). Dash line indicate the cut-off point = 1656. 
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  Figure 8.3. Kit 2. Mean of antibody titres against aMPV at 14dpi. Data presented 
as SEM (n= 10). Different letters demonstrate significant differences in response 
(P< 0.05). The cut-off titre= 396. 
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8.6. Discussion 
 
Nasal exudates ranging from clear to turbid were the only clinical signs observed 
during this experiment. This correlates with previous findings that experimental 
infection of chickens with aMPV produces very mild clinical signs (Catelli et al., 
1998; Nakamura et al., 1998). In this study, subtype A infected birds showed less 
severe and delayed onset of clinical signs when compared to birds infected with 
subtype B alone or in the co-infection of A+B.  A previous study in broiler chicks 
also demonstrated that subtype A infected birds showed less severe clinical signs 
than those infected with subtype B (Aung et al., 2008). In another study, reported 
that a higher percentage of turkeys exhibited clinical signs after subtype B 
inoculation than of the subtype A (Liman and Rautenschlein, 2007). 
In this study, up to the peak of clinical signs, the scores were significantly higher 
and more prolonged in the group given subtype B either singly or dually compared 
to the group that received only subtype A. There were significant differences in the 
clinical signs observed between birds infected with subtype B alone and those with 
co-infection. This suggests that the clinical severity was primarily contributed by the 
subtype B, as the initial virus inocula were virtually the same. Such enhanced 
disease severity was limited to the early phase of the infection, as at and after the 
peak of the clinical signs, there were no significant differences between these 
groups. It has been reported that different aMPV strains may display differences in 
virulence in chickens and turkeys (Cook et al., 1993; Liman and Rautenschlein, 
2007) and in this study, a substantial differences were observed between the strains 
of aMPV subtype A and subtype B. We used aMPV subtype isolates from our 
laboratory and the results produced inevitably reflect the virulence of these isolates.  
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Globally, as each of aMPV isolate (either subtype A or B) may differ in its 
virulence, the findings reported here may not be representative of all or most A and 
B subtypes. 
In term of aMPV detection in swabs or tissues, previous studies have shown that 
neither virulent subtype A or B were detected at or after 14 dpi in commercial 
broiler chicks (Aung et al., 2008; Rautenschlein et al., 2011).  However, in this study 
aMPV B was detected in the turbinate, lung and spleen up to 14 dpi. Our findings 
are consistent with another study with aMPV subtype C, where the viral genome was 
detected in blood and lungs of infected chickens up to 15 dpi (Shin et al., 2000a). It 
is likely that in addition to the virus isolates used, the type of birds used may have 
influenced the outcome. Similar to our study, others have infected turkey poults with 
subtypes A and B and the viral genome of both subtypes were detected in the nasal 
turbinate for up to 14 dpi (Liman and Rautenschlein, 2007). 
During the course of this study, we also found that birds infected with aMPV 
subtype B, either singly or as part of a co-infection with subtype A, were aMPV B 
positive for a longer period than in birds infected with subtype A alone. Subtype B  
has been shown higher virulence, a wider tissue distribution pattern and longer 
persistence than subtype A (Aung et al., 2008). In addition, aMPV was consistently 
detected in OP swabs and turbinate. This suggests that in chicks, for regular 
diagnostic and research purposes, OP swabs and turbinate could be the preferred 
samples of choice for aMPV detection. Using TOCs, subtype B was re-isolated from 
the turbinate up to 7 dpi and from the trachea for up to 5dpi. Previous studies have 
reported re-isolation of virulent aMPV B from nasal and sinus tissues, trachea and 
lungs of experimentally infected broilers up to 5 dpi and the virus was rarely 
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recovered thereafter (Catelli et al., 1998; Gharaibeh and Shamoun, 2012). Overall, 
there was poor isolation of subtype A as it was only isolated from the OP swabs at 3 
dpi. Moreover, we were unable to detect subtype A in birds co-infected with both 
subtypes either by RT-PCR or VI. It is possible that virulence of this virus may have 
played an important role, where it was quickly eliminated by the host immune 
responses.   
Birds infected with both subtypes together showed significantly higher levels of the 
antibody titre when compared to subtype B only infected birds as measured by both 
ELISA kits. In this study, with kit 1 low or no antibodies were detected in the 
subtype A infected chicks. In comparison, 80% of the same sera were positive for 
aMPV antibodies when the ELISA kit 2 was used. The choice of the coating antigen 
may have influenced the outcome, as the sensitivity of ELISA to detect antibodies 
varies with the kit and the coating antigen used (Eterradossi et al., 1995; Mekkes and 
de Wit, 1998). Previous studies have demonstrated that post infection 
sero-conversion induced by the French and UK aMPV isolates are significantly 
better detected if an antigenically related ELISA antigens were used (Eterradossi et 
al., 1992; Toquin et al., 1996). It appears that for a conclusive diagnosis of aMPV, 
appropriate ELISA kits should be used to screen the flocks and should be 
supplemented with molecular detection of the field aMPV subtypes. 
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9.1. Abstract 
 
The feasibility of using FTA cards for the molecular detection of aMPV by RT-PCR 
was investigated. Findings showed that no VI was possible from aMPV-inoculated 
FTA cards, confirming viral inactivation upon contact with the cards. The detection 
limits of aMPV from the FTA card and TOC medium were 10
1.5 
CD50/ml and 
10
0.75 
CD50/ml respectively. It was possible to perform molecular characterization of  
both subtypes A and B aMPV using inoculated FTA cards stored for up to 60 days at 
4-6
o
C. Tissues of turbinate, trachea and lung of aMPV-infected chicks that were 
sampled either by direct tissue impression smears or inoculation of the respective 
tissue supernatants onto the FTA cards were positive by RT-PCR. However, the 
latter technique yielded more detection. FTA cards are suitable for collecting and 
transporting aMPV-positive samples, providing a reliable and hazard-free source of 
RNA for molecular characterization. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                
Chapter Nine                                                               Detection of aMPV-FTA Cards
                                                                                                                    
194 
 
9.2. Introduction  
 
RT-PCR has been established for detection of aMPV (Cavanagh et al., 1999). 
However, in some countries, due to lack of RT-PCR technology, expertise and 
economic factors, it is expedient to send the specimens for diagnosis to specialised 
laboratories in countries where expertise exists. Shipments of infectious material 
must comply with strict regulation in most of these countries and organisms must be 
inactivated by chemicals, such as phenol or formalin, before being transported 
(Snyder, 2002). However, chemically inactivated samples might not always prove 
efficient in terms of subsequently attempting to detecting the virus, due to problems 
in nucleic acid extraction (Coombs et al., 1999). An alternative and safe form of 
transportation of infectious material is the use of FTA cards (Moscoso et al., 2004). 
FTA cards comprise cotton-based cellulose paper which when treated with anionic 
detergents and buffer, provides a stable matrix for the immobilisation of genome for 
molecular characterization but free from the living host cells or organisms (Natarajan 
et al., 2000; Whatman, 2009). This technology simplifies the method of genome 
collection, storage, transportation, extraction, and consequently reduces the cost and 
time required (Mbogori et al., 2006).  
The ability to use the FTA card for detection of several avian pathogens has been 
shown previously including Mycoplasma (Moscoso et al., 2004), IBV (Moscoso et 
al., 2005), NDV (Perozo et al., 2006), IBDV (Moscoso et al., 2006; Purvis et al., 
2006), FAdV (Moscoso et al., 2007), Marek’s disease (MD) (Cortes et al., 2009) and 
AIV (Abdelwhab et al., 2011). To date, no information has been published on the 
use of FTA cards for detection of aMPV. In this study, using aMPV subtypes A and 
B, we investigated; the use of the FTA cards in inactivating aMPV (Experiment 1),  
                                                                                                
Chapter Nine                                                               Detection of aMPV-FTA Cards
                                                                                                                    
195 
 
validating the detection limits for aMPV-inoculated FTA cards (Experiment 2), the 
effects of different storage temperatures on the detections of aMPV (Experiment 3). 
We also compared aMPV detections using two sampling techniques: tissue 
impression smears directly onto the FTA cards and same tissue macerated, and 
subjected to a freeze-thaw process and the supernatant inoculated onto FTA card 
(Experiment 4).   
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9.3. Materials and methods 
 
9.3.1. Viruses 
aMPV subtypes  A  and B  were used in this study (Chapter 8.3.2). 
9.3.2. FTA cards  
FTA cards are a commercial product developed by the Whatman Corporation and are 
designed to transport and store a variety of biological materials including viral and 
bacteriological samples and blood (Figure 9.1). Infectious material applied to the 
cards is inactivated on contact as the cells are lysed but the genome is preserved for 
molecular recognition (Whatman, 2009).   
 
 
 
 
 
 
 
                      
                     Figure 9.1. Flinders Technology Associates (Whatman Card). 
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9.4. Experimental design 
 
9.4.1. Experiment 1.  Confirmation of aMPV inactivation by FTA cards 
One hundred microliters of stock culture of aMPV subtype A or subtype B were 
spotted onto the matrix area of an FTA card and allowed to air-dry at RT for 1hour. 
The spotted areas of the FTA card were cut out using sterile scissor and forceps. 
Each sample was placed into a bijou bottle containing 2 ml of TOC medium and 
processed for VI (Chapter 2.8.ii).   
9.4.2. Experiment 2.  Detection limits of aMPV on FTA cards 
To determine the sensitivity of the RT-PCR in detecting subtype A or subtype B, 
serial 10-fold dilutions up to 10 
-7 
were made from each subtype from the initial 
stock (Figure 9.2, A). For the each dilution, 100 µl was applied onto the matrix areas 
of the FTA cards which were air-dried for an hour at RT and kept away from direct 
light. For comparison, 300 µl of the same viral dilutions were subjected directly to 
RT-PCR. The RT-PCR reactions were run for each sample to determine the lowest 
dilution where viral RNA can be detected (Chapter 2.10.iii).  
 
9.4.3. Experiment 3.  Effects of storage temperature on detection of aMPV on 
FTA card 
A volume of 100 µl of stock culture of aMPV subtype A or B was spotted onto the 
matrix circles of FTA cards. After air-drying as above, the cards were placed in 
sealed polythene bags and kept at three different temperatures, i) in a refrigerator, 
with temperature range of 4-6 
o
C, ii) in an incubator at 25
o
C, or iii) in an incubator at 
41
o
C. On each of the following days: 1, 5, 10, 15, 20, 25, 30, 40, 50 and 60, one of 
the FTA cards was removed for the detection of aMPV by RT-PCR.  
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9.4.4. Experiment 4. Detection of aMPV subtypes from FTA cards versus tissue 
supernatants 
To assess the different methods of sample submissions and to demonstrate any 
variations in aMPV detection, groups that infected with aMPV subtype A, subtype B 
and control birds (Chapter 8.4) were used in this experiment. At 1, 3, 5, 7, 9 and 
14 dpi, samples of turbinate, trachea and lung were collected from five birds in each 
group.  
The five tissues were each applied directly onto FTA cards. The same type of tissues 
was pooled. An impression smear was made by gently pressing the tissues onto the 
matrix area of the cards (Figure 9.2, B-C). The cards were labelled and air-dried but 
protected from direct sun light for an hour at RT. The remaining tissues were pooled 
according to the type, group and day of sampling (Figure 9.2, D) and stored at -70 
o
C 
until further use.  
The same type of tissues was pooled and was manually macerated with sterile sand 
in a pestle and mortar, and 3 ml of TOC medium. After three cycles of 
freeze-thawing and centrifugation, 100 µl of each supernatant was spotted directly 
onto an FTA card and allowed to dry for 1 hour at RT. The FTA cards prepared with 
tissue impression smear and those which were inoculated with processed tissue 
supernatants were all examined for aMPV RNA.  
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 Figure 9.2. Shows application of tissue or medium into the FTA card. 
 
9.4.5. Sample preparation for aMPV RT-PCR 
 
Samples impregnated onto the matrix of the FTA cards (described above) and those 
with impression smear of fresh tissues were cut using sterile scissors and forceps and 
placed in bijou bottles containing 2ml of solution D then stored at -20
o
C. For 
extraction of the RNA from TOC medium, 300 µl was added to 300 µl of solution D. 
The RNA was extracted using phenol-chloroform method (Chapter 2.10.i) and 
RT-PCR was carried out as described in Chapter 2.10.iii. 
 
 
 A  B 
 C  D 
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9.5. Results 
 
9.5.1. Experiment 1. Confirmation of aMPV inactivation by FTA cards 
No ciliostasis was seen in the TOCs inoculated with elutions from either aMPV 
subtype-inoculated matrix of FTA cards. In contrast, in TOC rings that received the 
stock culture of subtype A or subtype B, ciliostasis occurred within 5-7dpi.   
9.5.2. Experiment 2.  Detection limits of aMPV on FTA cards 
 
The detection limits by RT-PCR of the subtype A and subtype B aMPVs, based on 
either serially diluted stock cultures in the TOC medium or similar levels onto matrix 
of the FTA cards are shown in Table 9.1. Detection limits for subtypes A and B were 
10
1.56 
CD50/ml and 10
1.51 
CD50/ml respectively for the samples processed from on the 
FTA cards. The detection limits of the subtypes processed from TOC medium were 
one log better than the FTA cards. 
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Table 9.1. Detection limits of aMPV subtype A or B on FTA cards. 
 
 
Virus 
dilution 
Initial stock of aMPV A (10
4.56
 CD50/ml) and aMPV B (10
4.51
 CD50/ml) 
FTA card
*
 TOC medium
≠
 
aMPV A aMPV B aMPV A aMPV B 
10
0
 + + + + 
10
-1
 + + + + 
10
-2
 + + + + 
10
-3
 + + + + 
10
-4
 - - + + 
10
-5
 - - - - 
10
-6
 - - - - 
10
-7 
- - - - 
 
*
Hundred microliters of serial dilutions up to 10 
-7 
applied into the circles present in the FTA cards; 
≠
Three hundred microliters of serial dilutions up to 10 
-7 
from TOC medium which contains the virus 
was used directly to RT-PCR.  
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9.5.3. Experiment 3. Effects of storage temperature on detection of aMPV on 
FTA cards  
The stability of viral genome on FTA cards was measured by performing RT-PCR 
on the stock virus spotted onto FTA cards and stored at different temperatures for up 
to two months. The viral genome of both subtypes A and B was detected when 
stored at 4
o
C for up to 60 days post storage (dps). Subtype A RNA was detected only 
up to 1 dps at 25 
o
C and 41
o
C. In contrast, subtype B RNA was detected up to 30 dps 
at 25
o
C and for up to 5 dps for when stored at 41
o
C (Table 9.2).  
 
Table 9.2. Stability of aMPV RNA on the FTA cards under differing storage 
temperatures.   
 
dps aMPV A* aMPV B* 
 4
o
C 25
o
C 41
o
C 4
o
C 25
o
C 41
o
C 
1
 
+ + + + + + 
5
 
+ - 
- 
 
+ + + 
10
 
+ - 
- 
 
+ + - 
15
 + 
 
- 
- 
 
+ + - 
20
 
+ - 
- 
 
+ + - 
25
 + 
 
- 
- 
 
+ + - 
30
 + 
 
- 
- 
 
+ + - 
40
 + 
 
- 
- 
 
+ - - 
50 + - - + - - 
60 
 
+ - - + - - 
 
* Hundred microliter of the initial stock of the aMPV subtype A or B were spotted on the active area 
of the FTA and stored at three different temperatures. 
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9.5.4. Experiment 4. Detection of aMPV subtypes from FTA cards versus tissue 
supernatants 
No virus was detected in the control birds. Table 9.3 shows the results for the 
infected groups. For subtype A, there were less frequent detections than subtype B. 
Subtype A was detected up to 7 dpi only, compared to subtype B, which was 
detectable up to 14 dpi (end of the experiment). In comparison of the tissue 
impression smears and supernatants, for subtype A, there were marginally more 
frequent detections in the tissue impression smears.  In contrast, for the subtype B, 
there were no obvious differences with detection in the turbinates with either method 
of sampling; virus was detected at almost at all sampling intervals, except at 5 dpi 
where the virus was detected only in the tissue impression sample. For tracheal 
samples, there was obvious difference between the methods but for lungs there was 
slightly longer detection by tissue impression methods (up to 9 dpi). Overall, for 
subtype A and B infections, by either sampling methods (impression smear or tissue 
supernatant), the greatest level of detection was seen at 5 dpi.    
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Table 9.3. A comparison of the detection of aMPV by RT-PCR on samples collected 
on FTA cards either as tissue impression smear or inoculated with tissue supernatant. 
 
 
 
Tissue 
 
Groups 
Methods of 
tissue sampling 
onto FTA card 
dpi 
 
1 3 5 7 9 14 
 
Turbinate 
 
A 
Impression* 
- 
 
+ + + - - 
Supernatant 
≠ + 
 
+ + - - - 
 
B 
Impression 
 
+ + + + + + 
Supernatant 
+ 
 
+ - + + + 
 
 
Trachea 
 
 
A 
Impression 
- 
 
- + + - - 
Supernatant 
- 
 
+ + - - - 
 
B 
Impression 
- 
 
- + - - - 
Supernatant 
+ 
 
+ + - - + 
 
 
 
Lung 
 
 
A 
Impression - + + - - - 
Supernatant - - + - - - 
 
B 
Impression - - + + + - 
Supernatant + - + + - - 
 
*imprint was made by gently pressing the tissue against providing matrix area of the FTA card; 
≠
One 
hundred microliters of the tissue supernatant that had undergone three times of freeze-thaw was 
spotted directly onto FTA card.  
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9.6. Discussion 
 
Definitive diagnosis of aMPV infection requires identification of the virus in clinical 
material which is most often achieved nowadays by RT-PCR. However, PCR 
technology is unavailable in some countries and requires transportation of samples in 
a safe way to specialist laboratories, with international shipment of samples needing 
high standards of biosafety procedures (Snyder, 2002), including for aMPV. In 
assessing the suitability of detecting aMPV subtype A or B, or both, we are reporting 
the results of experiments on inactivation of aMPV on FTA card, aMPV detection 
limits when the viruses are sampled on FTA cards, effects of different temperatures 
on storage of FTA cards containing aMPV, and a cross-comparison between two 
sampling methods (direct impression smear versus inoculation of tissue supernatant 
onto FTA cards). 
The absence of ciliostasis of the TOCs inoculated with elution from aMPV subtype 
A or subtype B indicated no viable virus presence, confirming that the FTA card 
inactivates the aMPV viruses. The ability of FTA cards to inactivate other avian 
pathogens such as IBV, NDV, IBDV, AIV and FAdV have been reported before 
(Moscoso et al., 2005; Moscoso et al., 2006; Perozo et al., 2006; Moscoso et al., 
2007; Narayanan et al., 2010; Abdelwhab et al., 2011).  
In our hands for samples on FTA cards, the detection limits for subtype A and 
subtype B were 10
1.56
 CD50/ml and 10
1.51
 CD50/ml respectively. These values were 
approximately one log lower than the detection limits of viruses in the TOC medium. 
These data are in agreement with similar study on detection of multiple poultry 
respiratory pathogens on FTA cards (Awad et al., 2012). It appears that there could 
be a small loss of RNA in the process of inoculation onto the FTA card matrix, 
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storage or extraction processes. However, such loss would out-weight the benefit of 
aMPV detection, particularly for samples transported from thousands of miles. 
Ideally, for successful virus detection, the FTA card should preserve and protect 
against deteriorations of viral genome. The FTA card manufacturer states that the 
card could be used for sampling and transportation of  RNA viruses and the FTA 
card can be stored for a short term at RT or longer at -20
o
C or -70
o
C (Whatman, 
2009). However, to date, there is no published information of the effects of various 
environmental temperatures on the detection of aMPV by RT-PCR. Our study 
demonstrated that following inoculation of FTA cards and storage in air-tight 
plastics bags at 4-6 
o
C subtypes A and subtype B were both detected for up to 
60 days. Interestingly, at 25 
o
C, aMPV subtype B was detected up to 30 days but 
only for 1 day for the subtype A. The reason for this discrepancy is unclear even 
though virus titres of the viruses were almost the same. When the FTA card were 
stored at 41
o
C, mimicking  summer temperature in some countries, the subtype A 
was again only detected for one day but the subtype B was detected up to 5 dps. This 
reflects poor preservation of aMPV RNA at this temperature. The decrease in the 
sensitivity could be due to that RNA denatures over time and is faster at higher 
temperatures (Rogers and Burgoyne, 2000; Moscoso et al., 2005; Perozo et al., 
2006). As such, FTA cards intended for aMPV RT-PCR, ideally need to be stored at 
low temperature as possible, preferably 4-6 
o
C.  RT-PCR detection of IBV or IBDV 
in samples stored on FTA cards at -20
o
C, 4 
o
C or 41 
o
C indicates that the RNA was 
stable for at least 15 days (Moscoso et al., 2005; Moscoso et al., 2006). NDV was 
stable on the FTA card for at least 20 days at both RT and 4
o
C and for 18 months at 
-20
o
C (Narayanan et al., 2010). AIV RNA was also stable on FTA cards for at least 
five months at RT (Abdelwhab et al., 2011). It appears that other than the intrinsic 
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nature of the viruses, the variations in the virus titres and differences in the PCR 
protocols may have influenced the outcome.   
Experiment 4 was organised to answer field questions on the appropriate methods of 
samplings onto FTA cards for optimal detection. The question was whether it was 
better to do a tissue impression smear directly onto the FTA card or should the 
tissues be processed in the normal manner for VI and freeze-thawed three times, 
before applying a drop of 100 µl onto the FTA cards. Our study showed that there 
was slightly better chances of detecting aMPV RNA when the sample supernatant 
were used compared to tissue impression smears. These findings suggest that with 
tissue impression smears there could be a reduced amount of RNA left on the FTA 
card. In contrast, for the tissue supernatant, it is likely that maceration and later 
freeze-thaw processes have allowed cells to rupture and release of more viral RNA 
into the supernatant. In a study with AIV RNA from swab samples from the field 
adsorbed to and extracted from FTA cards was detected with reduced sensitivity 
when compared to RNA directly extracted from swab fluids (Abdelwhab et al., 
2011).Thus, it appears that to increase the chances of aMPV detection, it is 
worthwhile to grind the tissues (a pool of five or more tissues), subjected them to a 
freeze-thaw process, centrifuge (or allow to stand-still) and apply the supernatant 
onto the FTA cards.    
These findings showed that the virus could be detected on FTA card samples taken 
from the turbinate, trachea and lung. However, the length of time for which detection 
was possible varied according to the organ type, sampling time and variation 
between aMPV subtypes A and B. For example, with samples taken from the 
turbinate, aMPV subtype A and B were detectable up to 7 and 14 dpi respectively, 
and with those from the lung were positive up to 5 and 9 dpi for aMPV A and B 
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respectively. These indicate that subtype B virus can be detected for a longer period 
than subtype A (Aung et al., 2008), even though, similar titres of the viruses were 
used. The highest detections of aMPV was recorded at 5 dpi and this is in agreement 
with previous work in  broilers (Gharaibeh and Shamoun, 2012) and turkeys (Liman 
and Rautenschlein, 2007).  
We conclude that FTA cards are suitable for collecting and transporting aMPV 
samples worldwide but the cards must be stored at lower temperatures for optimal 
chances of aMPV detection. 
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This chapter outlines the salient features of the experimental results described 
previously. Various aspects of the immunopathogenesis, molecular diagnosis and 
vaccination programmes of IBV and aMPV were examined in these experiments and 
on the basis of our findings some possible future work is discussed.   
 
The constant emergence of variant strains of IBV poses a serious threat to 
vaccination strategies. One of the most prominent IBV strains in the Middle East and 
North Africa designated as IS/885/00 remains a major threat to the poultry industry 
since first reported in Israel in 2000 (Meir et al., 2004). Very little information is 
available in the literature regarding the manifestations of the disease caused by this 
variant strain of IBV. Hence, a study was conducted on the immunopathogenesis of 
this strain in one-day old SPF and IBV MDA positive broiler chicks (Chapter 3). 
The IS/885 strain was found to be pathogenic to both types of birds. An important 
finding in this study was one broiler bird suffering from mild head swelling. 
Samples taken post mortem and subjected to VI and RT-PCR were found to be 
positive for IBV. On sequencing the virus isolated was found to be 100% similar to 
original challenge virus (IS/885). Though, IBV M41 has been associated with SHS 
in chicks (Droual and Woolcock, 1994), this appears to be the first report on 
development of head swelling following IBV infection under experimental 
condition. 
In addition, the characteristic cystic oviduct previous reported for IBV strain M41 
(Crinion et al., 1971; Crinion and Hofstad, 1972a) and QX (Benyeda et al., 2009; de 
Wit et al., 2011b; Ganapathy et al., 2012) infections was observed in two female 
SPF chicks infected with IS/885. IBV isolated from the cystic fluid showed, on 
sequencing of the part-S1 gene a 99% similarity to the original IS/885 inoculum. As 
a result of our findings, further work is needed to understand the pathogenesis of this 
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variant IBV on the development of cystic oviducts and subsequent effects on egg 
production and quality. 
It has been shown that the conventional Mass vaccines alone do not provide 
sufficient protection against IS/885/00 and IS/1494/06 (Meir et al., 2004; Kahya et 
al., 2013). Thus, the study in Chapter 4 was designed to evaluate the protection 
induced by commercial live IBV vaccines in day-old commercial broiler chicks 
against challenge with these strains. It appears that a combination of live H120 and 
CR88 vaccines given at day-old followed by CR88 vaccine at day 14 of age confer 
an excellent protection against both variant IS/885 and IS/1494 viruses. The  H120 
at day-old followed by CR88 at 14 days-old, provided somewhat lower protection, in 
particular against IS/885. Further work is required to understand the underlying 
immune mechanisms for such higher and broader of protection conferred by these 
distant vaccine viruses.  
Relatively little research exists regarding cellular and local immune responses 
induced by IBV vaccination. To this end, the role of humoral, cellular and local 
immunity induced by administration of different live IBV vaccines in one-day old 
IBV MDA positive broiler chicks were studied in Chapter 5. It was observed that 
CD4+ cells were recruited into the trachea earlier than CD8+. This observation was 
in accordance with a previous study, which observed that CD4+ cells outnumbered 
CD8+ cell in the trachea (Janse et al., 1994). In contrast, Dhinakar Raj and Jones 
(1996a) reported that CD8+ cells were recruited into the trachea earlier than CD4+ 
cells after infection with virulent 793B. Based on these conflicting results further 
investigations are required. One possible explanation for this anomaly could be due 
to differences in IBV strains.  
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To our knowledge, there has been no information available regarding circulating 
IBV variant in Libya. In June 2012, swabs and tissue samples were collected from 
diseased broiler flocks experiencing high mortality and respiratory distress 
(Chapter 6). IBVs with high similarity to regionally important strains IS/885/00-like 
and IS/1494/06-like were detected by RT-PCR. Further studies on the spread of IBV 
in Middle Eastern countries and North Africa should include the mode of spread, 
isolation and serotyping/genotyping of IBVs in the region.    
Previous studies (Cook et al., 2001b; Ganapathy et al., 2005a; Tarpey et al., 2007) 
suggested that CMI may have played an important role in conferring the protection 
against challenge viruses of NDV, aMPV or IBV. In Chapter 7, we evaluated the 
cell-mediated and local immune responses in the trachea of birds following 
administration of single, dual or triple combinations of live NDV, aMPV and IBV 
vaccines using IHC. In the vaccinated groups a significant increase was observed in 
the expression of CD4+, CD8+ and IgA-bearing B cells in the trachea when 
compared to the unvaccinated group. However, within the vaccinated groups, the 
levels of expression of each of the cells did not differ significantly. These 
observations demonstrate the role of the CMI response following NDV, aMPV and 
IBV vaccination in chickens. 
In Chapter 8, even though similar titres of the viruses were used, the result 
demonstrated that aMPV subtype B was more pathogenic than subtype A. Our 
findings are in agreement with those of Aung et al. (2008) who observed that in a 
subtype B infected group, higher numbers of broilers showed clinical signs, a wider 
tissue distribution and a longer period of aMPV-positive samples than in subtype A 
infected group. Following on from these findings it would be interesting in the future 
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to conduct further studies encompassing other aMPV subtypes A and B isolated 
from different region to see if similar results are found. 
In chapter 9 a diagnostic study using FTA cards for the molecular detection of 
aMPV by RT-PCR was investigated. One of the key findings showed that at 25 
o
C 
aMPV subtype B was detected up to 30 dps but only for 1 dps for the subtype A. 
The reason for this discrepancy is unclear and it needs further investigation.  
 
In summary, the studies undertaken for this project have provided some useful 
practical insights in the pathogenicity, immunity, diagnosis and control of IBV and 
aMPV infection in chickens. Our results have been published in scientific journal 
and presented in national and international meetings.  
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Appendix 1 
(Reagents and protocols) 
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Stock solution D   
Guanidine thiocyanate 
40
                                                                                 100.00 g
                                                      
0.75M sodium citrate 
40
                                                                                   7.04 ml
                         
10% lauryl sarcosine 
40
                                                                           10.50 ml
                                  
Sterile distilled water                                                                                         7.04 ml
                       
Kept for one month at 4
o
C 
 
 
Working solution D  
Stock solution D (see sol D)                                                                              25 ml  
Mercaptoethanol
40
                                                                                          180 μl
                            
TOC culture medium and supplements  
10x Minimum Essential Medium-Eagles 
41
                                                        100 ml                                                                
7.5% sodium bicarbonate 
40
                                                                                  20 ml                                                                                                
Sterile distilled water                                                                                          900 ml                                                                                                 
Penicillin-streptomycin solution                                                                             4 ml                                                                                      
 
Stock antibiotic solution 
Crystapen
42
                                                                                                         600 mg                                                                                                                      
Streptomycin sulphate BP 
43
                                                                                  1.0 g                                                                                               
Sterile distilled water                                                                                              4 ml                                                                                                            
                                                          
40
 Sigma-Aldrich, UK 
41
 Life Technology, UK                                                      
42
 Glaxo, Greenford, UK 
43
 Evans Medical, Greenford, UK 
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4ml of this stock solution was added to 1000 ml of medium for a 1x solution. For 
preparing 10x antibiotic medium, 4ml was added to 100ml of medium. 
 
HEPES buffer  
HEPES 
44
                                                                                                           2.95 gm                                                                                                                        
 NaCI
45
                                                                                                                 4.09 g                                                                                                                                
CaCl2 
45
                                                                                                                 0.08 g                                                                                                                             
Add sterile distilled water to 500ml distilled water, pH adjusted to 6.5 with 1N 
NaOH 
 
Phosphate buffered saline (PBS) 
NaCl                                                                                                                85.00 g
                                                        
Di-sodium hydrogen orthophosphate (Na2HPO4)                                          10.70 g  
                       
Sodium dihydrogen orthophosphate (NaH2PO4.2H2O)                               3.90 g  
                       
Made up to 1 litre with sterile distilled water 
 
2M sodium acetate 
Glacial acetic acid
46
                                                                                       19.00 ml
                                
Sodium acetate
47
                                                                                          5.46 g
                            
Made up to 200 ml with sterile distilled water 
 
                                                          
44
 Life Technology, UK                                                      
45
 Sigma-Aldrich, UK 
46
 VWR International Ltd 
47
 Sigma-Aldrich, UK 
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0.75M Sodium citrate pH7.0 
Citric Acid Monohydrate                                                                                           31.52 g                                                                                                           
NaOH pellets                                                                                                                16.8 g                                                                                                                             
Sterile distilled water                                                                                                   200 ml                                                                                                                                                                                                                                           
 
 
Resuspending (RS) water  
RNasin, RNAse inhibitor 
48
                                                                               2.5 μl
                            
Dithiothreitol (DTT) 
49
                                                                                             5 μl
                                           
Ultra-pure water 
47
                                                                                              92.5 μl
                           
 
Reconstitute stock primers according to delivery details, Dilute stock oligos 
1:10 to give working solutions  
 
IBV Oligos
50
 
Working Oligo            Stock Oligo                           Sigma Water                  
SX4-        10µl                                   90 µl                                             
       A      B 
SX1+    10 µl    10 µl                                  80 µl                                              
SX3+    10 µl    10 µl                                                        80 µl                                       
SX2-    10 µl   10 µl                                  80 µl                                               
                                                          
48
 Promega, Madison,USA 
49
 Invitrogen, Paisley, Scotland 
50
 Invitrogen, Paisley, Scotland 
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aMPV Oligos
 50
 
Working Oligo      Stock Oligo                               Sigma Water 
G6-     10 µl                                                                    90 µl
                                                   
G5-     10 µl                                                                    90 µl
                                                   
G8+A     10 µl                                                                   90 µl
                                                   
G9+B     10 µl                                                                    90 µl
                                                   
                 A B 
G1+    10 µl 10 µl                                                        80 µl 
 
NDV Oligos 
51
  
Working Oligo                  Stock Oligo                                                  Sigma Water 
MFS+                                            10 µl                                                                 90 µl                                                                          
MSF-                                             10 µl                                                                 90 µl                                                                             
 
10mM dNTP’s Working Solution 
dATP, dCTP, dGTP, dTTP at 100mM
 51
  
Take 20µl of each dNTP, total volume 80µl 
Add 120µl of sigma water to give 200µl of 10mM dNTP’s 
 
                                                          
51
 Invitrogen, Paisley, Scotland 
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RT-PCR reaction for IBV/aMPV 
5X Buffer
 51
                                                                                                            1 µl                     
DTT                                                                                                                      0.5 µl                 
dNTP
 51
                                                                                                               0.25 µl                      
Ultra-pure Water                                                                                                 2.13 µl                      
RNase inhibitor                                 0.12 µl                                                                                                                 
Superscript II (200 µ/ µl)
 51
                                                                                 0.25 µl                                                                            
Negative Oligo (10 pmoles/µl) (IBV SX2-) (aMPVG6-) (MFS-)                     0.75 µl                                                                                                                                           
Nested PCR 1 protocol 
PCR Supermix 
52
                                                                                                    19 µl                                   
+ Oligo (IBV SX1+) (aMPV G1+) (MSF-)                                                          0.5 µl                                                        
- Oligo (IBV SX 2- ) (aMPV G6-) (MSF+)                                                          0.5 µl                                                              
 
Nested PCR 2 protocol  
 PCR Supermix                                                                                                   23.5 µl                                                                                                               
+ Oligo (IBV SX3+) (aMPV G8-A)                                                                     0.5 µl                                                                              
- Oligo (IBV SX 4- ) (aMPV G9+B)                                                                    0.5 µl 
- Oligo (aMPV G5-0 (aMPV)                                                                               0.5 µl                                                                                 
 
Loading Buffer  
Ficol                                                                                                                         3 g                                                                                                                                       
1XTBE                                                                                                                  20 ml                                                                                                                                 
                                                          
52
 Invitrogen, Paisley, Scotland 
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10x Tris-borate-EDTA (TBE)
53 
This was purchased at 10X concentration and diluted to1X concentration when 
required. 
Gel preparation 
1.5% agarose
 53
                                                          0.58 g
                                          
TBE                                                                                                                       35 ml
     
                                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
53
 Sigma-Aldrich, UK 
                                                                                               
Appendices                
                                                                                                                                                        
                                                                                    
                                                                                                                    
252 
 
 
QlAamp viral RNA extraction 
Equilibrate samples and buffers to RT 
Addition of carrier RNA to buffer AVL 
 Add 310 µl Buffer AVE to the tube containing 310 µg lyophilized carrier 
RNA 
 Dissolve the carrier RNA completely  
 If extracting 55 samples add the 310 µl reconstituted carrier RNA to 31ml 
Buffer AVL 
 This is stable in the fridge for 48h.  Look out for precipitation.  To dissolve 
any precipitate, heat at 80
o
C for no more than 5 min (no more than 6 times) 
 If extracting smaller numbers of RNA see table in booklet with kit for 
amounts and storage of reconstituted carrier RNA    
Protocol 
1. Add 560 µl of prepared buffer AVL containing reconstituted carrier RNA 
into 1.5 ml eppendorf tubes 
2. Add 140 µl of sample 
3. Vortex for 15sec 
4. Incubate at RT for 10min 
5. Pulse centrifuge  
6. Add 560 µl of 100% ethanol 
7. Vortex for 15sec 
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8. Pulse centrifuge 
9. Label spin columns 
10. Carefully remove 630µl from tube (step 6) into spin column 
11. Centrifuge at 8000 rpm for 1minute, discard flow through 
12. Place spin column in clean collection tube and repeat steps 10 and 11 
13. Place spin column in clean collection tube add 500 µl of buffer AW1 
14. Centrifuge at 8000 rpm for 1min, discard flow through 
15. Place spin column in clean collection tube add 500 µl of buffer AW2 
16. Centrifuge at 13,000 rpm for 3minutes, discard flow through 
17. Place spin column in clean 1.5 ml eppendorf tube add 60 µl of sigma water 
18. Incubate at RT for 1 minute 
19. Centrifuge at 8000 rpm for 1min, discard spin column and save flow through 
(RNA)  
20. Store RNA at -20oC 
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Appendix 2 
(Data collection sheets) 
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Result sheet for ciliostasis test 
 
     Group................ 
  
 
 
 
 
 
Ring 
No 
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 
1 
 
          
2 
 
          
3 
 
          
4 
 
          
5 
 
          
6 
 
          
7 
 
          
8 
 
          
9 
 
 
         
10 
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Result sheet for IBV clinical signs 
 
Group................. 
Date Day dpi Comments  
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Result sheet for gross lesions  
 
dpi  ............ 
Bird 
No 
 
Control  IS/885 IS/1494 
Trachea Kidney Trachea Kidney Trachea Kidney 
1       
2       
3 
 
 
     
4       
5       
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Multiwall data sheet ELISA or HI 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C      
 
      
D             
E             
F             
G             
H             
 
Date: 
Name: 
Project: 
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Result sheet for IHC data 
 
  Group .............. 
 
Flied 
Number of birds (Tracheal ring) 
1 2 3 4 5 
1      
2      
3      
4      
5      
 
 
 
 
 
 
 
 
 
 
 
                                                                                               
Appendices                
                                                                                                                                                        
                                                                                    
                                                                                                                    
260 
 
 
 
 
 
 
 
Appendix 3 
 
(Published manuscripts) 
 
